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Abstract 
Tacrolimus (FK506) is a calcineurin inhibitor (CNI), and the main 
immunosuppressant used in organ transplantation. It causes complications such 
as hypertension, hyperkalaemia, hypercalciuria and acidosis. Together with 
insulin resistance, dyslipidaemia and obesity, they comprise the metabolic 
syndrome.  
CNIs induce hypertension through the activation of the WNK-NCC cascade, 
causing an increase in sodium chloride reabsorption, and phosphorylation is an 
important post-translational modification that alters the activity of the members in 
the WNK-NCC cascade. Using quantitative phosphoproteomics and several 
bioinformatic techniques, a phosphoproteome profile of the renal cortices from 
FK506-treated mice was generated and phosphoproteins involved in renal 
tubular transport were identified. In this data, AKT was phosphorylated by FK506 
and was suggested to act as the intermediary protein in the calcineurin-WNK 
cascade. In addition, ERK1/2 was also dysregulated by FK506 and was 
suggested to regulate NCC through the WNK4-ERK1/2 pathway. The 
phosphoproteome profile also revealed several FK506-dysregulated 
phosphoproteins that are involved in sodium, acid-base, glucose and potassium 
handling. 
CNIs have been suggested to cause hypercalciuria through a decrease in TRPV5 
and calbindin-D28K expression, however, the effect of FK506 on other regulatory 
and transport proteins involved in calcium handling is unclear. In contrast to 
previous studies, FK506 did not dysregulate TRPV5 expression, but instead 
increased the expression of the basolateral calcium transporters, NCX1 and 
PMCA. Based on these findings, a novel mechanism explaining CNI-induced 
hypercalciuria, driven by the activation of NCC, is proposed and the relationship 
between sodium and calcium handling in the DCT is discussed.  
The effects of calcineurin inhibition on renal electrolyte transporters and their 
potential regulators induce salt-sensitive hypertension and hypercalciuria. The 
findings presented in this thesis contribute to the understanding of the underlying 
mechanism that governs sodium and calcium handling in the DCT and full 
elucidation of this molecular machinery is of interest and clinical importance.   
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1.1 Hypertension and the metabolic syndrome crisis 
Hypertension is the single most important modifiable risk factor for premature 
mortality in the world. In 2000, hypertension affected 26.4 % of adults worldwide 
and this is estimated to increase to 29.2 % by 2025 (1). Hypertension is a major 
risk factor for cardiovascular diseases (2) and one of the leading risk factors for 
renal failure in the Western world (3), and increasingly in the developing world. 
Hypertension is responsible for 9.4 million deaths per year (4) and is accountable 
for 45 to 51 % of deaths associated with strokes and ischemic heart diseases (5). 
Hypertension is a public health epidemic and an estimated 10 % of healthcare 
expenditure is related to hypertension and its complications, therefore finding a 
strategy to reduce the morbidity of hypertension has become a priority in modern 
medicine (6).  
The development of hypertension can involve both genetic and behavioural risk 
factors. The existence of monogenic hypertensive disorders, such as familial 
hyperkalaemic hypertension (FHHt) (7,8), familial hyperaldosteronism type III (9) 
and Liddle syndrome (10), has led to the discovery of specific mutations in 
thirteen hypertension genes in the kidneys and the renin-angiotensin-aldosterone 
system (RAAS) (11). Behavioural factors which involve increased salt and fat 
consumption, a diet low in fruit and vegetables (low dietary potassium), excessive 
alcohol consumption, lack of exercise, use of tobacco and poor stress 
management are key determinants in the development and the progression of 
hypertension (12). Not only can these behavioural factors cause hypertension 
over time, but in combination with insulin resistance, dyslipidaemia and obesity, 
they comprise the metabolic syndrome (13). 
1.1.1 What is the metabolic syndrome? 
The metabolic syndrome was first defined by Reaven in 1988 (14) as a cluster of 
biochemical and physiological disorders, which include hypertension, 
hyperglycaemia, hypertriglyceridemia, abdominal obesity and low high-density 
lipoprotein cholesterol (HDL-C) levels. The metabolic syndrome is a growing 
epidemic and affects a reported 10 to 84 % of the population worldwide (15). This 
estimation of incidence has a wide variability due to several contributing factors. 
For example, the disparity in definitions of the metabolic syndrome and some 
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environmental factors, such as the region and socioeconomic status of the 
population studied, contribute to the variability of the estimated prevalence of the 
syndrome (15,16).  
Several clinical definitions of the syndrome have emerged since its first 
characterisation, the key features that comprise the metabolic syndrome remain 
unchanged, and instead, the parameters for each criterion differ slightly. The 
World Health Organization (WHO) (17), the National Cholesterol Education 
Programme Adult Treatment Panel III (18), the American Association of Clinical 
Endocrinologists (19), the European Group for the study of Insulin Resistance 
(20) and the International Diabetes Federation (21) have all provided criteria for 
diagnosing the metabolic syndrome. As the defined diagnostic criteria differs 
between each of these organisations, this creates discrepancies in the 
assessment and intervention of the metabolic syndrome. Using the diagnostic 
criteria recommended by the WHO (Table 1.1-1), the metabolic syndrome was 
estimated to affect over 33.9 % of women and over 44.8 % of men aged between 
40-65 in England (22). 
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Table 1.1-1 The WHO diagnostic criteria of the metabolic syndrome 
Clinical measures 
Requirement Insulin resistance or type 2 diabetes  
and at least two of the criteria listed below 
Abdominal obesity 
Waist/hip ratio in men: >0.9 
Waist/hip ratio in women: >0.85 
or 
BMI: >30 kg/m2 
Hypertension 
Systolic blood pressure: ≥140 mmHg 
Diastolic blood pressure: ≥90 mmHg 
Dyslipidaemia 
Triglycerides level: ≥150 mg/dL 
HDL-C levels in men: <35 mg/dL 
HDL-C levels in women: <39 mg/dL 
Microalbuminuria 
Urinary albumin excretion: ≥20 µg/min 
or 
Albumin/creatinine ratio: ≥30 mg/g 
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1.1.2 Complications associated with the metabolic syndrome 
The cause of the metabolic syndrome is not entirely understood, but it is known 
to be strongly associated with the development of cardiovascular diseases and 
type 2 diabetes. Individuals with the metabolic syndrome have a two-fold 
increased risk of developing cardiovascular diseases and a five-fold increased 
risk of developing diabetes over a five to ten year period (23). 
Other complications are also associated with the metabolic syndrome, these 
include non-alcoholic fatty liver disease (24), gout (25), osteoporosis (26), and 
kidney stone disease (27). Both osteoporosis and kidney stone disease can result 
from renal tubular dysfunction caused by defective calcium and phosphate 
handling, which also cause hypercalciuria and hypophosphatemia (28–30). Bone 
demineralisation can lead to osteoporosis, which has been reported to cause over 
9 million bone fractures per year (31). Kidney stone disease has become 
increasingly common with a rise in global incidence and prevalence (27,32–34). 
Kidney stone disease was estimated to affect 11.62 % of the population in the 
U.K., as of 2011, and the number of hospital episodes of kidney stone disease 
has risen by 63 % over the last decade (35). The trend shown in these studies 
indicates that osteoporosis and kidney stone disease are major public health 
issues with high morbidity and mortality, and are a great burden on the healthcare 
system. 
1.1.3 Immunosuppressants and the metabolic syndrome 
The conventional immunosuppressive protocol after kidney transplantation is the 
use of the triple therapy approach, consisting of a calcineurin inhibitor (CNI), a 
steroid and a conjugating immunosuppressant (mycophenolate mofetil or 
azathioprine). Of the medications used in this regimen, CNIs are the most 
effective for preventing allograft rejection (36,37). Cyclosporine A (CyA) was the 
first effective CNI, and it revolutionised transplant medicine in the 1980s (38). 
This was followed by tacrolimus (FK506) in the 1990s, which has a lower acute 
rejection rate compared to CyA (39). CNIs have become the first line 
pharmacological agents recommended by the Kidney Disease Improving Global 
Outcome and they are prescribed to at least 96 % of transplant recipients, along 
with mycophenolate mofetil (40).  
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The use of this triple immunosuppressive regimen has led to an annual graft 
survival rate greater than 90 % (41). However, the metabolic side effects 
associated with immunosuppressants (e.g. hypertension, type 2 diabetes, 
dyslipidaemia, obesity and renal injury) (42,43), have become risk factors for 
morbidity and decreased graft function (44,45). Post-transplant metabolic 
syndrome occurs in 63 % of kidney transplant recipients (46) and 43 to 58 % of 
liver transplant recipients (45,47), accounting for 30 to 49 % of cardiovascular-
induced mortality in transplant recipients with functional grafts (48,49).  
1.1.4 The similarities between CNIs and thiazides-associated side effects, FHHt 
and Gitelman syndrome 
CNI-induced hypertension is a major clinical problem in transplant medicine. The 
prevalence of hypertension in renal transplant recipients ranges from 47 to 82 % 
in paediatric recipients and 50 to 80 % in adult recipients (50). CNI-induced 
hypertension is relatively common and is caused by abnormally avid reabsorption 
of sodium and chloride in the distal convoluted tubule (DCT), triggered by sodium 
chloride cotransporter (NCC) overactivity (51). Renal tubule dysfunction is 
another common adverse effect of CNI treatment. It is manifested by 
hyperkalaemia (52,53), metabolic acidosis (54,55), hypercalciuria (56,57), 
hypomagnesaemia (57,58), and hypophosphatemia (59). These side effects 
resemble the phenotype of FHHt, a rare autosomal dominant disorder 
characterised by NCC overactivity (60,61), suggesting that the pathogenesis of 
CNIs and FHHt may share similarities. 
Gitelman syndrome is also an inherited renal disorder that is a mirror-image 
syndrome to FHHt. The pathogenesis of Gitelman syndrome is the loss of NCC 
function (62), causing blood volume depletion with a resulting hyperreninemic 
hyperaldosteronism which leads to a hypokalaemic metabolic alkalosis. Gitelman 
syndrome is also associated with hypocalciuria and hypomagnesaemia (63). The 
resemblance between the handling of sodium, calcium and magnesium in 
Gitelman patients and patients taking thiazide diuretics (a class of 
antihypertensive medication that inhibits NCC), reflects the genetic and 
pharmacologic inactivation of the same transport protein (64).  
It is evident that CNIs cause electrolyte abnormalities through tubular 
dysfunction, however the pathogenesis remains unclear. The distal nephron is 
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responsible for the fine-tuning of electrolyte homeostasis, such as sodium and 
calcium reabsorption in the kidney, and this thesis will focus on investigating the 
pathogenesis of CNI-induced hypertension and hypercalciuria, salt and calcium 
handling in the distal renal tubules, and the pleiotropic effects of calcineurin. 
1.2 Blood pressure homeostasis 
Blood pressure is regulated by the cardiovascular, renal and neuroendocrine 
systems. These systems are interlinked through multiple feedback mechanisms 
and ensure both short and long-term maintenance of blood pressure and blood 
volume. 
1.2.1 Autonomic nervous system 
The cardiovascular and autonomic nervous system plays an important role in 
maintaining blood pressure via the baroreceptor reflex. There are two types of 
baroreceptors, located in different pressure receptor zones. High-pressure 
arterial baroreceptors are located at the aortic arch and carotid sinuses, and their 
activity is dependent on changes in arterial pressure. These baroreceptors are 
activated when blood pressure is increased and signals are sent to the rostral 
ventrolateral medulla, which trigger changes in heart contractions and systemic 
vascular resistance. Low-pressure baroreceptors are mainly situated in the venae 
cavae, pulmonary veins and atria, and are involved in blood volume regulation. 
They are activated during hypovolemia and induce activation of the RAAS. RAAS 
increases fluid retention in the kidneys and increases cardiac output, thereby 
restoring blood volume. The baroreceptor reflex provides a constant negative 
feedback loop to the brainstem and is the faster acting of the three systems that 
regulate blood pressure, the other two being the renal and endocrine system (65).  
1.2.2 Renin-angiotensin-aldosterone system 
The RAAS is part of the endocrine system that is involved in blood pressure 
regulation. It can be activated by a decrease in blood pressure, which is detected 
by stretch receptors in the vascular walls and by macula densa cells in the distal 
nephron, resulting in renin secretion by juxtaglomerular cells. Plasma renin 
cleaves angiotensinogen present in the plasma into angiotensin (ANG) I. 
Angiotensin-converting enzyme (ACE) expressed and secreted by endothelial 
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and renal epithelial cells, then converts ANGI to ANGII in the plasma. This causes 
arteriole constriction, leading to an increase in blood pressure, the stimulation of 
aldosterone secretion from the adrenal cortex, and the secretion of vasopressin 
from the posterior pituitary gland. Aldosterone binds to the mineralocorticoid 
receptors (MR) on the basolateral membrane of the DCT and increases sodium 
reabsorption. Further down the nephron, vasopressin binds to the arginine 
vasopressin receptor 2 (AVPR2) on the basolateral membrane of the collecting 
duct (CD) and causes water retention.  
1.2.3 Renal system 
In the kidney, salt and water reabsorption are key determinants of blood volume 
and therefore blood pressure regulation. Sodium reabsorption is regulated by the 
RAAS and is mediated by specific transporters: the sodium chloride potassium 
cotransporter 2 (NKCC2) in the thick ascending limb of loop of Henle (TALH), 
NCC in the DCT, and the epithelial sodium channel (ENaC) in the CD. More 
recently, sodium and chloride cotransport has been described in the CD by the 
paired action of pendrin and the sodium-driven chloride/bicarbonate exchanger 
(66). Throughout most of the nephron, water reabsorption is not regulated, 
instead it is reabsorbed through passive transport and coupled to solute 
reabsorption. In the CD, water reabsorption is regulated by vasopressin via 
AVPR2 and transported through aquaporin-2 (AQP2). When aldosterone binds 
to the MR at the DCT and vasopressin binds to AVPR2 at the CD, sodium chloride 
and water is reabsorbed into the bloodstream through these transport proteins 
(67). 
1.3 The Distal Convoluted Tubule 
The DCT is the shortest segment in the nephron, and lies immediately 
downstream of the macula densa and upstream of the CD. Even though the DCT 
is short in length, averaging 5 mm in humans (68), it plays an important role in 
electrolyte homeostasis. The DCT is responsive to hormonal stimulus and 
sensitive to changes in the concentration of electrolytes in the tubular fluid. The 
DCT is also where the fine-tuning of electrolytes occurs; this involves sodium and 
chloride reabsorption, potassium excretion and the handling of calcium, 
magnesium and acid-base. 
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1.3.1 Structure of the DCT 
The distal tubule is composed of a short segment of TALH, the DCT, which is 
divided into early (DCT1) and late DCT (DCT2), and the connecting tubule (CNT). 
Aldosterone is a mineralocorticoid secreted in response to volume depletion and 
hyperkalaemia. Aldosterone has a chemical structure similar to glucocorticoids, 
such as cortisol. Both aldosterone and cortisol bind to the MR expressed in the 
DCT with equal affinity and compete for binding (69). The 11-β hydroxysteroid 
dehydrogenase 2 (11HSD2) allows exclusive binding of aldosterone to the MR 
by metabolising cortisol to cortisone, which is an inactive form of cortisol that does 
not bind to the MR, thereby preventing cortisol from triggering its signal 
transduction pathways. 11HSD2 is not expressed in the cytoplasm of DCT1 cells, 
but is present in DCT2, the CNT and cortical CD, which comprises the 
aldosterone-sensitive distal nephron (70).  
Most electrolytes are reabsorbed through active transcellular transport in the DCT 
and require an electrochemical gradient to drive their entry via the apical 
membrane. The basolateral electrolyte pumps, such as the sodium-potassium 
adenosine triphosphatase (Na+/K+-ATPase) (71) and the plasma membrane 
calcium ATPase (PMCA), are responsible for providing this and require 
adenosine triphosphate (ATP) for their activity (72). These basolateral pumps 
consume a high amount of ATP, therefore DCT cells are packed with 
mitochondria that accumulate at the basolateral infoldings to accommodate for 
their needs (73). 
1.3.2 Salt handling by the DCT  
1.3.2.1 Sodium transport in the DCT 
The DCT reabsorbs 5 to 10 % of filtered sodium (74) primarily through NCC. NCC 
is an electroneutral cation-coupled chloride cotransporter that co-transports Na+ 
and Cl- in a 1:1 ratio and is expressed in the apical membrane of DCT cells 
(75,76). In DCT1, NCC is chiefly responsible for sodium chloride reabsorption, 
whereas both NCC and ENaC are responsible for this process in DCT2. ENaC is 
an electrogenic sodium channel expressed in the apical membrane of DCT2, 
CNT and CD. The uptake of sodium through ENaC causes lumen negativity, thus, 
the transepithelial voltage progressively decreases from DCT1 to the CD (77). 
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This provides an electrical gradient for chloride reabsorption or the promotion of 
potassium secretion via the renal outer medullary potassium channel (ROMK). In 
addition to NCC and ENaC, the electroneutral sodium/hydrogen exchanger 2 
(NHE2) is also expressed in the DCT. NHE2 transports Na+ into the cell and 
exports H+ into the urine. NHE2 is highly expressed in the apical membrane of 
TALH, DCT and CNT (78) and is activated when luminal bicarbonate levels are 
high, suggesting that NHE2 is primarily involved in the acidification of urine (79). 
The reabsorption of sodium largely relies on the basolateral Na+/K+-ATPase 
which maintains the sodium gradient (80). After sodium influx through NCC and 
ENaC, sodium is exported via Na+/K+-ATPase into the peritubular fluid. Na+/K+-
ATPase exports three Na+ out of the cell and imports two K+ into the cell, resulting 
in a decrease in voltage across the basolateral membrane (-60 mV to -90 mV). 
This is a driving force for sodium influx (71). In order for transcellular reabsorption 
of sodium to occur, the rate of sodium influx and efflux must reach equilibrium 
and basolateral potassium efflux plays an important role in this process (81) 
(Figure 1.3-1).  
1.3.2.2 Chloride transport in the DCT 
In addition to the driving force provided by Na+/K+-ATPase, the intracellular 
chloride concentration and basolateral extrusion of chloride also play an 
important role in sodium influx (82). Chloride depletion increases the activity of 
NCC, therefore the removal of excess intracellular chloride is crucial for 
maintaining a transmembrane sodium gradient (82). Chloride exits the cell 
through the chloride voltage-gated channel Kb (CLCNKB)-Barttin complex; the 
electrochemical gradient provided by Na+/K+-ATPase aids this process (83). 
Chloride can also exit the cell through the electroneutral potassium chloride 
cotransporter (KCC), which is stimulated by hypotonicity (84,85). There are four 
members of the KCCs and similar to NCC and NKCC2, they belong to the 
electroneutral cation-coupled chloride cotransporter family, SLC12. KCC1 is 
expressed ubiquitously and it is widely expressed in the DCT in humans (86), 
KCC2 is only expressed in the brain (87), KCC3 is expressed throughout the 
entire nephron (88) and KCC4 has been reported to be expressed in the rabbit 
DCT (84) and in α-intercalated cells of mice and rats (89)  
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In addition to transcellular reabsorption, 2 to 3 % of filtered chloride is reabsorbed 
into the peritubular fluid through paracellular transport. This process is dependent 
on ENaC, which provides a lumen-negative transepithelial voltage that drives this 
process, and claudins, which determine the paracellular permeability of ions (90). 
Claudins are a large family of transmembrane proteins that accumulate in the 
tight junctions at the apical side of the epithelium and connect adjacent epithelial 
cells. Different combinations of claudins define ion selectivity in different nephron 
segments. Claudin-1, -3, -4, -7, -8 and -14 are expressed in the DCT and claudin-
3, -10, -11 and -16 at the TALH (91). Claudins can function as both a barrier and 
a pore at the tight junctions. In vitro studies of claudin-4 and claudin-8 showed 
that when they are overexpressed, they act as a barrier (92,93), whereas under 
normal conditions, claudin-4 and claudin-8 interact with each other to assemble 
at the tight junction, where they act as a pore for chloride ions in the distal tubule 
(94) (Figure 1.3-1). 
1.3.2.3 Potassium transport in the DCT 
Approximately 10 % of filtered potassium reaches the DCT after it is reabsorbed 
in the proximal tubule and the loop of Henle. Potassium is secreted throughout 
the entire distal nephron and the rate of secretion significantly increases as the 
tubular fluid travels down the DCT, which leads to an increase in transepithelial 
voltage (95,96). Potassium secretion in the DCT is voltage and urinary flow- 
dependent, and is mediated by the inward rectifying potassium channel, ROMK, 
and the “big” K+ channel (BK) (97,98). ROMK is expressed in the apical 
membrane of the DCT2, the CNT and the cortical CD, and potassium excretion 
in these segments is primarily mediated by it. ROMK-mediated potassium 
excretion is dependent on the activity of ENaC. An electrogenic driving force is 
generated through ENaC-mediated sodium uptake, which depolarises the apical 
membrane, acting as a stimulus for potassium excretion through ROMK. BK is 
expressed throughout the entire distal nephron. Under normal urinary flow, BK 
remains relatively inactive, however when urinary flow increases, sheer stress on 
DCT cells increases, resulting in BK activation and an increase in the rate of 
potassium efflux. The underlying mechanism for BK activation is not clear, 
however increased intracellular calcium concentration and nitric oxide (NO) 
production was suggested to stimulate BK activity (99,100). 
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Basolateral potassium efflux plays an important role in sodium reabsorption in the 
DCT (81). Whilst Na+/K+-ATPase pumps potassium into the cell, in exchange for 
sodium, potassium is recycled back into the peritubular fluid via the inward-
rectifying potassium channel (KCNJ)10 (101,102), and to some degree KCC (84). 
KCNJ10 and KCC are not the only potassium transport proteins expressed at the 
DCT, KCNJ15 and KCNJ16 are also expressed at the basolateral membrane and 
are members of the inward-rectifying potassium channel (103). Expression of 
KCNJ10/16 heterotetramers have been reported in the distal nephron and they 
are thought to also play a role in the recycling of potassium (102) (Figure 1.3-1).   
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Figure 1.3-1 Sodium, chloride and potassium transport at the DCT. 
Na+/K+-ATPase provides the driving force for sodium influx through the apical 
membrane. This gradient is maintained by KCNJ10/16, and to some degree KCC, 
which recycles the potassium ions inside the cell. Sodium enters the DCT through 
the electroneutral NCC and the electrogenic ENaC. The electrochemical gradient 
generated by ENaC can promote chloride reabsorption through claudins or 
potassium secretion through ROMK. Chloride ions that entered the cell through 
NCC exit through CLCNKB-Barttin complex and KCC.  
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1.3.2.4 Regulation of sodium, chloride and potassium handling in the DCT 
Sodium and potassium handling at the DCT is regulated by dietary sodium 
chloride (104), dietary potassium (105,106) and hormonal stimuli, such as ANGII 
(107–109), aldosterone (110), vasopressin (111,112) and insulin (113,114). 
Distal sodium delivery is a major determinant of NaCl reabsorption in the DCT, 
the morphology of which changes in response to sodium delivery and adapts to 
the physiological needs (115). An increase in the surface area of the basolateral 
infoldings, mitochondrial size and activity of the Na+/K+-ATPase and NCC, 
enhances the capacity for sodium reabsorption in response to an increase in 
sodium delivery. When luminal sodium is high, NCC stored in vesicles are 
trafficked to the apical membrane to facilitate NaCl entry. The activity of NCC can 
be increased by phosphorylation to enhance NaCl influx; this process involves 
the STE20-like proline-alanine rich kinase (SPAK) and the oxidative stress 
responsive kinase 1 (OSR1) (82,116,117). Upstream regulators of SPAK and 
OSR1 are part of a family of serine/threonine kinases: ‘With No lysine (K)’ kinase 
(WNK) (118–120), and have been shown to regulate NCC both dependent and 
independent of SPAK and OSR1 (116,121). 
During hypovolemia, RAAS is activated, serum aldosterone and ANGII increase 
and act in synergy to increase sodium reabsorption. Increased serum 
aldosterone causes translocation of the MR at the DCT to the nucleus, inducing 
serum and glucocorticoid-regulated kinase 1 (SGK1) transcription. SGK1 is a 
serine/threonine kinase that is expressed ubiquitously. SGK1 is a transcriptional 
target of aldosterone and can be rapidly induced by aldosterone secretion in the 
distal nephron (122), regulating NCC, ENaC and ROMK through the WNK 
cascade (110,123). In addition, circulating ANGII binds to the ANGII receptors 
(ATR) expressed on the apical and basolateral membrane of the proximal 
convoluted tubule (PCT), the TALH and the DCT (124). ANGII increases sodium 
reabsorption and decreases potassium secretion through regulatory pathways 
involving the WNK kinases (109,125,126) and protein tyrosine kinase (PTK) 
(127–129) in the DCT (Figure 1.3-2). Details of the regulatory mechanism 
involved in sodium handling are discussed in Section 1.6.  
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Figure 1.3-2 RAAS regulation of sodium and potassium homeostasis in the 
DCT 
In the event of hypovolemia, the RAAS system is activated and serum ANGII and 
aldosterone are increased. ANGII causes sodium retention by increasing NCC 
and ENaC activity, and suppresses potassium excretion by decreasing ROMK 
membrane expression. Aldosterone causes sodium retention and potassium 
excretion by increasing the activity and surface abundance of NCC, ENaC and 
ROMK. 
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1.3.3 Divalent cation handling in the DCT 
1.3.3.1 Calcium transport in the DCT 
The DCT reabsorbs around 7 to 10 % of filtered calcium. Unlike other parts of the 
nephron that reabsorb calcium passively through claudins, calcium is exclusively 
reabsorbed through transcellular transport in the distal nephron (130). When 
filtered calcium arrives at the distal nephron, an electrochemical gradient drives 
calcium into the DCT cells through the apically expressed transient receptor 
potential cation channel subfamily V (TRPV) member 5 (131,132). Once calcium 
enters the cell, free calcium ions bind to the calcium binding protein calbindin-
D28K, which acts as a buffer for maintaining low intracellular calcium levels, and 
shuttles calcium to the basolateral membrane for extrusion (133,134). At the 
basolateral membrane, PMCA1, PMCA4 and the electrogenic sodium/calcium 
exchanger 1 (NCX1), which exports one Ca2+ in exchange for three Na+, are all 
involved in calcium efflux (135). 
TRPV6 is another apical calcium channel that is expressed in the DCT2, CNT 
and CD (136,137), but its expression is not exclusive to the nephron and has 
been detected in various tissues, including the intestines, pancreas and the 
stomach (138). TRPV6 is best known for its role in calcium absorption in the 
intestine (139). However, the regulatory pathway that governs TRPV6 activity is 
unclear in the kidneys, therefore it is widely accepted that TRPV5 is the primary 
calcium channel responsible for transcellular transport of calcium in the distal 
nephron. 
The transport mechanism of calcium differs between the early and late DCT. In 
the DCT, TRPV5 is absent in DCT1 (136,140) but NCX1 and PMCA are 
expressed at the basolateral membrane (140). This suggests that calcium may 
enter DCT1 through other calcium channels, possibly one similar to TRPV5 or 
through different subunits and isoforms of TRPV5 which have been previously 
identified in rats (132) and mouse DCT (mDCT) cells (141). Overall, TRPV5, 
calbindin-D28K, NCX1 and PMCA are most abundant at DCT2 and their 
expression progressively decreases down the nephron (140). This suggests that 
most of the calcium reabsorption occurs at DCT2 and lessens when calcium 
reaches the CNT, with negligible calcium transport at the cortical CD (140) 
(Figure 1.3-3).   
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Figure 1.3-3 A schematic diagram of calcium transport at the DCT 
In the DCT, calcium is driven into the cell through the apically expressed calcium 
channels, such as TRPV5. On entry, free calcium binds to calbindin-D28K to 
maintain low intracellular level of free calcium, and is shuttled across the cell to 
the basolateral membrane for extrusion. At the basolateral membrane, NCX1 and 
PMCA are involved in the efflux of calcium, providing an electrochemical gradient 
for calcium reabsorption.   
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1.3.3.2 Regulation of calcium handling in the DCT 
Active transport of calcium is dependent on the activity of NCX1 and PMCA in 
the basolateral membrane. The electrochemical gradient generated by NCX1 
accounts for 70 % of calcium uptake by TRPV5 and the remainder is provided by 
PMCA. Calcium reabsorption in the DCT is regulated by hormonal stimuli, such 
as parathyroid hormone (PTH), vitamin D3, β-glucuronidase klotho (klotho) and 
oestrogen. PTH is released during hypocalcaemia from the parathyroid gland and 
binds to its receptor, PTH 1 receptor (PTH1R), expressed in the apical and 
basolateral membrane of the glomerular podocytes, the PCT, the cortical part of 
TALH and the DCT (142). PTH stimulates the synthesis of 1,25-dihydroxyvitamin 
D3 (1,25(OH)2D3), the active form of vitamin D3. 1,25(OH)2D3 binds to its 
receptors, vitamin D3 receptors (VDR), that are abundantly expressed in the 
cytoplasm of the DCT and cortical CD in humans (143,144) and together with 
PTH increases calcium reabsorption in the DCT (131,145). Klotho is a 
transmembrane protein expressed abundantly at the distal nephron (146). It 
increases calcium uptake in the DCT by increasing the expression and activity of 
TRPV5 (147,148). In addition, klotho is also involved in regulating PTH secretion 
and 1,25(OH)2D3 synthesis through the fibroblast growth factor 23 (FGF23). 
These calcium regulatory mechanisms are interlinked and complex and involve 
several negative feedback loops. Details of these regulatory mechanisms are 
discussed in Section 1.9. 
1.3.3.3 Magnesium transport in the DCT 
Around 50 to 60 % of magnesium is reabsorbed via paracellular transport in the 
TALH (149), while, approximately 3 to 7 % of magnesium is reabsorbed through 
transcellular pathways in the DCT. In comparison to other electrolyte transport 
pathways, the mechanism for magnesium handling at the DCT is poorly 
understood. It is however known that the uptake of magnesium is at least in part 
mediated by the apically expressed TRP cation channel subfamily M member 6 
(TRPM6). TRPM6 is a voltage-driven cation channel that belongs to the same 
family as the TRPV channels. TRPM6 is expressed throughout the entire DCT 
and is permeable to divalent cations, such as magnesium and calcium. TRPM6 
has a 5-fold preference for magnesium ions over calcium ions, which allows it to 
preferentially function as a magnesium channel (150). Unlike other electrolytes, 
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the electrochemical gradient for magnesium influx is relatively low, therefore the 
activity of TRPM6 is primarily deterred by the voltage across the apical 
membrane.  
The fate of magnesium ions upon entry into the DCT is currently unknown, and a 
unique magnesium binding protein has yet to be identified. However, many 
different proteins, such as ATP, calbindin-D28K and parvalbumin are known to 
bind free magnesium non-specifically (150,151). These potentially have the 
capacity to shuttle magnesium ions across the cell, thereby aiding the 
transcellular reabsorption process. Free magnesium ions can also be absorbed 
by subcellular organelles and function as cofactors in cellular processes that 
occur in the mitochondria, nucleus and the endoplasmic reticulum (ER) (151).  
The mechanism for basolateral efflux of magnesium is currently unclear, but 
similar to the calcium extrusion system, a sodium/magnesium exchanger 
(152,153) and a plasma membrane magnesium ATPase (154) have been 
postulated as candidates involved (155). Other putative candidates, such as the 
ancient conserved domain-containing protein 2, cyclin M2, is expressed at the 
basolateral membrane of the distal nephron and has been suggested to act as a 
magnesium/ion transporter with magnesium sensing properties (156,157). 
Another candidate is the solute carrier family 41 member 1 (SLC41A1), which is 
a magnesium transporter expressed at the basolateral side of the DCT (158) 
(Figure 1.3-4).  
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Figure 1.3-4 A schematic diagram of magnesium transport at the DCT 
In the DCT, magnesium is known to be driven into the cell through TRPM6. It has 
been suggested that magnesium binding proteins, such as calbindin-D28K, ATP 
and parvalbumin, maintain intracellular magnesium levels and shuttle 
magnesium ions towards the basolateral membrane for extrusion. The 
basolateral magnesium efflux is currently unclear, but a sodium/magnesium 
exchanger and a plasma membrane magnesium ATPase, along with other 
candidates, such as cyclin M2 and SLC41A1 are thought to be involved.   
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1.3.3.4 Regulation of magnesium handling in the DCT 
The regulation of magnesium handling in the DCT is poorly understood. It has 
been suggested that the membrane voltage of the DCT plays an important role 
in magnesium handling, as shown in multiple disorders of renal magnesium 
wasting, including isolated dominant hypomagnesaemia (IDH) and the EAST 
syndrome (epilepsy, ataxia, sensorineural deafness and salt-wasting renal 
tubulopathy). The γ-subunit of Na+/K+-ATPase is mutated in IDH (159–161) and 
KCNJ10 is mutated in EAST syndrome (162). These mutations dysregulate the 
mechanism of potassium transport at the basolateral membrane of the DCT, 
resulting in altered basolateral membrane potential and a decrease in 
transcellular magnesium transport. 
In addition, changes in the apical membrane potential of the DCT may also 
regulate magnesium reabsorption. Shaker-related voltage-gated potassium 
channel (Kv1.1) is exclusively expressed at the apical membrane of DCT1 and 
excretes potassium into the tubular lumen. Potassium efflux through Kv1.1 
increases lumen positivity, providing a gradient for magnesium uptake through 
TRPM6. Inactivating mutations in Kv1.1 alter the apical membrane potential and 
diminish the driving force for magnesium influx, causing an autosomal dominant 
form of hypomagnesaemia (163,164). In addition to membrane potential, 
epidermal growth factor (EGF) is an important upstream regulator of magnesium 
homeostasis in the DCT (165). The precursor of EGF is highly expressed in the 
apical and basolateral membrane of the DCT and its extracellular domain can be 
cleaved to form EGF. EGF then binds to its receptors at the basolateral 
membrane and increases TRPM6 membrane expression by activating the 
extracellular signal-regulated kinase 1 and 2 (ERK1/2) (166,167).  
1.4 DCT Pathophysiology 
1.4.1 Gitelman syndrome 
Gitelman syndrome, also known as familial hypokalemia-hypomagnesaemia, is 
one of the most prevalent inherited renal tubular disorders, with a prevalence 
estimated at 1:40,000 (168). Gitelman patients are volume depleted with a 
resulting hyperreninemic hyperaldosteronism which causes a hypokalaemic 
metabolic alkalosis. Hypomagnesaemia and hypocalciuria are also associated 
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with Gitelman patients (63), causing symptoms such as muscle weakness, tetany 
and chondrocalcinosis. The clinical phenotype is generally quite mild and patients 
are often diagnosed in early adulthood, usually by incidental blood tests 
performed for another reason altogether (168). The clinical characteristics of 
Gitelman syndrome (hypokalaemic metabolic alkalosis) are very similar to Bartter 
syndrome. For this reason, Gitelman syndrome was initially considered as a 
milder subset of Bartter syndrome. 
1.4.1.1 Renal pathophysiology of Gitelman syndrome 
The cause of Gitelman syndrome was identified as inactivating mutations in NCC 
(62,169). NCC is encoded by SLC12A3 and over 140 SLC12A3 mutations (168) 
have subsequently been identified in Gitelman patients. Loss of function 
mutations in NCC lead to defective sodium reabsorption at the DCT and 
moderate intravascular volume contraction (168,169). This contraction activates 
the RAAS, resulting in increased sodium reabsorption in the cortical CD via ENaC 
and subsequent secretion of potassium and protons into the tubular lumen, 
causing hypokalaemia and metabolic alkalosis (168,169).  
1.4.2 Gitelman-like disorders  
1.4.2.1 Isolated dominant hypomagnesaemia  
IDH is a rare autosomal dominant disorder that comprises of magnesium wasting, 
tetany and epileptiform convulsions. The phenotype of IDH closely resembles 
Gitelman syndrome (168) as patients with IDH have low serum magnesium levels 
often accompanied with secondary hypocalciuria. IDH patients also have a 
normal acid-base status and renin and aldosterone activity (159,170). 
1.4.2.1.1 Renal pathophysiology of isolated dominant hypomagnesaemia 
The γ-subunit of Na+/K+-ATPase is mutated in IDH patients (159). The γ-subunit 
is not expressed ubiquitously like the α- and β- subunits of Na+/K+-ATPase, 
however, it is highly expressed in the TALH, the DCT and the CNT (171). A 
mutation at G41 of the γ-subunit prevents the subunit from trafficking towards the 
cell surface membrane and therefore alters the pump function (160,161). This 
dysregulates the basolateral membrane potential in the distal nephron, 
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eliminating transcellular magnesium transport, resulting in a reduction in 
magnesium reabsorption. 
1.4.2.2 EAST syndrome 
EAST syndrome is a rare autosomal recessive disorder comprises of epilepsy, 
ataxia, sensorineural deafness and salt-wasting renal tubulopathy. The salt-
losing tubulopathy phenotype of EAST syndrome, characterised by 
hypokalaemia, metabolic alkalosis, hypomagnesaemia and hypocalciuria, 
resembles that of Gitelman and Bartter syndromes (162,169). 
1.4.2.2.1 Renal pathophysiology of EAST syndrome 
The cause of EAST syndrome was identified as a loss of function mutation in 
KCNJ10 (162). KCNJ10 is expressed in the brain, eye, ear and at the basolateral 
membrane of the distal nephron and it is involved in a pump-leak coupling 
process that recycles potassium from the Na+/K+-ATPase back into the 
peritubular fluid (101). The KCNJ10 gene is located on chromosome 1q23.2 in 
humans and 14 pathogenic mutations have been identified (162). These 
mutations reduce KCNJ10 activity to less than 20 %, as reported in 
electrophysiological studies (172–174), reducing the efficiency of the recycling 
process and resulting in a reduction in Na+/K+-ATPase activity. 
1.4.3 Familial hyperkalaemic hypertension  
FHHt, also known as Gordon syndrome or pseudohypoaldosteronism type II, is a 
mirror-image syndrome to Gitelman syndrome. FHHt is a rare autosomal 
dominant disorder, caused by abnormally avid reabsorption of sodium and 
chloride in the DCT (175,176). FHHt is exquisitely sensitive to thiazide diuretics, 
which relieve hypertension, hyperkalaemia and the hyperchloraemic metabolic 
acidosis in FHHt patients (60). 
1.4.3.1 Renal pathophysiology of Familial hyperkalaemic hypertension 
FHHt sensitivity to thiazides prompted the hypothesis that FHHt is due to NCC 
overactivity (8). Increased activity of NCC increases sodium reabsorption, 
resulting in a lower concentration of sodium in the solute that arrives at the CD; 
this decreases sodium reabsorption via ENaC and consequently alters the Na+ 
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and K+ exchange system, resulting in the decrease in potassium secretion via 
ROMK. A number of gene products, such as the WNK kinases, Kelch-like protein 
3 (KLHL3) and Cullin-3 (CUL3), regulate NCC expression and activation. 
Pathogenic mutations responsible for FHHt have been identified in WNK1, 
WNK4, CUL3 and KLHL3 (7,8,61,177), the first of which to be identified were 
those in the WNK kinases (details of FHHt-type mutations are provided in 
individual sections). These mutations activate the WNK-NCC cascade increasing 
sodium chloride reabsorption. 
Alternatively, the pathophysiological mechanism of FHHt may also be caused by 
an increase in chloride reabsorption - a ‘chloride shunt’. Rapid chloride 
reabsorption at the distal nephron diminishes the luminal negative driving force 
that drives potassium secretion under normal physiological circumstances 
(178,179). Alternative anions (e.g. sulphate) can act as a substitute for chloride 
ions in the tubular fluid when luminal potential is too high. This will ameliorate the 
shunt effect restoring the lumen electrical difference that was required for K+ 
secretion (178). If the luminal potential is restored, paracellular chloride 
reabsorption will increase and thereby increase luminal sodium influx by ENaC in 
the CD and thus causing hypervolaemia (178,179).  
1.4.4 CNI-induced hypertension 
The phenotype of CNI-induced hypertension is very similar to that seen in FHHt, 
displaying hyperkalaemia and a variable metabolic acidosis. The prevalence of 
this phenotype seen in CNI-treated patients ranges from 16 to 30 % (180,181) 
with 33 % of FK506-treated patients exhibiting hypertension and hyperkalaemia. 
Hypertension may be more common in patients undergoing CyA treatment in 
comparison to FK506, but hyperkalaemia seems to be less common (182). 
1.4.4.1 Renal pathophysiology of CNIs 
CNIs cause hypertension by increasing NCC phosphorylation and the abundance 
of WNK3, WNK4 and SPAK (51). Calcineurin itself is a serine/threonine protein 
phosphatase (183). It has a number of transcriptional effects mainly due to the 
activation of the transcription factor NFATc (cytoplasmic nuclear factor of 
activated T cells), but it is the phosphatase activity that may act to inhibit the 
cascade of serine threonine kinases that ultimately control NCC activity.  
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1.5 NCC 
Pharmacological agents (CNI and thiazides) and renal tubular disorders 
(Gitelman syndrome and FHHt) have focused much attention on NCC and the 
molecular mechanisms of its regulation in the DCT. NCC belongs to the SLC12 
family, sharing ~50 % of its identity with NKCC1 and NKCC2 and ~25 % with 
KCC1 and KCC4. The SLC12A3 gene is located on chromosome 16q13 in 
humans (184), chromosome 8 in mice (185) and 19p12-14 in rats (186). 
SLC12A3 displays high (88.6 %) sequence conservation across humans, mice 
and rats. A sequence alignment of SLC12A3 in human, mouse, rat and rabbit 
showed that human NCC and rabbit NCC contain an additional 17-26 amino acids 
in the C-terminus; these residues encode for a protein kinase A (PKA) site that is 
not present in mouse NCC and rat NCC (187). The precise function of this site is 
unknown. 
1.5.1 NCC Structure  
NCC is a transmembrane protein made up of 1002-1028 amino acids. The 
predicted topology of NCC consists of a central hydrophobic region flanked by a 
short cytoplasmic N-terminus and a long cytoplasmic C-terminus. The central 
hydrophobic region defines NCC function and consists of twelve transmembrane 
(TM) domains that are connected by five intracellular and six extracellular loops 
(188,189). The N- and C-terminus, however, have been suggested to play no role 
in coding for key residues (190,191).  
1.5.2 Functional properties of NCC 
NCC forms a functional dimer (192) and is glycosylated at multiple residues. A 
study by Hoover et al. in 2003 focused on two N-linked glycosylation sites, N404 
and N424, found in extracellular loop-4 (188,189). The elimination of either 
glycosylation site resulted in NCC activity being reduced by over 50 %, and the 
removal of both sites exhibited a decrease in activity of greater than 95 % (188). 
Overall, elimination of these glycosylation sites in NCC has triple effects: a 
reduction of NCC abundance in the plasma membrane, a decrease in 
cotransporter activity, and an increase in chloride and thiazide affinity (188).  
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1.5.3 Thiazide and ion affinity  
1.5.3.1 Affinity controversy  
Several research groups have investigated the ion and thiazide binding affinity of 
NCC with contradictory results (188,190,193). Tran et al. (193) was the first to 
propose that chloride and thiazide compete for the same binding site on NCC, 
and that this binding site is separate from the sodium binding site. This theory 
was further supported by Hoover et al. (188) who showed that the elimination of 
residues N404 and N424 in extracellular loop-4 of rat NCC increased chloride 
and thiazide affinity, and reduced NCC activity (188). In contrast, the elimination 
of residues N404 and N424 in flounder NCC had no effect on thiazide affinity in 
the Moreno et al. 2006 study (190). This study also showed that chloride and 
thiazide binding is non-competitive as different flounder NCC TM domains are 
involved. This study demonstrated that the affinity-defining segment for chloride 
ions lies within TM domain-1 to domain-7 and the region that defines thiazide 
affinity lies within TM domain-8 to domain-12. Both of these regions were 
suggested to be involved in defining sodium affinity. As these studies presented 
conflicting evidence, Moreno et al. proposed that the effect of glycosylation site 
elimination on thiazide affinity is a unique feature of rat NCC, and that sodium 
and chloride binding may cause conformational changes in NCC, potentially 
resulting in reduced thiazide affinity (190).  
1.5.3.2 Chloride affinity 
A further study by Moreno showed that a highly conserved glycine residue 
(G264), located in TM domain-4, plays an important role in determining chloride 
affinity. A glycine to alanine single nucleotide polymorphism (SNP) caused a 50 
% reduction in NCC activity and an increased affinity for chloride ions (194). 
Cases where patients with Gitelman syndrome were identified with the G264A 
mutation exhibit a greater diuretic response when furosemide is administrated 
(195). Furosemide is a loop diuretic that inhibits NKCC2 activity in the TALH, 
therefore the exaggerated diuretic effect is possibly a result of increased salt 
delivery and impaired NCC function, causing a salt wasting phenotype.  
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1.5.4 Phosphorylation of NCC 
The activity of NCC is increased by SPAK and OSR1-mediated phosphorylation. 
SPAK and OSR1 phosphorylate NCC at T46, T55 and T60 in humans, 
homologous to T44, T53 and T58 in mice (116). 
1.6 WNK kinases 
The WNK kinases comprise a family of serine/threonine kinases, four members 
have been identified in humans, WNK1-4. The WNK kinases play a crucial role 
in sodium, chloride and potassium homeostasis by regulating cation-chloride 
cotransporters, which includes KCC4, NKCC2, NCC, ROMK and ENaC in the 
kidneys (89,196–198). The WNK kinases have been localised on the following 
human chromosomes: WNK1 at 12p13.33, WNK2 at 9q22.31, WNK3 at Xp11.22 
and WNK4 at 17q21.31. In the nephron, WNK1 and WNK3 are ubiquitously 
expressed in humans and mice (199,200). WNK4 is expressed in the cytoplasm 
and close to tight junctions of the DCT and the CD, and it is also expressed at a 
reduced level in the TALH (8,201). WNK2 expression has not been reported in 
the nephron.  
1.6.1 Structure of WNK kinases 
The catalytic domain of WNK kinases is located at the short N-terminus and lacks 
the typical lysine that is responsible for catalytic activity in other kinases (120). 
The four WNK kinases share 85-90 % sequence identity at the kinase domain 
(202). Within the C-terminus lies a highly conserved autoinhibitory domain, two 
coiled-coil domains and three proline-rich regions (203). The kinase domain also 
encodes for the substrate binding groove and two residues, V318 and A448 on 
WNK1 and their corresponding residues on the other WNK kinases, are 
suggested to play a role in defining substrate specificity (204) (Figure 1.6-1).  
The autoinhibitory domain in the WNK kinases share 46 % identity (203). It binds 
to the catalytic domain to suppress its kinase activity and two highly conserved 
residues, F524 and F526 are known to play an important role in this function 
(203,205). The activation of the WNK kinases requires the autoinhibitory domain 
to dissociate from the catalytic domain and autophosphorylation of a serine 
residue in the activation loop (203,205). Proline-rich motifs are involved in 
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interactions with SH3-domains of the target proteins (203). These motifs are 
highly conserved and mutations within this region in WNK1 and WNK4 are 
pathogenic in FHHt. WNK proteins tend to form oligomers and may function as a 
tetramer (206). WNK kinases are also capable of inhibiting each other, as shown 
in several in vitro studies where WNK4 was phosphorylated by WNK1 and WNK3 
(207), and that WNK4 can also inhibit WNK1 (205–207). 
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Figure 1.6-1 Alignment of the residues encoding for substrate specificity in 
WNK1-4 
In humans, WNK1-V318 and WNK1-A448, and the corresponding residues on 
the other WNK kinases, in the substrate binding groove define substrate 
specificity (red). The valine residue is conserved in WNK1-3, which suggests that 
WNK1-3 may share the same substrate. In contrast, the second residue is not 
conserved, potentially suggesting different substrates for each WNK kinases. 
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1.6.2 WNK1 
Amongst the four WNK proteins, WNK1 is the most comprehensively 
characterised. WNK1 is more commonly expressed in comparison to the other 
WNK proteins and it is most abundant in the kidneys, testis, heart and skeletal 
muscles (208). There are two different isoforms of WNK1, each of which has 
tissue-specific distributions, however both isoforms are expressed in the kidneys 
(208,209). L-WNK1 is the full-length WNK1 that is ubiquitously expressed and 
contains a catalytic kinase domain. Kidney specific-WNK1 (KS-WNK1) is a 
shorter transcript that lacks the kinase domain and is expressed in the DCT and 
CNT (201). Although KS-WNK1 is only expressed in the DCT and CNT, on a 
transcript level, KS-WNK1 expression is more abundant than L-WNK1 in these 
segments (208).  
WNK1 contains 28 exons and its isoforms arise from different promoters; KS-
WNK1 is generated from a promoter upstream of exon 4a, an exon that is 
different from exon 4 in L-WNK1 (208,209). KS-WNK1 encodes a 30 amino acid 
cysteine-rich region instead of the catalytic kinase domain (208,209). The 
remaining sequence of KS-WNK1, exon 5-28 is identical to L-WNK1 (208,209).  
1.6.2.1 Influence of aldosterone, dietary potassium and sodium on WNK1 
The activity of WNK1 is dependent on dietary potassium intake (210). Studies 
have shown that an increase in potassium loading increases the KS-WNK1 to L-
WNK1 ratio (97,201,211), an effect that is also shown in chronic aldosterone 
excess (201). Aldosterone increases KS-WNK1 expression and has no effect on 
L-WNK1, analysis of the two isoforms revealed a glucocorticoid response 
element that is present in KS-WNK1 but absent in L-WNK1 (209). This response 
element allows activated MR to bind, possibly initiating transcriptional activation. 
Extracellular sodium concentration has not been shown to have a significant 
effect on the activity of L-WNK1, however, a low sodium diet significantly 
decreased expression of KS-WNK1 (201). This effect seems to be in contrast 
with the effect shown in chronic aldosterone excess and it is possible that the 
decrease in KS-WNK1 during low sodium intake is a response induced by 
hypovolemia, causing hyperaldosteronism. Recently, Piala et al. showed that the 
activity of WNK1 is sensitive to chloride. Chloride ions directly bind to WNK1 at 
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the catalytic domain and inhibit WNK1 autophosphorylation and activation in vitro 
(212), however the effect of chloride in vivo requires further investigation. 
1.6.2.2 WNK1 and electrolyte transporters 
Although there is no evidence of a direct interaction between the two isoforms of 
WNK1 and NCC, WNK1 regulation of NCC is mediated by the other WNK kinases 
through protein interactions, as demonstrated in the heteromeric complex that 
comprises WNK1 and WNK4 (213), and the phosphorylation of WNK4 by WNK1 
(207). The two isoforms of WNK1 have opposing effects on WNK4-induced 
inhibition of NCC (214); L-WNK1 prevents WKN4-induced inhibition of NCC, 
whilst, KS-WNK1 exhibits a dominant-negative effect by interacting with the 
protein complex of L-WNK1, downregulating NCC (215).  
WNK1 also regulates ENaC and ROMK. L-WNK1 increases ENaC membrane 
abundance through SGK1 (216). L-WNK1 induces phosphorylation of SGK1, 
causing it to phosphorylate and inhibit Nedd4 (E3 ubiquitin-protein ligase). Nedd4 
is known to promote endocytosis of ENaC, which causes a reduction in ENaC 
expression in the apical membrane. Both aldosterone and insulin activate SGK1-
mediated phosphorylation of L-WNK1. This promotes endocytosis of ROMK, 
decreasing its membrane expression and suppressing potassium secretion 
(217). Similar to SGK1, KS-WNK1 is also targeted by aldosterone. Aldosterone 
stimulates KS-WNK1, causing it to inhibit SGK1-mediated phosphorylation of L-
WNK1, thereby suppressing ROMK endocytosis (97,197,211) (Figure 1.6-2). The 
activation of both SGK1 and KS-WNK1 may not have a net effect on the 
membrane abundance of ROMK, therefore it is possible that aldosterone may 
increase potassium excretion through ROMK by enhancing sodium reabsorption 
via ENaC. 
1.6.2.3 Phosphorylation of WNK1 
L-WNK1-T58 is a phosphorylation target of SGK1 and protein kinase B (AKT), 
and has been shown to reduce the membrane abundance of ROMK, decreasing 
potassium secretion (217). 
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Figure 1.6-2 WNK1 regulation of the distal sodium and potassium 
transporters 
L-WNK1 and KS-WNK1 have opposing effects on WNK4-induced inhibition of 
NCC. L-WNK1 prevents WNK4 from inhibiting NCC and KS-WNK1 reverses the 
L-WNK1-induced inhibition on WNK4. SGK1 and the L-WNK1/KS-WNK1 play an 
important role in the regulation of ENaC and ROMK. L-WNK1 induces 
phosphorylation of SGK1 and inhibits Nedd4-mediated ENaC endocytosis. Upon 
stimulation by aldosterone, SGK1 phosphorylates L-WNK1 and inhibits ROMK. 
This process is reversed by KS-WNK1, which is also a target of aldosterone. 
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1.6.2.4 FHHt type mutation in WNK1 
WNK1 has large intronic deletions at its first intron in FHHt patients, altering the 
ratio of KS-WNK1 and L-WNK1 (8). Xenopus Laevis oocyte studies of WNK1 
harbouring FHHt-mutations showed lower levels of KS-WNK1 and higher levels 
of L-WNK1 expression, causing an increase in NCC activity (218). Other in vivo 
studies in mouse models with a deletion of the first intron of WNK1 have also 
shown increased L-WNK1 expression in DCT, however an increase in KS-WNK1 
was also observed (219). KS-WNK1 exerts its inhibitory effect by interacting with 
the protein complex of L-WNK1, therefore the deletion of the first intron may alter 
this interaction, supressing the inhibitory effect of KS-WNK1. 
1.6.3 WNK3 
WNK3 is expressed throughout the whole nephron and also in the brain, lungs, 
liver and pancreas (220,221). WNK3 contains 24 exons and similar to WNK1, the 
distribution of WNK3 is dependent on its splice variants (221).  
1.6.3.1 WNK3 and the electrolyte transporters 
WNK3 has been proposed as a modulator of cell volume and intracellular chloride 
concentration due to its association with the cation-coupled chloride 
cotransporters. The net chloride movement in cells is suggested to rely on WNK3 
for its activation of NKCC1, NKCC2 (222) and NCC (200), and the inhibition of 
KCC1-4 through WNK3-induced phosphorylation. (200,223) This activation by 
WNK3 is associated with the phosphorylation of two highly conserved threonines 
in the N-terminus of NKCC1 and NKCC2: T184 and T189 (200,223). These 
threonines are also highly conserved in NCC. As NCC, NKCC1 and NKCC2 are 
stimulated by intracellular chloride depletion and are phosphorylated at the same 
residues, it has been suggested that NCC may also be phosphorylated by WNK3 
(82,116,119).  
Oocyte studies have shown that a catalytically inactive mutation at the kinase 
domain of WNK3 (WNK3-D294A) had an opposing effect on the cotransporters 
that are normally activated by WNK3. NKCC1, NKCC2 and NCC were strongly 
inhibited and all four KCCs became highly activated even under isotonic 
conditions (85,222). Studies of oocytes injected with KCC1, KCC3 and KCC4 
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suggest that their expression is affected by extracellular osmolarity. KCC1, KCC3 
and KCC4 activity increases in hypotonic conditions and decreases in isotonic 
environments (85,224). When KCC is activated it induces cell shrinkage which in 
turn activates NKCC1 and NKCC2 and inhibits KCC; the response is reversed 
during cell swelling (225). This activation of KCC can be prevented by calyculin 
A and cyclosporine A, suggesting that protein phosphatases 1 and 3 (i.e. 
calcineurin) are involved in this activation (222). 
1.6.3.2 WNK3 splice variants and NCC 
Splice variants of WNK3 have different cellular distributions. Two isoforms of 
WNK3 have been identified in the brain (B-WNK3-18a and B-WNK3-18b). Both 
isoforms contain exon 22, however B-WNK3-18a contains a shorter version of 
exon 18 compared to B-WNK3-18b, a difference of 47 amino acids. The structure 
of renal WNK3 (R-WNK3) differs from B-WNK3, as it lacks exon 22 and carries 
the shorter version of exon 18 (221,226). It has been suggested that WNK3 
increases NCC activity (200), and an oocyte co-expression study (226) 
demonstrated that different splice variants of WNK3 had opposing effects on 
NCC. NCC was activated by R-WNK3 by a SPAK-independent mechanism 
whereas B-WNK3 inhibited NCC through a SPAK- dependent mechanism. As B-
WNK3 expression has not been demonstrated in renal tissues, this interaction 
between WNK3 and NCC may be unique to brain cells.  
1.6.4 WNK4 
In comparison to the other WNK kinases, WNK4 is much smaller and only 
contains 19 exons. In addition to expression in the distal nephron (8,201), WNK4 
has also been detected in the pancreas, bile ducts, colon, brain, epididymis and 
skin (227,228). 
1.6.4.1 Influence of aldosterone, dietary potassium and sodium on WNK4 
The activity of WNK4 is dependent on dietary potassium levels. Low dietary 
potassium can cause hyperpolarisation of the basolateral membrane in the DCT 
and decrease the intracellular chloride concentration, resulting in activated 
WNK4-NCC cascade and increased sodium chloride retention (229). Similar to 
WNK1, dietary sodium has no significant effect on the expression of WNK4 (201). 
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Chronic aldosterone excess has no effects on the transcription of WNK4 (201), 
however, two putative negative glucocorticoid response elements have been 
identified at -285 and -337 in the promoter of human WNK4 gene (230). 
Stimulation of the glucocorticoid receptors has been shown to decrease WNK4 
transcription in vivo and in vitro, which suggests that WNK4 is sensitive to 
mineralocorticoids and glucocorticoids, and that the mechanism underlying 
aldosterone regulation of WNK4 may involve other factors to allow tight regulation 
of WNK4 (230,231).  
1.6.4.2 WNK4 and electrolyte transporters 
Studies investigating the effect of WNK4 on NCC have generated conflicting 
results. WNK4 has been reported to both inhibit (121,232–234) and activate NCC 
through SPAK/OSR1 (119,120,235). In vivo, WNK4 was reported to activate NCC 
through SPAK/OSR1 (235). In vitro, WNK4 was shown to inhibit NCC by 
decreasing its surface expression and enhancing its degradation; this was 
demonstrated in Xenopus laevis oocytes (121,214) and epithelial cells (236).  
WNK4 inhibits NCC, ENaC and ROMK through different mechanisms. Using 
oocytes co-expressing a kinase-inactive WNK4 (WNK4-D318A) and different ion 
transporters, several studies have shown that the inhibition of NCC is dependent 
on the kinase domain of WNK4 (233,237), whereas the inhibition of ENaC (238) 
and ROMK (237) by WNK4 is kinase independent (238). Although ENaC 
inhibition is independent of the kinase domain, the inhibitory effect is still 
alleviated by the FHHt-causing mutation in the kinase domain of WNK4 (238). 
Other ion transport proteins modulated by WNK4 include claudin-4 and NKCC2 
in the kidney, NKCC1 in the vasculature and the ubiquitous KCC. Claudin-4 is a 
mediator of paracellular Cl- permeability at the distal nephron and has been 
shown to be phosphorylated by WNK4, resulting in the increase in paracellular 
Cl- flux (239).  
1.6.4.2.1 Hyperkalaemia and WNK4 regulation of ion transporters 
Hyperkalaemia induces the release of aldosterone and inhibits the secretion of 
renin. Aldosterone may influence WNK4 in regulating NCC, ENaC and ROMK via 
SGK1. SGK1 inhibits WNK4-induced lysosomal degradation of NCC and 
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activates a series of phosphorylation in the WNK-NCC cascade, resulting in an 
increase in the surface expression and the activity of NCC (110). SGK1 increases 
ENaC (240) and ROMK (129,241) activity through direct phosphorylation or by 
alleviating WNK4 inhibition (123). An increase in the activity of ENaC generates 
lumen negativity, thereby providing a driving force for potassium secretion into 
the tubular lumen. (Figure 1.6-3).  
1.6.4.2.2 Hypovolemia and WNK4 regulation of ion transporters 
ANGII and aldosterone are released in response to RAAS activation during 
intravascular volume depletion. ANGII increases sodium retention by increasing 
the abundance of NCC on the apical membrane (108), WNK4-mediated NCC 
phosphorylation (107,242), and ENaC channel open probability (125,243). ANGII 
inhibits ROMK by activating PTK. PTK phosphorylates ROMK, decreasing its 
membrane abundance (127,128), and reverses the effect of SGK1 on WNK4-
induced ROMK inhibition (129), resulting in a decrease in potassium secretion 
(Figure 1.6-3).  
1.6.4.3 Phosphorylation of WNK4 
In vivo studies revealed that increased serum aldosterone stimulates SGK1 and 
WNK1 to phosphorylate WNK4 at S1169 in mice, a residue that is homologous 
to S1190 in humans (110,123) and is responsible for reversing the inhibitory 
effect of WNK4 on NCC, ENaC and ROMK once phosphorylated. 
Phosphorylation of WNK4 by WNK3 has also been reported in vitro (207); at both 
the N and the C-terminus, however, these phosphoresidues were not mapped. 
WNK3 competes with WNK4 in NCC regulation, therefore it is possible that 
phosphorylation of these residues is responsible for WNK4 interaction and 
inhibition (207). Increased circulating ANGII stimulates protein kinase C (PKC) 
and PKA-induced phosphorylation of WNK4 at S64 and S119. Phosphorylation 
of these residues increases WNK4 autophosphorylation, enhancing its kinase 
activity, increasing SPAK phosphorylation (244).  
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Figure 1.6-3 Influence of hypovolemia and hyperkalaemia on WNK4-
modulated ion transporters 
Hypovolemia activates the RAAS and increases serum ANGII and aldosterone. 
Hyperkalaemia induces the release of aldosterone and decreases renin 
secretion. Increased serum aldosterone induces SGK1-mediated 
phosphorylation of WNK4 and reverses its inhibitory effect on NCC, ENaC and 
ROMK, promoting sodium reabsorption and potassium secretion. ANGII 
increases WNK4 and SPAK dependent phosphorylation of NCC and increases 
the activity of ENaC. ANGII signals PTK to phosphorylate ROMK and reverses 
the inhibitory effect of SGK1 on WNK4-induced ROMK endocytosis, resulting in 
reduced ROMK membrane abundance.  
61 
 
1.6.4.4 FHHt-type mutation in WNK4 
It was shown that three FHHt genetic pedigrees were harbouring WNK4 
mutations at E562K, D564H and Q565E (8). In vivo studies on transgenic mice 
WNK4 D561A/+, which have a FHHt phenotype, were responsive to thiazide 
treatment, and displayed increased phosphorylation of SPAK and increased 
abundance of NCC-pS71 in the apical membrane of DCT (234).  
FHHt-type mutations also alleviate the basal inhibitory effect of WNK4 on ENaC 
(238) but enhances ROMK inhibition (123). Enhanced inhibition of ROMK is not 
dependent on the kinase activity of WNK4, instead it is dependent on clathrin-
mediated endocytosis (237). Furthermore, FHHt mutations at the catalytic site of 
WNK4 increase phosphorylation of claudin-4. This increases the Cl- permeability 
at the tight junctions of the DCT and possibly creating a ‘chloride shunt effect that 
drives sodium chloride into the cell via NCC (196,239).  
1.6.5 SPAK/OSR1 
SPAK and OSR1 both belong to the STE20 kinase subfamily and have similar 
structures. Key features include a catalytic domain at the N-terminus, two highly 
conserved serine-motifs and a conserved C-terminus (120). The C-terminus is 
involved in recognising the SPAK/OSR1 binding motifs, Arg-Phe-Xaa-Val/Ile 
(RFx[V/I]), expressed on the upstream regulators and downstream targets of 
SPAK/OSR1 and allows SPAK/OSR1 to interact with them (119,245,246). In 
addition to the core domains, an alanine and proline rich region is located at the 
N-terminus of SPAK, however, this region is not present in OSR1 (120). 
SPAK and OSR1 participate in the regulation of NCC by the WNK cascade. 
SPAK/OSR1 phosphorylate and activate NCC by binding to the RFx[V/I] motifs 
at the cytoplasmic N-terminus of NCC; an important interaction that maximises 
phosphorylation (116). SPAK and OSR1 phosphorylate NCC at T46, T55 and 
T60 in humans (homologous to T44, T53 and T58 in mice), increasing the activity 
of NCC (116,117). In addition to their role in NCC regulation, SPAK/OSR1 also 
regulate other members of the SLC12 family, such as NKCC1 (247,248) and 
NKCC2 (249). SPAK/OSR1 were also proposed to play additional roles as 
scaffolding proteins. A study by Piechotta et al. (248) showed that both 
SPAK/OSR1 interact with different cytoskeletal components and bring them into 
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proximity with cotransporters of interest in the presence of a stress stimuli. 
Whether this mechanism is induced by upstream regulators or sensing properties 
of these kinases are unclear (248).  
1.6.5.1 Phosphorylation of SPAK and OSR1 
WNK1 and WNK4 activate SPAK and OSR1 by phosphorylating T233 and T185 
in the catalytic domain (118–120). WNK1 and WNK4 also phosphorylate SPAK 
at S373 and OSR1 at T325 in the conserved serine-motifs, however, the 
functional role of this residue is unclear (118–120). WNK3 also phosphorylates 
SPAK/OSR1 at the serine residue in vitro, however, phosphorylation of T233 and 
T185 has not been reported (119). The structure and functional properties of 
SPAK and OSR1 are similar, however, it has been reported that WNK1 and 
WNK4 phosphorylate OSR1 at a higher efficiency than SPAK. This is possibly 
due to the presence of a proline and alanine rich motif located at the N-terminus 
and a ~40 amino acid spanning region at the C-terminus of SPAK, both of which 
may affect protein conformation and its interaction with the WNK kinases (120).  
1.6.5.2 Evolution of SPAK and OSR1 
SPAK/OSR1 share 68 % identity in their amino acid sequences, with 89 % identity 
in the catalytic regions. SPAK and OSR1 (250) belong to one of the four groups 
of STE20 family kinases. In this family the STE20 Related Adapter (STRAD) α 
and STRADβ kinases (251,252) resemble SPAK and OSR1. STRADα and 
STRADβ share ~30 % identity with the catalytic regions of SPAK and OSR1 
(120). STRADα and STRADβ are catalytically inactive pseudokinases that form 
a complex with the ubiquitously expressed tumour suppressor liver kinase B1 
(LKB1) and the mouse embryo scaffolding protein (MO25) (LKB1-STRAD-MO25) 
(251,252). LKB1-STRAD-MO25 is involved in the phosphorylation of T172 in the 
α-subunit of the adenosine monophosphate-activated protein kinase (AMPK) 
(253,254), which is involved in regulating glucose, lipid and cholesterol 
homeostasis and is a major drug target for diabetes (255). A recent study by 
Filippi et al. demonstrated that MO25 is an upstream regulator of SPAK/OSR1 
(256). The interaction between MO25 and SPAK/OSR1 is unclear, however, it 
has been suggested that MO25 may activate SPAK/OSR1 in a similar fashion to 
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STRAD. As a result of SPAK/OSR1 activation, MO25 is able to induce 
phosphorylation of NCC, NKCC1 and NKCC2 (256).  
1.6.6 KLHL3 & CUL3 
KLHL3 is an adaptor protein of the BCR (Broad-Complex, Tramtrack and Bric a 
brac-Cullin3-RING-box protein 1) E3 ligase complex that is involved in mediating 
the binding of substrates to the E3 ligase complex. KLHL3 has a Broad-Complex, 
Tramtrack and Bric a brac domain at the N-terminus, a BACK domain and six 
kelch motifs at the C-terminus (257). Kelch motifs are evolutionally conserved 
and involved in many cellular processes, such as cell morphology, gene 
expression and protein interactions (258). CUL3 is the core component of the 
BCR E3 ligase complex. Together with KLHL3, they interact and form a CUL3-
KLHL3 E3 ligase complex that mediates and promotes substrate ubiquitination. 
This complex binds to WNK1 and WNK4, targeting them to proteasomal 
degradation and subsequently regulating NCC through the WNK ubiquitination 
(259,260). In addition, there is evidence that KLHL3 is co-expressed with NCC 
and that it directly downregulates NCC expression at the DCT by recruiting NCC 
for proteasomal degradation (177). 
1.6.6.1 Phosphorylation of KLHL3 and CUL3 
Increased ANGII and vasopressin induces PKA and PKC-mediated 
phosphorylation of KLHL3 at S433. This prevents KLHL3-WNK4 interaction and 
ubiquitination, resulting in an increase in WNK4 protein abundance (261,262).  
1.6.6.2 FHHt-type mutation in KLHL3 and CUL3 
KLHL3 and CUL3 mutations were identified in 63 % of FHHt pedigrees that did 
not have WNK mutations (263). Mutations in KLHL3 can inhibit its ability to bind 
to CUL3, WNK1 and WNK4, resulting in a decrease in proteasomal degradation 
of the WNK kinases, thereby increasing NCC activity (264–266). Multiple rare 
non-synonymous exonic SNPs in KLHL3 have been shown to cause FHHt; of 
which the most commonly found mutation in the KLHL3 protein is L387P. All of 
these polymorphisms lie within the evolutionarily conserved kelch-repeat 
domains (263). All CUL3 mutations are intronic and cause defective splicing of 
exon 9. The precise pathogenesis of CUL3 mutations is unclear, but ultimately it 
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results in increased WNK1, WNK4 and NCC abundance (263,267). Other 
mutations identified in FHHt patients, such as WNK4-E562K, WNK4-Q565E and 
mutations in the non-catalytic region of WNK1, WNK1 Q479-N667, lead to 
decreased interactions with KLHL3 and the abrogation of the ubiquitination 
process, which results in an increase in the abundance of WNK1 and WNK4 
(264). 
1.7 WNK-NCC cascade 
The WNK kinases control NCC membrane abundance and its activity through 
SPAK and OSR1. The WNK cascade is complex and involves a sequential 
inhibitory cascade between various WNK proteins. Several research groups have 
proposed models of the WNK-SPAK-NCC cascade, however, a unifying model 
has yet to be generated. 
1.7.1 The orthodox model of the WNK-NCC cascade 
The orthodox model of the WNK-SPAK-NCC cascade arose from the 
understanding of FHHt-type mutations in the WNK kinases. KS-WNK1 is the 
predominant form of WNK1 in the nephron that lacks the ability to phosphorylate 
proteins. KS-WNK1 inhibits L-WNK-1 and L-WNK1 inhibits WNK4, which 
supresses WNK4-induced lysosomal degradation of NCC (121,214). WNK3 and 
WNK4 mutually inhibit one another and whilst WNK3 is stimulating the trafficking 
of NCC to the apical membrane, WNK4 inhibits it (207). L-WNK1 and WNK4 both 
phosphorylate and activate SPAK/OSR1 (118–120). An increase in SPAK/OSR1 
activity increases NCC phosphorylation and its transport activity (116,117). The 
ratio of KS-WNK1 to L-WNK1 and WNK3 to WNK4 are tightly controlled by 
ubiquitination. KLHL3 binds to L-WNK1 and WNK4 and these are subject to 
degradation through the KLHL3-CUL3 E3 ligase complex (259) (Figure 1.7-1). 
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Figure 1.7-1 The orthodox model of the WNK-NCC cascade 
The WNK kinases regulate the membrane expression and activity of NCC. KS-
WNK1 inhibits L-WNK-1 and L-WNK1 inhibits WNK4. WNK3 and WNK4 mutually 
inhibit one another and whilst WNK3 is stimulating the trafficking of NCC to the 
apical membrane, WNK4 is inducing lysosomal degradation of NCC. L-WNK1 
and WNK4 both phosphorylate and activate SPAK/OSR1. Activated SPAK/OSR1 
increases NCC phosphorylation and enhances its transport activity. KLHL3 binds 
to L-WNK1 and WNK4 and these are subject to degradation via the KLHL3-CUL3 
E3 ligase complex.   
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1.7.2 The effect of FHHt on the WNK-NCC cascade  
FHHt is caused by the overactivity of NCC, resulting in increased sodium and 
chloride reabsorption in the DCT. In FHHt patients, mutations in KLHL3 and CUL3 
prevent the interaction between KLHL3 and the WNK kinases, and the formation 
of the E3 ubiquitin ligase. This means that L-WNK1 and WNK4 are not 
ubiquitinated and accumulate in the cytosol, which activates SPAK/OSR1, 
resulting in increased NCC phosphorylation. In patients with WNK1 mutations, 
the ratio of L-WNK1 and KS-WNK1 is altered and L-WNK1 protein expression 
increases. This enhances the basal inhibitory effect of L-WNK1 on WNK4, and 
activates SPAK/OSR1, increasing phosphorylation of NCC. In patients with FHHt 
mutations in WNK4, WNK4 becomes a NCC activator and its degradation by the 
E3 ubiquitin ligase complex is prevented. This increases SPAK/OSR1 activity, 
causing an increase in NCC phosphorylation and activity, resulting in an increase 
in sodium chloride reabsorption (Figure 1.7-2). 
1.7.3 The effect of CNIs on the WNK-NCC cascade 
Similar to FHHt-induced hypertension, CNI causes hypertension by activating the 
WNK-NCC cascade (51). CNI increases the protein abundance of WNK3, WNK4, 
SPAK and phosphorylated NCC (51) and its effects on WNK1 is unclear. 
Increased expression of WNK3 causes an increase in the trafficking of NCC to 
the apical membrane. WNK4 phosphorylates and activates SPAK/OSR1, 
increasing NCC phosphorylation and cotransporter activity (51), causing an 
increase in sodium and chloride reabsorption (Figure 1.7-3).  
In addition to increased sodium chloride reabsorption, CNIs also alter potassium, 
calcium, magnesium and acid-base homeostasis. As calcineurin is a protein 
phosphatase, and CNIs have been shown to alter the activity of serine/threonine 
kinases and dysregulate the phosphorylation status of proteins, this suggests that 
phosphorylation may be a key post-translational modification determining the 
CNI-induced activity of electrolyte transporters. 
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Figure 1.7-2 FHHt-mutations in the WNK-NCC cascade 
Under normal conditions, L-WNK1 is a positive regulator of NCC and inhibits 
WNK4-induced inhibition of NCC. Both L-WNK1 and WNK4 bind to the CUL3-
KLHL3 E3 ubiquitin ligase complex and are subjected to degradation. a) FHHt 
mutations in KLHL3 and CUL3 prevent the formation of the E3 ubiquitin ligase 
complex and the interaction between KLHL3 and the WNK kinases. This leads to 
L-WNK1 and WNK4 accumulation, activating SPAK/OSR1 and increasing NCC 
phosphorylation. b) FHHt mutations in WNK1 increase L-WNK1 protein 
expression. L-WNK1 inhibits WNK4 and activates SPAK/OSR1, increasing 
phosphorylation of NCC. c) FHHt mutations in WNK4 convert WNK4 to a NCC 
stimulator and prevent WNK4 from degradation by the E3 ubiquitin ligase 
complex. An Increase in WNK4 phosphorylates SPAK/OSR1 and increases NCC 
phosphorylation. 
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Figure 1.7-3 The effect of CNIs on the WNK-NCC cascade 
CNIs activate NCC through the increase in WNK3, WNK4 and SPAK activity. The 
interactions between calcineurin and the WNK kinases are unclear, but since 
CNIs have a positive effect on WNK3 and WNK4, calcineurin may act as their 
negative regulator under normal conditions. An increase in WNK3 expression 
stimulates the trafficking of NCC to the apical membrane and the increase in 
WNK4 phosphorylates and activates SPAK/OSR1. An increase in SPAK/OSR1 
activity increases NCC phosphorylation, and NCC transport activity is enhanced.  
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1.8 Calcineurin 
Calcineurin is a serine/threonine protein phosphatase that is calcium and 
calmodulin dependent. Calcineurin is best known for its role in the immune 
system, stimulating the expression of cytokines involved in proliferation and 
differentiation of leukocytes. Calcineurin functions as a heterodimer that is 
composed of calcineurin A, a catalytic subunit that is ~60 kDa in size and 
calcineurin B, a regulatory subunit of ~19 kDa. These two calcineurin subunits 
are ubiquitous in mammalian tissues, highly concentrated in the brain (268) and 
notably present in B and T lymphocytes, kidneys (269), pancreas (270), sperm 
(271) and smooth muscle cells (272). The isoforms of calcineurin subunits and 
the abundance of these isoforms can be tissue specific (273,274). 
1.8.1 Structure 
Calcineurin A encodes a large catalytic domain at the N-terminus and three 
regulatory domains that encode for a calcineurin B binding domain, calmodulin 
binding domain and an autoinhibitory domain at the C-terminus (268,272) (Figure 
1.8-1). Calcineurin A consists of three highly conserved isoforms: α, β and γ. All 
three isoforms share homology with other serine/threonine protein phosphatases 
with a unique C-terminus regulatory domain (275).  
Calcineurin B has highly conserved isoforms: the ubiquitously expressed 
calcineurin B α and calcineurin B β, that is only expressed in the testes (276). 
Calcineurin B encodes for four EF-hand motifs and each EF-hand motif binds to 
one calcium ion (277). These EF-hand motifs exhibit different affinities; the two 
EF-hand motifs at the N-terminus have lower affinities for calcium than the two 
encoded at the C-terminus (278). These EF-hand motifs also play an important 
role in stabilising the heterodimeric structure of calcineurin, mediating the binding 
of calmodulin to calcineurin A and the stimulation of calcineurin when free calcium 
ions are bound.  
1.8.2 Calmodulin 
Calmodulin is a highly-conserved calcium sensor and shares 35 % homology with 
calcineurin B. Calmodulin is expressed in all eukaryotic cells and is involved in a 
range of cellular processes, such as cell proliferation, motility and apoptosis. 
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Similar to calcineurin B, calmodulin also has two globular domains located at the 
N- and C-terminus and each of these globular domains contains two EF-hand 
motifs. In contrast to calcineurin B, calcium ions bind to the EF-hands at the N-
terminus at a higher efficiency than to the motifs at the C-terminus, giving 
versatility for calmodulin to adapt to different levels of intracellular calcium 
(279,280). The binding of calcium alters the interhelical angles in the EF-hands, 
exposing a hydrophobic region that allows calmodulin to interact with the 
canonical calcium loaded calmodulin binding sequences on the target proteins.  
1.8.3 Activation of calcineurin 
Calcium and calmodulin are essential for the activation of calcineurin. This 
process is dependent on calcineurin B, calcium and calmodulin, and involves 
conformational changes of calcineurin A (281). The autoinhibitory domain of 
calcineurin binds to the catalytic domain of calcineurin A to prevent activation 
(282). In the event of high intracellular calcium, free calcium binds to calcineurin 
B, causing it to bind to calcineurin A triggering a conformational change and 
exposing the calmodulin binding site (283). The subsequent binding of calmodulin 
disrupts the association between the autoinhibitory domain and the catalytic site 
on calcineurin A, stimulating phosphatase activity (281) (Figure 1.8-1). 
1.8.4 Function 
Calcineurin plays an important role in the activation of the immune response. This 
begins with the recognition of antigens by T cell antigen receptors, which causes 
the release of calcium from intracellular stores and triggers calcium influx, 
resulting in increased intracellular calcium and calcineurin activation. Calcineurin 
subsequently dephosphorylates and activates NFATc, resulting in NFAT 
translocation to the nucleus where it binds to the DNA (Deoxyribonucleic acid), 
causing an increase in transcriptional activation of the cytokines, including 
interleukin (IL) -2, IL-3, IL-4 and tumour necrosis factor-α (TNF-α) (284). 
Together, the expression of these cytokines stimulates the proliferation and 
differentiation of leukocytes, inflicting an immune response. 
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Figure 1.8-1 Calcineurin activation 
Free intracellular calcium ions bind to both calmodulin and calcineurin B. Calcium-activated calcineurin B binds to calcineurin A and exposes 
the calmodulin binding site. Calmodulin then binds to the calcineurin A-B complex and disrupts the association between the autoinhibitory 
domain and the catalytic site on calcineurin A, stimulating phosphatase activity. 
7
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1.8.5 The association between calcineurin and the RAAS 
Calcineurin is ubiquitous and pleiotropic. Calcineurin plays a regulatory role in the 
RAAS by regulating aldosterone synthase (CYPIIB2) expression (285,286). 
ANGII-induced expression of CYPIIB2 and aldosterone secretion in 3T3-L1 
adipocytes are dependent on the calcineurin-NFAT signalling pathway (285,286). 
ANGII was able to stimulate calcineurin activity and induce NFAT translocation 
to the nucleus (287,288). CNIs and NFAT inhibitors were shown to suppress 
ANGII-induced aldosterone secretion.  
1.8.6 Immunophilins  
Immunophilins are sequence conserved molecular chaperones that exhibit 
peptidylprolyl cis-trans isomerase (PPIase) activity. PPIase catalyses the cis-
trans isomerisation of peptide bonds at proline residues of proteins to facilitate 
protein folding and also its own folding process (289). The two main families of 
immunophilins are the cyclosporine-binding cyclophilins and the FK506 binding 
proteins (e.g. FKBP12). As their name suggests, cyclophilins bind to CyA and 
FKBPs bind to FK506 (as well as rapamycin) (290). These immunosuppressants 
bind to their immunophilins with high affinity, form complexes with them and 
inhibit their PPIase activity.  
1.8.7 Calcineurin inhibitors  
Calcineurin inhibitors, such as CyA and FK506, are immunosuppressants widely 
used in transplant medicine to prevent rejection and also in treating autoimmune 
diseases (291). CyA and FK506 form complexes with cyclophilin A and FKBP12 
respectively (290), and adopt different signalling mechanisms. CyA-cyclophilin 
and FK506-FKBP12 complexes bind to calcineurin, suppress its phosphatase 
activity and prevent the dephosphorylation of NFATc. This prevents the 
translocation of NFATc into the nucleus, and as a result, the signal transduction 
required for an immune response is suppressed.  
Rapamycin is a macrolide produced by Streptomyces hygroscopicus that is used 
to prevent organ transplant rejection. Rapamycin is not a CNI, however its mode 
of action is similar to FK506, which involves forming a complex with FKBP12. The 
rapamycin-FKBP12 complex binds to and inhibits the mechanistic (or 
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mammalian) Target Of Rapamycin (mTOR), also known as FKBP-rapamycin-
associated protein and inhibits the secretion of IL-2 (292) (Figure 1.8-2). 
1.8.7.1 Other side effects of CNIs 
Hyperkalaemia (52,53), hypercalciuria (56,57), hypomagnesaemia (57,58), 
metabolic acidosis (54,55) and hypophosphatemia (59) are also common side 
effects of CNIs and are risk factors for morbidity and decreased graft function 
(44,45).  
Hyperkalaemia can be life-threatening especially in patients taking 
antihypertensive medications, such as ACE inhibitors and ANG receptor 
blockers. Hyperkalaemia occurs in 5 to 40 % of CNI-treated patients (52,53) and 
it is characterised by inefficient potassium excretion. CNI reduces the surface 
expression of ROMK and promotes paracellular chloride reabsorption through the 
WNK kinases (293). Increased chloride reabsorption reduces lumen negativity, 
thus reducing the driving force for potassium secretion. A low potassium diet, loop 
diuretics or thiazides and sodium bicarbonate supplements have been 
recommended for treating CNI-induced hyperkalaemia (294).  
CNI-induced hypercalciuria is characterised by urinary calcium wasting and is 
associated with increased bone-turnover and osteoporosis. CNIs are thought to 
prevent calcium reabsorption by reducing TRPV5 and calbindin-D28K expression 
in the DCT (51,57). Thiazide treatment can lower urinary calcium excretion by 50 
% and is the recommended treatment for CNI-induced hypercalciuria (295). CNI-
induced hypomagnesaemia is caused by inefficient magnesium reabsorption in 
the distal tubules, possibly induced by lowered TRPM6 expression (57).  
Metabolic acidosis is generally asymptomatic in CNI-treated patients. It occurs in 
13 to 17 % of CNI-treated patients (54,55,296) and is characterised by 
bicarbonate wasting and inefficient excretion of hydrogen ions (54). Similar to 
metabolic acidosis, hypophosphatemia is also generally asymptomatic in CNI-
treated patients. Hypophosphatemia is characterised by urinary phosphate 
wasting. Renal phosphate reabsorption relies on the sodium phosphate 
cotransporter (NaPi)-IIa expressed in the PCT (59) and CNIs, such as CyA, inhibit 
NaPi-IIa and supress phosphate reabsorption (59). Patients with severe cases of 
CNI-induced hypophosphatemia are treated with phosphate.  
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Figure 1.8-2 The immunosuppressive effects of CNIs 
Calcineurin inhibitors (CyA and FK506) form complexes with immunophilins 
(cyclophilin A and FKBP12). CyA-cyclophilin and FK506-FKBP12 complexes 
bind to calcineurin, suppress its phosphatase activity and inhibit the activation of 
NFATc by preventing its dephosphorylation. Inactive NFATc cannot enter the 
nucleus and trigger cytokines transcription, preventing an immune response from 
being triggered. The mode of action of Rapamycin is similar to FK506. Rapamycin 
forms a complex with FKBP12 and inhibits mTOR, which supresses IL-2 
secretion.  
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1.9 Calcium transport in the distal nephron 
Many studies have hypothesised that an underlying mechanism governing both 
sodium and calcium handling exists (297,298). Calcium reabsorption is regulated 
by calciotropic hormones and between 1-2 % of calcium filtered in the kidneys 
(10 g) is excreted per day. The rest of the filtered calcium is reabsorbed back into 
the serum; 60 to 70 % in the PCT, 25 % in the TALH, 10 % in the DCT, and 5 % 
in the CD. Calcium is reabsorbed by paracellular routes involving claudin-2, 10 
and 17 in the PCT (299,300) and the remainder 20 to 30 % of the calcium flux is 
reabsorbed through transcellular transport with an unknown underlying 
mechanism (301). In the TALH, calcium is mostly reabsorbed via claudin-10, 16 
and 19 through paracellular transport driven by a lumen-positive electrochemical 
gradient generated by NKCC2, ROMK and basolateral chloride and sodium 
transporter (302,303). In addition to paracellular transport, calcium is also 
reabsorbed through transcellular pathways in the TALH, however, since this 
percentage of reabsorption is relatively low, it is unlikely to have a significant 
effect on the overall reabsorption (304,305). Similar to sodium handling in the 
DCT, the fine-tuning of serum and urinary calcium concentration also occurs at 
the distal nephron. In the DCT, calcium is transported exclusively through 
transcellular pathways by TRPV5. Calcium enters the cell through TRPV5, which 
is highly expressed in the DCT cell (137), and binds to calbindin-D28K in the 
cytosol, which acts as a calcium buffering protein and shuttles calcium towards 
the basolateral membrane. Calcium is exported into the peritubular fluid through 
NCX1 and PMCA (Figure 1.9-1).  
1.9.1 Regulators of DCT calcium transport 
1.9.1.1 PTH 
PTH is secreted from the parathyroid glands in response to hypocalcaemia, 
glucocorticoids and oestrogen, and it is degraded in response to hypercalcaemia 
by the endopeptidase in parathyroid cells (306). PTH is responsible for increasing 
the serum calcium concentration by inducing bone resorption, increasing dietary 
absorption of calcium in the intestine, and active calcium reabsorption in the 
nephron (Figure 1.9-2). PTH is known to upregulate NCX1 activity (307) and 
TRPV5 (308). The regulatory mechanism for PTH-induced NCX1 activation is 
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currently unknown, however it may involve PKA and PKC. The interaction 
between PKA/PKC and NCX1 is complex, controversial and possibly dependent 
on the tissue-specific splice variants of NCX1 (309–312), thus the precise 
interaction between PKA/PKC and NCX1 require further investigation. The 
regulation of TRPV5 involves two different mechanisms, the PKA and PKC 
signalling pathways (313,314). PTH stimulates TRPV5 through activation of the 
adenylyl cyclase (ADCY)-PKA pathway, upon activation of this pathway, PKA 
phosphorylates TRPV5, decreases calcium dependent inactivation and 
encourages the opening of the channel for calcium uptake (314). Alternatively, 
PTH has been reported to stimulate TRPV5 transcription and signals PKC to 
inhibit caveola-mediated endocytosis of TRPV5, resulting in the accumulation of 
TRPV5 at the cell membrane (313,315) (Figure 1.9-1).  
1.9.1.2 Vitamin D3 
1,25(OH)2D3 is the active form of vitamin D3 and it is derived from a series of 
hydroxylation reactions. Vitamin D3 is a steroid that can be absorbed through the 
diet and can be synthesised in the skin in the presence of ultraviolet light. Vitamin 
D3 is hydroxylated into 25-hydroxyvitamin D3 (25(OH)D3) by 25-hydroxylase 
secreted from the liver, and 25(OH)D3 is hydroxylated into 1,25(OH)2D3 by the 
renal enzyme, 1α-hydroxylase, or into the metabolically-inactive 24,25-
dihydroxyvitamin D3 (24,25(OH)2D3) by 24α-hydroxylase (316). 1,25(OH)2D3 then 
binds to VDR and target gene transcription is initiated. The activity of 1α-
hydroxylase is stimulated by PTH and hypocalcaemia and it is suppressed in a 
negative feedback loop by 1,25(OH)2D3, and also by Klotho, FGF23 and 
hypercalcaemia, to enable the fine-tuning of serum calcium concentration (317–
319) (Figure 1.9-2). 1,25(OH)2D3 has been shown to stimulate TRPV5, calbindin-
D28K and PMCA expression, resulting in an increase in calcium reabsorption 
(131,145) (Figure 1.9-1). Analysis of the TRPV5 amino acid sequence revealed 
several vitamin D3 response elements at the promoter region, which suggests 
that vitamin D3 may directly regulate the transcription of TRPV5 (320).  
1.9.1.3 Klotho  
Klotho is a transmembrane protein that is expressed in the kidneys, parathyroid 
gland (321) and the vasculature (322). In the kidneys, klotho is most abundantly 
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expressed in the DCT and expressed to a lesser extent in the PCT (323). Even 
though klotho is a transmembrane protein, it is also abundantly expressed in the 
cytosol (324) and can be secreted into the serum (325), where it has the potential 
to be involved in various signalling pathways.  
Klotho is a β-glucuronidase/sialidase that can hydrolyse D-glucuronic acid 
residues on mucopolysaccharides. Klotho has been shown to increase calcium 
entry by hydrolysing TRPV5, removing the terminal sialic acid residues from the 
glycan chains and exposing the galectin-1 ligands on TRPV5. The ligands then 
bind to the galectin-1 lattices on the plasma membrane and secures TRPV5 to 
the plasma membrane (147,148) (Figure 1.9-1). 
Furthermore, klotho also increases calcium reabsorption by interacting with the 
FGF23 receptor expressed in the PCT and the DCT. FGF23 is a bone-derived 
hormone that is secreted in response to PTH and 1,25(OH)2D3. FGF23 is best 
known for its role in suppressing phosphate reabsorption in the PCT, PTH 
secretion and 1,25(OH)2D3 synthesis. Klotho binds to the FGF receptor, and 
coverts it into a FGF23-specific receptor (326). When FGF23 binds to its receptor, 
the FGF23 signalling pathway is triggered and the activity of 1α-hydroxylase is 
suppressed in the nephron (318) (Figure 1.9-2). Mice with FGF23 deficiency have 
hypercalciuria and increased vitamin D3 levels (327). The underlying mechanism 
that causes hypercalciuria in FGF23 deficient mice is unclear, but it is possible 
that this is due to a decrease in TRPV5 membrane abundance since FGF23 has 
been reported to increase TRPV5 membrane expression.  
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Figure 1.9-1 Regulation of calcium reabsorption in the DCT 
Calcium homeostasis at the DCT is regulated by PTH, 1,25(OH)2D3 and klotho. 
Through PKA and PKC signalling, PTH stimulates an increase in apical calcium 
uptake through an increase in TRPV5 surface abundance and activation. PTH 
also increases NCX1 activity. 1,25(OH)2D3 stimulates TRPV5, calbindin-D28K 
and PMCA expression to encourage calcium reabsorption. Klotho increases 
TRPV5 cell surface expression by preventing TRPV5 endocytosis. 
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Figure 1.9-2 The PTH-Vitamin D3-FGF23 axis in the nephron 
Hypocalcaemia triggers the release of PTH from the parathyroid gland. PTH 
increases calcium reabsorption by stimulating TRPV5 and NCX1. In addition, 
PTH stimulates 1α-hydroxylase activity, causing an increase in 1,25(OH)2D3 
synthesis. An increase in 1,25(OH)2D3 stimulates TRPV5, calbindin-D28K and 
PMCA, which further increases calcium reabsorption. Calcium reabsorption in the 
DCT is governed by several negative feedback loops. 1,25(OH)2D3 provides 
negative feedback to PTH and 1α-hydroxylase via FGF23 and PTH stimulates 
FGF23 to inhibit 1α-hydroxylase.  
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1.9.2 TRPV5 
There are six members of the TRPV channel family (TRPV1-6). Genes encoding 
for TRPV5 and TRPV6 have been localised on chromosome 7q34-35 in humans 
(328). TRPV5 and TRPV6 share the highest sequence homology amongst the 
TRPV members and possess unique characteristics, such as a high affinity for 
calcium and calcium-dependent inactivation (329). TRPV5 is expressed in the 
apical membrane of the DCT and the CNT and is sensitive to hormonal stimuli, 
diuretics, high intracellular calcium and extracellular acid-base ratio. 
1.9.2.1 Structure of TRPV5 
TRPV channels contain large cytoplasmic N and C-termini, flanking 3-6 ankyrin 
repeat motifs and six TM domains (330). An in vitro experiment performed on 
oocytes showed that TRPV5 either forms a homotetramer or forms a 
heterotetramer with TRPV6. The loop between TM5 and TM6 is involved in pore 
formation in the middle of the subunits (331). The N-terminus plays an important 
role in the subunit assembly of TRPV5, and the ankyrin repeat motifs have been 
suggested to induce a molecular zippering process that generates an intracellular 
anchor for the assembly of the subunits (332). Both the N and C-terminus contain 
a calmodulin binding region (333). W702 and R706 were identified in the C-
terminus of the calmodulin binding region in rabbit TRPV5 and these were 
reported to play an important role in calcium-dependent inactivation of TRPV5 by 
enabling calmodulin binding; mutations at these residues were shown to abolish 
calmodulin binding, thereby reducing calcium-dependent inactivation (334). 
1.9.2.2 Functional properties of TRPV5 
The selectivity for calcium ions in TRPV5 is defined by D542, a residue situated 
in the loop between TM5 and TM6, homologous to D541 on TRPV6. Mutations 
at D541 in TRPV6 induce changes in the pore diameter (335). Substitution 
mutations replacing the negatively charged aspartic acid with residues that have 
a shorter side chain, alanine and glycine, increase TRPV6 permeability to larger 
molecules and reduce the affinity for calcium (335). In addition to calcium-
dependent inactivation, uptake studies in Xenopus oocytes showed that 
extracellular protons also suppress TRPV5 activity (131). TRPV5-E522 was 
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reported to play an important role in acid sensitivity and this mutant, containing 
the non-titratable glutamine, resulted in decreased TRPV5 activity (336). 
1.9.2.3 TRPV5 and WNK4 
WNK4 appears to have contradictory effects on TRPV5; WNK4 was shown to 
stimulate caveola-mediated endocytosis of TRPV5 (337) but was also shown to 
increase TRPV5 surface expression, an effect that was reduced by NCC (338). 
Co-expression studies of WNK4-Q565E, a mutation commonly identified in FHHt 
patients with hypercalciuria, and TRPV5 showed that the WNK4-Q565E retained 
its ability to stimulate TRPV5 but this effect was reduced by NCC when NCC was 
co-expressed (338). This suggests that FHHt-induced hypercalciuria may result 
from a decrease in TRPV5 expression mediated by SPAK-NCC activation.  
Furthermore, WNK4 may also play a role in the PKC-TRPV5 signalling pathway. 
When WNK4 was co-expressed with PKC and TRPV5, WNK4 was shown to 
amplify the stimulatory effect of PKC on TRPV5, despite its basal-inhibitory effect, 
which was reported in the same study (337). These studies examined the effects 
of WNK4 in vitro, therefore the effect of WNK4 on TRPV5 in vivo requires further 
investigation. Moreover, WNK4 has been reported to have different roles under 
different cellular environments (244), therefore it is conceivable that another 
regulatory pathway may also be involved in the WNK4-TPRV5 signalling 
pathway. 
1.9.2.4 Phosphorylation of TRPV5 
Phosphorylation of TRPV5 at S299 and S654 by PKC, and T709 by PKA are 
critical for TRPV5 activation (314,315). Co-expression studies of TRPV5, SGK1 
and the scaffold protein that regulates the surface expression of transmembrane 
protein, NHE regulatory factor (NHERF) 2, demonstrate that SGK1 and NHERF2 
simultaneously and directly stimulate TRPV5 activity (339). This stimulatory effect 
was eliminated in SGK1 knockout mice and in an oocyte model of kinase-inactive 
SGK1 (339,340), indicating that the stimulation of TRPV5 might be mediated by 
phosphorylation. Furthermore, the SGK1 knockout model caused hypocalciuria 
and also decreased the abundance of calbindin-D28K (340). 
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1.9.3 NCX1 
In the distal nephron, NCX1 is expressed at high levels in the basolateral 
membrane and is known to contribute to transcellular calcium reabsorption (341). 
NCX1 is an electrogenic transporter that exchanges three Na+ per Ca2+ across 
the basolateral membrane.  
There are three members of the NCX transporters (NCX1-3), of which NCX1 has 
been most comprehensively characterised. The NCX1 gene is localised on 
chromosome 2p22.1 in humans (342). NCX1 is ubiquitously expressed; high 
levels have been detected in the kidneys (135), heart (343) and brain (344). 
NCX2 and NCX3 are highly expressed in the brain and skeletal muscles, but their 
expression in the kidneys have not been reported (345). 
1.9.3.1 NCX1 splice variants 
Tissue specific variants of NCX1 are defined by alternative splicing. The splicing 
region, located on the second β repeat of NCX1, encodes for six small exons 
(346,347). Different combinations of the mutually exclusive exons (exon A and B) 
and the cassette exons (C, D, E and F) generate tissue and variant-specific 
distributions (345–347) (Figure 1.9-3). Over 32 variants can be generated from 
alternative splicing of NCX1. In general, NCX1 in excitable cells, such as 
cardiomyocytes and brain cells, contain exon A, and in non-excitable cells, such 
as those in the kidneys and astrocytes, contain exon B (344). Exon B-containing 
splice variants are sensitive to intracellular sodium whereas exon A-containing 
splice variants are insensitive (344). NCX1.2, NCX1.3 and NCX1.7 variants are 
reportedly expressed in the kidney but NCX1.3 is the most predominant form 
(312). 
1.9.3.2 Structure of NCX1 
Based on membrane topology predictions, NCX1 contains nine TM domains and 
an intracellular loop that divides the transporter into a N-terminal region, 
containing the first five TM domains, and a C-terminal region, containing four TM 
domains (348). Between TM2 and TM3 in the N-terminal region, and TM7 and 
TM8 in the C-terminal region, lie α repeats that are involved in ion binding and 
transport. The large intracellular loop is 500 amino acids in length and contains 
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two calcium binding domains (β repeats) that are responsible for regulating NCX1 
activity (349) (Figure 1.9-3). 
1.9.3.3 Functional properties of NCX1 
Different splice variants of NCX1 behave differently in response to their upstream 
regulators. AKT has been reported to stimulate NCX1.4 transcription, a variant 
that is commonly expressed in the brain (350). Calcineurin was reported to 
downregulate cardiac NCX1 (NCX1.1) through PKC α-mediated phosphorylation 
and also through a process that is independent from NCX1 phosphorylation 
(351). These studies exclusively investigated the effects of AKT and calcineurin 
on exon A-containing splice variants, therefore these results may not be 
representative of exon B-containing variants, such as NCX1.3. PKA and PKC are 
also upstream regulators of NCX1, however conflicting evidence were reported 
by several research groups (309–312), in which they concluded that the effects 
of PKA and PKC may not be as simple as direct phosphorylation of NCX1 and 
could involve other regulatory kinases. 
NCX1 has a low affinity and high transport capacity for calcium (352). NCX1 is 
sensitive to both intracellular calcium and sodium concentration and the polarity 
of NCX1 transport direction can reverse depending on the electrochemical 
gradient and transepithelial voltage (353,354). An increase in intracellular calcium 
increases NCX1 activity causing calcium efflux, whereas an increase in 
intracellular sodium can fully inhibit, partially inhibit or reverse the transport 
direction of NCX1 (344,354). In addition, depolarisation can also reverse the 
transport direction of NCX1, resulting in sodium efflux and calcium influx 
(354,355).  
1.9.3.4 Phosphorylation of NCX1 
Both PKA and PKC have been reported to phosphorylate NCX1 (309,310), 
however other studies reportedly failed to obtain similar results (311,312,356). 
This is possibly due to the characteristics of different NCX1 splice variants, such 
as that NCX1.3 is less sensitive to PKA in comparison to NCX1.1 (310), As these 
studies were conducted in vitro, any conclusion from these should bear in mind 
that these results may not be representative of behaviour in vivo.  
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Figure 1.9-3 Topology prediction of NCX1. 
Membrane topology modelling of NCX1 predicted nine TM domains (grey) and 
an intracellular loop that divides the transporter into an N-terminal region (TM1-
5) and a C-terminal region (TM6-9). The α repeats involved in the binding and 
transport of ions (purple) are located between TM2 and TM3, and between TM7 
and TM8. The two β repeats (blue) are located in the large intracellular loop and 
are responsible for regulating NCX1 activity. The splicing region is located on the 
second β repeat in NCX1. Different combinations of the mutually exclusive 
(yellow) and the cassette exons (green) generate tissue and variant-specific 
distributions. NCX1.3, the most predominant splice variant in the kidney, arises 
from exons B and D, NCX1.1 arises from exons A, C, D, E and F, and NCX1.4 is 
generated from exons A and D.  
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1.9.4 PMCA 
PMCA is a plasma membrane calcium ATPase that is expressed ubiquitously in 
calcium transporting tissues, such as the kidney (135), intestine (357), brain (358) 
and the heart (359). There are four isoforms of PMCA (PMCA1-4) and over thirty 
splice variants (360). PMCA isoforms share 80-90 % sequence homology (361). 
Genes encoding PMCAs have been localised on the following human 
chromosomes: ATP2B1 (PMCA1) at 12q21-q23 (362), ATP2B2 (PMCA2) at 
3p25-p26 (363), ATP2B3 (PMCA3) at Xq28 (363), and ATP2B4 (PMCA4) at 
1q25-q32 (362).  
PMCA1 and PMCA4 are the ubiquitously expressed dominant isoforms (364), 
whereas PMCA2 and PMCA3 are tissue specific and are most abundant in 
neuronal tissues (365). Expression of PMCA1 and PMCA4 has been detected in 
mouse (135) and rat renal tissue (366), and the splice variants, PMCA1b and 
PMCA4b, are specifically localised to the basolateral membrane of mDCT cells 
(135) and Madin-Darby canine kidney (MDCK) cells (367). Out of the two PMCAs, 
PMCA4 is the main regulated calcium pump that is dominantly expressed in the 
distal tubule and colocalises with TRPV5 in the DCT cell (368). This is 
demonstrated in TRPV5 KO mice, where the downregulation of PMCA4, NCX1 
and calbindin-D28K was reported, but PMCA1 remained unchanged (368,369). 
1.9.4.1 Structure of PMCA 
PMCA consists of ten TM domains and two large intracellular loops that are 
flanked by the cytoplasmic N- and C-terminus. The N-terminus of PMCA contains 
a 14-3-3 protein binding site, allowing a 14-3-3 protein to inhibit the pump activity 
(370). The two-intracellular loops, situated between TM2 and TM3, and between 
TM4 and TM5, play an important autoinhibitory role by binding to the calmodulin 
binding domain in the regulatory region of the C-terminus. The C-terminal 
regulatory domain consists of the calmodulin binding domain, PKA and PKC 
binding sites, and high affinity calcium binding sites. The C-terminus of PMCA 
also contains one of the two alternative splicing sites. This determines the number 
of exons expressed in the variant and will affect functional differentiation, such as 
calcium affinity (371). When intracellular calcium is high, calmodulin is activated 
and will bind to the C-terminal domain in PMCA. This will dissociate the 
interaction between the two intracellular loops and the C-terminus, thereby 
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activating PMCA (Figure 1.9-4). The first intracellular loop is involved in mediating 
acidic phospholipids-dependent pump activation and contains the second site for 
alternative splicing (372). The second intracellular loop contains a catalytic 
domain comprising the ATP binding site.  
1.9.4.2 Functional properties of PMCA 
Calmodulin is a positive regulator of PMCA; acting by inhibiting PMCA 
oligomerisation and promoting PMCA dimerisation, thus enhancing the pump 
activity (373,374). The expression of PMCA isoforms and variants are also 
regulated by physiological stimuli, such as the changes in intracellular calcium 
concentration (366). An increase in intracellular calcium alters the splicing of 
PMCA1 and a truncated variant is generated (375). This in turn increases mRNA 
expression of PMCA2 and PMCA3, and inhibits PMCA4 expression in a 
calcineurin-mediated process (376). PMCA2 and PMCA4 have been reported to 
inhibit the calcineurin-NFAT signalling pathway (377,378). PMCA2 and PMCA4b 
recruit calcineurin from the cytoplasm to the plasma membrane, where the 
concentration of intracellular Ca2+ is kept low, and interact with calcineurin 
through the binding of the catalytic domains present on both the PMCAs and 
calcineurin (377).  
PMCA has a high affinity for calcium and a relatively low transport capacity. The 
dissociation constant of PMCA for calcium is 10 to 20 µM under resting 
conditions, capable of decreasing to less than 1 µM upon interaction with 
calmodulin (379). As PMCA is accountable for a third of calcium extrusion in the 
DCT cell and it has a higher affinity for calcium than NCX1, PMCA may be 
responsible for the fine-tuning of cytosolic calcium levels.  
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Figure 1.9-4 Activation of PMCA 
a) The two-intracellular loops located between TM2 and TM3, and between TM4 
and TM5 play an important role in autoinhibition by binding to the calmodulin 
binding domain in the regulatory region of the C-terminus. b) When intracellular 
calcium is high, calmodulin is activated. Calmodulin will then bind and dissociate 
the interaction between the intracellular loops and the C-terminus, resulting in 
PMCA activation.  
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1.9.4.3 Phosphorylation of PMCA 
PKA and PKC phosphorylate PMCA by binding to their target sequences in the 
C-terminus. These phosphorylation sites are isoform specific and can result in 
activation or inactivation of the pump. PKA phosphorylates PMCA1b at S1178 
and increases its calcium affinity, however, this effect alone does not lead to full 
activation of PMCA1b, which indicates that additional regulatory mechanisms 
coordinate with PKA for full activation (380). PKC phosphorylates the inhibitory 
region that lie downstream of the calmodulin binding site in the C-terminus of 
PMCA4b, and partially stimulates the pump by reversing the effect of the 
inhibitory domain (381,382). 
1.9.5 Calbindin-D28K 
Calbindin-D28K is a cytosolic calcium binding protein that is exclusively 
expressed in the cytosol of the DCT, the CNT and principle cells, and co-localises 
with TRPV5 and NCX1 in the DCT. Calbindin-D28K binds to four calcium ions 
and is involved in shuttling calcium ions from the apical to basolateral membrane 
and buffering cytosolic calcium to maintain a low intracellular calcium 
concentration. In addition to its role as a calcium buffering protein, calbindin-D28K 
also interacts with the N and C-terminus of TRPV5 under low intracellular calcium 
concentrations. Calbindin-D28K buffers calcium ions close to the channel’s pore, 
preventing calcium-induced TRPV5 inactivation, and thereby promoting calcium 
influx (383). Similar to TRPV5, calbindin-D28K is also sensitive to hormonal 
stimuli, diuretics, high intracellular calcium and extracellular acid-base ratio.  
1.10 Relationship between sodium and calcium transport at the DCT 
1.10.1 Thiazide diuretics and calcium wasting 
Diuretics, such as furosemide and thiazides, are treatments for hypertension and 
other electrolyte disorders, such as hyperkalaemia, hypercalciuria, 
hypercalcemia and metabolic acidosis (62,176). Furosemide is a diuretic that 
targets NKCC2 and has been used for the treatment of hypercalcemia to reduce 
paracellular calcium transport in the TALH. However, furosemide increases 
TRPV5 and calbindin-D28K expression (384), which could be a result of a 
compensatory adaptation to increased calcium delivery to the distal nephron. 
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Thiazides are diuretics that target NCC and decrease urinary calcium excretion, 
causing hypocalciuria and hypercalcemia (385). Several groups have studied the 
effects of thiazide on calcium handling in the kidney but the pathogenesis of 
thiazide-induced hypocalciuria remains unclear. The studies by Nijenhuis et al. in 
2003 (386) and 2005 (64) reported that thiazide-induced hypocalciuria is a result 
of volume contraction, causing increased sodium and water reabsorption, thereby 
increasing passive paracellular calcium reabsorption in the PCT. The effects of 
thiazides on distal calcium transporters remain unclear due to conflicting results 
reported in the two studies; thiazides decreased the mRNA expression of TRPV5, 
calbindin-D28K and NCX1 in the 2003 study, but had no significant effect in the 
2005 study. Nijenhuis et al. explained that the decrease in calcium transporters 
initially observed in the 2003 study may have been a result of apoptosis of DCT 
cells provoked by high-dose thiazides treatment (64), an effect that has been 
reported previously (387). Furthermore, Lee et al. (388) reported that thiazide-
induced changes in the distal calcium transport proteins of mice are dependent 
on blood volume. Thiazides caused hypocalciuria and volume contraction but had 
no significant effects on TRPV5 and calbindin-D28K mRNA expression. 
However, when a salt supplement was administered to these mice, volume 
contraction was eliminated and the gene expression of TRPV5 and calbindin-
D28K increased (388). These studies indicate a link between sodium and calcium 
handling in the DCT, however the underling mechanisms that govern the handling 
of these two electrolytes are complex and require further investigation. 
1.10.2 Gitelman syndrome and hypocalciuria 
The pathogenesis of hypomagnesaemia and hypocalciuria in patients with 
Gitelman syndrome remains unclear, but the resemblance between the calcium 
and magnesium disturbances in Gitelman patients and thiazide-treated patients 
suggests that they may adopt the same or similar mechanism. In thiazide treated 
animals there is enhanced passive calcium reabsorption by the proximal tubule, 
causing a decrease in calcium delivery to the DCT (64). However, reduced NaCl 
influx and the continuous efflux of intracellular chloride through basolateral 
channels, such as CLCNKB, may influence the electrochemical gradient required 
for apical calcium entry. Furthermore, in patients with Gitelman syndrome and in 
the NCC-S707X knock-in mouse model, which corresponds to the S710X 
mutation found in Gitelman patients, the expression of TRPV5 is increased (389). 
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In addition, the mRNA expression of TRPV6, ROMK, BK and ENaC were also 
increased in this mouse model, which suggests that the upregulation of these 
channels may contribute to the hypocalciuric and hypokalaemic phenotype 
observed in Gitelman patients (389).  
1.10.3 FHHt and hypercalciuria 
Both hypercalciuria and hyperkalaemia appear at an early age in FHHt patients, 
before the onset of hypertension; hypertension appears 3-4 decades later and 
the cause of delayed onset is still unclear. Hypercalciuria in FHHt patients is 
generally associated with the WNK4-Q565E mutation (60,390). Co-expression 
studies of TRPV5 and WNK4-Q565E in oocytes showed that the WNK4-Q565E 
stimulated TRPV5-mediated calcium uptake, however this effect was reduced by 
NCC when NCC was co-expressed (338). This suggests that FHHt-patients with 
the WNK4-Q565E mutation may suffer hypercalciuria as a result of a decrease in 
TRPV5-mediated calcium transport through SPAK-NCC activation.  
Hypercalciuria has not been reported in the majority of other FHHt mutations, 
such as those in WNK1 (391), with the exception of the recently discovered 
KLHL3 mutations (392). FHHt patients with Q309R and R528H mutations in 
KLHL3 display a less severe calcium wasting phenotype than those with the 
WNK4-Q565E mutation (392). The pathophysiology of FHHt-induced 
hypercalciuria in patients with KLHL3 mutations is unknown, however since 
KLHL3 mutations cause FHHt by preventing WNK4 ubiquitination, it is possible 
this process is a result of WNK4 accumulation (392).  
1.10.4 Essential hypertension, hypercalciuria and kidney stones 
The association between hypertension and abnormalities in calcium handling is 
evident. It has been shown in several studies that hypertension is linked to an 
increase in urinary calcium excretion and a decrease in serum calcium 
concentration (393,394). As a high sodium diet is a major determinant in the 
development of hypertension, studies have also shown that dietary sodium 
determines urinary calcium excretion; an increase in dietary sodium in 
normotensive individuals causes excess urinary calcium excretion (395,396) and 
a decrease in dietary sodium significantly reduces calciuria (397), including 
calciuria induced by dietary potassium depletion (398). Studies of hypertensive 
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individuals also showed a reduction in the severity of hypercalciuria when dietary 
sodium intake is decreased (399–401). However, this effect is dependent on the 
individual’s sensitivity to dietary intervention, such that salt-resistant hypertensive 
individuals have a less severe form of hypercalciuria in comparison to salt-
sensitive individuals (402).  
Hypercalciuria is the most common risk factor for kidney stone formation (30). 
The risk of developing kidney stones is two-fold higher in hypertensive individuals 
in comparison to normotensive individuals (403). The association between 
hypertension and kidney stone disease was first reported back in 1761 by 
Giovanni Battista Morgagni (404), but the pathogenesis and the order of onset 
remains a mystery. A prospective study of a large cohort that consumed the 
Dietary Approaches to Stop Hypertension (DASH) diet, a diet low in sodium, high 
in fruits and vegetables, low in animal protein and consist of low fat dairy 
products, also showed a lower rate of kidney stone disease progression, onset 
and recurrence (405), further supporting the linkage between dietary sodium, 
hypertension, hypercalciuria and kidney stone formation.  
1.10.5 CNI-induced hypercalciuria 
CNI-induced hypercalciuria has been suggested to be caused by a decrease in 
the apical entry of calcium in the DCT. Several studies showed that CNI 
decreased mRNA expression and protein abundance of TRPV5 and calbindin-
D28K (51,57), thereby reducing calcium reabsorption. The association between 
hypertension, sodium and calcium handling is strongly supported by the studies 
discussed previously. Therefore, it is possible that CNI-induced hypercalciuria is 
associated with CNI-induced hypertension and the underling mechanism of 
hypercalciuria may be more complex than previously demonstrated.  
1.11 Aims of thesis 
The resemblance between the handling of electrolytes in Gitelman patients and 
thiazide-treated patients, and between FHHt patients and CNI-treated patients, 
suggest that NCC plays an important role in renal tubular transport of non-sodium 
electrolytes. The underlying mechanism that governs the WNK-NCC cascade is 
currently unclear but it is evident that the WNK kinases contribute to the 
pathogenesis of these tubular disorders. The experiments described in chapter 2 
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and chapter 3 were designed to identify the most important member of the WNK 
kinases for NCC regulation under the influence of FK506, and to identify the 
underlying mechanisms that regulate the WNK-NCC cascade downstream of 
calcineurin. Calcineurin has pleiotropic effects and CNIs cause electrolyte 
abnormalities through tubular dysfunction, therefore it was also the aim in chapter 
3 to investigate other FK506-dysregulated transporters, such as those involved 
in calcium handling. Furthermore, it is evident from the literature that there is an 
unidentified correlation between sodium and calcium handling in the nephron, 
therefore experiments in the subsequent chapter were designed to investigate 
this in the DCT under the effects of FK506. The overall aim of this thesis was to 
advance the understanding of the underlying mechanisms that regulate sodium 
and calcium reabsorption in the DCT.   
93 
 
 
 
 
 
 
Chapter 2. Interaction of intermediary proteins in the 
calcineurin-WNK-NCC cascade 
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2.1 Introduction  
CNI-induced hypertension is a significant clinical problem (180,181) that is 
caused by NCC overactivity (51). NCC is regulated by a complex cascade of 
WNK kinases. CNIs increase WNK3, WNK4, SPAK and phosphorylated NCC 
(51), which results in increased sodium chloride reabsorption thereby causing 
hypertension. Calcineurin and the WNK kinases are known to be upstream 
regulators of NCC but the signal transduction mechanisms upstream of the WNK 
kinases are unclear. Elucidation of the relationship between calcineurin, the WNK 
kinases and NCC may provide new drug targets for antihypertensives or 
therapies targeting salt losing disorders.  
The WNK kinases control NCC activity through SPAK and OSR1. SPAK/OSR1 
are phosphorylated by L-WNK1 and WNK4 (118–120), this increases 
SPAK/OSR1 activity, thereby increasing NCC activity (116,117). WNK3 and 
WNK4 have antagonistic effects on each other (207); WNK3 stimulates the 
trafficking of NCC to the apical membrane of DCT cells and this process is 
inhibited by WNK4. WNK1 affects NCC activity through WNK4. The two isoforms 
of WNK1, KS-WNK1 and L-WNK1 have opposing effects on WNK4-induced 
inhibition of NCC (214): L-WNK1 inhibits WNK4, which supresses WNK4-induced 
lysosomal degradation of NCC, and KS-WNK1 exhibits a dominant-negative 
effect by interacting with L-WNK1, resulting in downregulation of NCC (215). The 
ratio of KS-WNK1 to L-WNK1 and WNK3 to WNK4 are tightly controlled by the 
ubiquitin ligases. L-WNK1 and WNK4 is subject to degradation through KLHL3 
and CUL3; these are important determinants for the net effect of NCC. Using 
current knowledge of the calcineurin-WNK-NCC cascade and the stimulatory and 
inhibitory effects of WNK kinases, this study investigates the WNK-NCC cascade 
downstream of calcineurin.  
2.1.1 Aims 
• To use co-expression studies, under the influence of FK506, to determine the 
most important member of the WNK kinases for NCC regulation and to 
determine whether NCC activation requires all members of the WNK kinases. 
• To use co-expression studies to determine the effect of different co-
expression ratios of WNK kinases, KLHL3, CUL3 and SPAK in the regulation 
of NCC.   
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2.2 Materials and Methods 
A single oocyte chemiluminescence assay was developed to detect NCC 
expression on the surface membrane of oocytes; an NCC construct with an 
extracellular human influenza hemagglutinin (HA)-epitope tag was created for 
sensitive and reliable detection of NCC in this assay. Utilising this approach, NCC 
expression was measured in co-expression studies of NCC2HA with the WNK 
kinases, CUL3, SPAK, and KLHL3 in FK506 pre-treated oocytes. WNK1, WNK3 
and WNK4 DNA constructs were kindly gifted by Dr. J. Hadchouel and constructs 
of CUL3, SPAK and KLHL3 were cloned as described in Section 2.2.3.  
2.2.1 The insertion of HA-epitopes in NCC  
The topology of NCC from Mus musculus (NM_019415.2; Q543E4) was studied 
to determine a suitable introduction site for two HA-epitopes. The amino acid 
sequence of mouse NCC was submitted to Protter (406), an interactive protein 
visualization tool that predicts membrane topology and signal peptides through 
Phobius (407). Potential glycosylation sites were predicted with GlycoEP (408), 
an online software tool used for predicting glycosylation sites in eukaryotes. A 
pSDS vector (AY672108.1) containing the full-length mouse NCC 
(pSDS_mNCC) was a kind gift from Dr. K. O’ Shaughnessy and was used as a 
template to generate the new NCC2HA construct (pSDS_mNCC2HA). According 
to the results generated by Protter and GlycoEP, HA-epitopes were inserted into 
the second extracellular loop of NCC, at Q245.  
2.2.2 The insertion of HA-epitopes into CD8 and co-expression with NCC 
The pSDS_mNCC construct was also used to create an NCC construct with the 
addition of a truncated single transmembrane domain glycoprotein, cluster of 
differentiation 8 (CD8) (NM_001145873.1; P01732), with three extracellular HA-
epitopes introduced into CD8 at P21 (pSDS_mNCC_CD8HA). A pIRES-CD8 
plasmid was used as a template to generate CD8HA. The stop codon of CD8HA 
was removed and thus fused with the N-terminus of NCC for co-expression.  
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2.2.3 Plasmid construct synthesis of CUL3, KLHL3 and SPAK 
Constructs of pTLB_CUL3 (NM_016716.5), pTLB_KLHL3 (NM_001195075.1) 
and pTLB_SPAK (NM_016866.2) were created by amplifying mouse kidney 
cDNA. These cDNA templates were prepared by Dr. A. Zdebik. 
2.2.4 Molecular cloning protocol 
Amplification of DNA was performed using Phusion DNA Polymerase (New 
England Biolabs, USA), according the to manufacturer’s protocol (Table 2.2-1). 
The primers used to amplify these DNA inserts introduced two restriction sites on 
both ends of the polymerase chain reaction (PCR) product; these restriction sites 
were compatible with the pTLB (409) vector. The PCR product was separated by 
gel electrophoresis, as explained in Section 2.2.4.1, and the DNA fragment, 
containing the insert, was excised and purified from the agarose gel. Insert DNA 
(1 µg) and vector DNA (1 µg) were digested separately with the same restriction 
enzyme. Vector DNA (50 ng) and insert DNA (30 ng) were combined and ligated 
with T4 DNA ligase (New England Biolabs, USA), according to the manufacturer’s 
protocol. Primers used for cloning were purchased from Integrated DNA 
Technologies, Belgium. For details on the sequences of primers, refer to Table 
2.2-2. 
2.2.4.1 Gel electrophoresis and gel purification 
A 1 % agarose gel containing 0.5 µg/ml ethidium bromide was made in tris-
acetate-EDTA (TAE) buffer (Fisher Bioreagents, USA). Samples were loaded into 
the agarose gel with 0.04 % bromophenol blue, 0.04 % xylene cyanol and 5 % 
glycerol alongside the GeneRuler 1 kb Plus DNA ladder (Thermo Fisher 
Scientific, UK), for band size estimation. Agarose gels were imaged with a UV 
transilluminator (Peqlab, Netherlands). DNA fragments were excised from 
agarose gel under UV exposure and purified with an High Pure PCR Product 
Purification kit (Roche, UK) according to the manufacturer’s protocol. 
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Table 2.2-1 PCR program and reagents 
 
  
PCR program 
Initial denaturation 94 ˚C 2 minutes 
30 cycles of 
Denaturing 
Annealing 
Extension 
98 ˚C 
55 ˚C 
72 ˚C 
20 seconds 
30 seconds 
1 minute 
Extension 72 ˚C 5 minutes 
PCR reagents 
Template DNA 150 ng 
10 µM Flanking 
Forward primer 
1 µl 
10 mM dNTPs 1 µl 
10 µM Flanking 
Reverse Primer 
1 µl 
5 x Phusion HF 
buffer 
10 µl MilliQ Water 
Up to 50 µl total 
volume 
Phusion DNA 
Polymerase 
0.5 µl   
1 µM Inner 
Forward primer * 
1 µl   
1 µM Inner 
Reverse primer * 
1 µl   
* Inner primers required for long recombinant inserts 
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Table 2.2-2 Primers used in molecular cloning  
  
Name Function Sequence 
NCC Forward flanking primer TATTGTCGTTAGAACGCGGC 
NCC Reverse flanking primer TCCCCATGGTAGCTGTAGAAG 
NCCexHA Forward inner primer 
ctacccAtatgacgtGccagattatgcgATCAAT
GACATCCGCATCATC 
NCCexHA Reverse inner primer 
cgcataatctggCacgtcataTgggtaGGGGTC
TACGATGGGTGTG 
CD8 Forward flanking primer 
gtaCCCGGGATGATAAGCTTGCCacaac
c 
CD8 Reverse flanking primer 
gagctcgagTTAGACGTATCTCGCCGAA
AG 
CD8HA Forward inner primer 
gcgGTcTAGaGCAGCCAGTTCCGGGT
GTCG 
CD8HA Reverse inner primer 
GTGGTGGTGGTGGTGcgcataatctggCa
cgtcataagggtaCGGCCTGGCGGCGTGG 
mKLHL3 Forward primer CACTCGAGAtggcctactatatcatgatc 
mKLHL3 Reverse primer ggtctagagtcacagggatttgtgaatcacagc 
mCUL3 Forward primer CGCTCGAGatgtcgaatctgagcaaaggc 
mCUL3 Reverse primer aatctagattatgctacatatgtgtatactttgc 
mSPAK Forward primer gcctcgagATGGCGGAGCCGAGCG 
mSPAK Reverse primer gctctagagTCAGCTCACACTCAACTG 
99 
 
2.2.4.2 Electroporation and Cloning 
Preparation of electrocompetent Escherichia coli and the electroporation 
procedure were performed according to an established protocol (410). The 
experimental procedure in brief is as follows: electrocompetent cells were 
prepared in advance and snap frozen in liquid nitrogen. The ligation reactions 
that were prepared in advance were desalted by drop dialysis with 25 nm 
nitrocellulose membrane (Millipore, USA) at room temperature for 20 minutes. 
The ligation reaction was recovered and added to 30-40 µl of thawed 
electrocompetent cells and electroporated by a Gene pulser (Bio-Rad) connected 
to a pulse controller (Bio-Rad) at 1.8 kV, 25 µF, 200 ohm resistance. The cell 
suspension was recovered and resuspended in 120 µl of Super Optimal Broth 
with catabolite repression, incubated at 37 ˚C for 1 h, and 100 µl of bacterial 
culture was plated onto Lysogeny Broth (LB) agar plate containing 100 µg/ml 
ampicillin and incubated at 37 ˚C overnight.  
A number of colonies from the bacterial plates were picked and incubated in 5 ml 
LB medium containing 100 µg/ml ampicillin for 16 h at 37 ˚C, 200 rpm. Plasmid 
DNA was purified from 3 ml of bacterial culture harbouring the plasmid of interest 
using a Nucleospin Plasmid kit (Macherey-Nagel, Camlab, UK), according to 
manufacturer’s protocol. Concentrations of DNA were calculated from the 
absorbance at 280 nm measured using a NanoDrop-1000 spectrophotometer 
(Labtech International, UK). 
2.2.4.3 Restriction digestion and sequencing 
Different restriction enzymes were used to digest the DNA constructs depending 
on the restriction site it harbours. The standard protocol for restriction digestion 
involved 1 µg of DNA and 10 U of restriction enzyme of choice along with its 
recommended buffer and incubated at its recommended temperature for 1 h. All 
restriction enzymes were purchased from New England Biolabs or Fermentas 
(Thermo Fisher Scientific, UK). 
Restriction digestion analysis were performed on the purified DNA constructs and 
constructs that were successfully digested were selected for sequencing. DNA 
(0.5 µg) from selected clones and 0.5 µl of primer (10 µM) were added to the 
sequencing reaction, prepared with 1 µl of the BigDye Terminator v1.1 cycle 
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sequencing kit (Applied Biosystems), according to the manufacturer’s protocol. 
The sequencing reaction was precipitated using sodium acetate and ethanol. 
Primers used for sequencing were purchased from Integrated DNA 
Technologies, Belgium. For details on the sequences of primers, refer to the 
Table 2.2-2. 
2.2.4.4 cRNA synthesis for oocyte injections 
DNA constructs (15 µg) were linearised by a chosen restriction enzyme under 
recommended conditions; successful linearisation was checked by gel 
electrophoresis. Products of linearisation were purified by High Pure PCR 
Product Purification kit (Roche, UK), from which cRNA was synthesised using an 
mMessage mMachine SP6 Transcription Kit (Ambion, Thermo Fisher Scientific, 
UK), according to manufacturer’s protocol. The cRNA pellet was dissolved and 
diluted in water treated with diethylpyrocarbonate and the concentration was 
measured using a NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific, 
UK). Integrity of cRNA was confirmed by gel electrophoresis on a 1 % agarose 
gel. 
2.2.5 Animal Studies 
The use of Xenopus laevis (African clawed frog) oocytes in these studies was 
approved and carried out under the UK Animals (Scientific Procedures) Act 
(ASPA), 1986, Amendment Regulations 2012. Protocols were approved by UCL 
(Royal Free Campus) Comparative biology Unit Animal Welfare and the ethical 
review body (AWERB) committee (PPL: 70/8064) (PIL: l3635E6BF).  
X. laevis were euthanised under Schedule 1 of the ASPA act. Animals were 
deeply anesthetised by immersion in 1 % MS-222 (Sigma-Aldrich, Germany) [pH 
7-8, buffered with sodium bicarbonate]. Following successful anaesthesia, which 
was determined by the loss of righting and pain reflexes, the brain was concussed 
by striking the cranium, followed by decapitation. To ensure brain death, double-
pithing of the frog was performed to destroy the brain and a major vessel was 
severed during oocyte harvesting.  
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2.2.5.1 Oocyte harvesting  
Ovarian lobes extracted from the abdomen of X. laevis were washed in ND96 [96 
mM NaCl, 2 mM KCL, 1.8 mM CaCl2.2H2O, 1 mM MgCl2.6H2O, 5 mM HEPES 
and 4.5 mM NaOH, pH 7.5] at 4 ˚ C. The ovarian lobes were torn open and washed 
with ND96 until the solution was clear. Oocytes were defolliculated by incubation 
with 2 mg/ml collagenase type II (Fisher Scientific, UK) in ND96 for 1.5-2 h at 
room temperature. Oocytes at stage V-VI were selected and maintained at 17 ˚C 
in ND96 containing antibiotics [50 µg/ml penicillin, 50 µg/ml tetracycline and 0.1 
mg/ml ampicillin]. cRNA (30 ng) was injected into oocytes by pipettes pulled using 
a DMZ-universal puller (Zeitz Augsburg, Germany). Oocytes were maintained in 
ND96 solution at 17 ˚C for three days. 
2.2.5.2 Oocyte protein preparation  
Oocytes were washed in cooled homogenisation buffer [1 X Tris-Buffered Saline 
(TBS), 300 mM sucrose and 5 mM EDTA, pH 7.5] containing protease (cOmplete 
tablets, Roche, Mannheim, Germany) and phosphatase inhibitors (PhosSTOP 
tablets, Roche, UK). Ten oocytes per treatment group were homogenised with 
homogenisation buffer (5 µl per oocyte) at 4 ˚ C. The homogenate was centrifuged 
at 5000 g (3 x 2 minutes) at 4 ˚C. After each centrifugation, the interphase was 
collected, discarding the lipid layer and the debris pellet. Protein concentration 
was determined using a BCA protein assay kit (Pierce, Loughborough, UK), 
according to the manufacturer’s protocol; absorbance was measured at 650 nm 
using a Multimode detector DTX 880 (Beckman Coulter, California, USA). 
2.2.5.3 Western blot of oocyte proteins 
Proteins were reduced by adding 10 mM dithiothreitol (DTT) and denatured at 65 
˚C for 10 minutes. Thirty micrograms of protein were separated by 
electrophoresis on a 7-10 % sodium dodecyl sulphate-polyacrylamide 
electrophoresis (SDS-PAGE) gel. Proteins were transferred onto polyvinylidene 
difluoride (PVDF) membrane (Bio-rad) with a Trans-Blot SD Semi-Dry Transfer 
cell (Bio-rad). PVDF membrane was blocked with 5 % skimmed milk (Marvel, UK) 
in TBS with 0.05 % NP-40 (Thermo Fisher Scientific, UK). Membranes were 
probed against NCC (1:500; MRC-PPU, Dundee) and HA (3F10) (1:1000; Roche, 
Mannheim, Germany). All antibodies were diluted in the blocking buffer and 
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incubated overnight at 4 ˚C. Prior to and post-secondary antibody incubations, 
membranes were washed in TBS for 15 minutes at room temperature. Secondary 
antibodies were also diluted in blocking buffer at 1:1000 and incubated for 1 h at 
room temperature. Equal volumes of ECL-luminol [0.25 mM 3-Aminopthalic acid 
hydrazide, 0.04 mM p-Coumaric acid, 100 mM Tris and 200 mM NaCl; pH 
adjusted to pH 8.5] and ECL-H2O2 [0.04 % H2O2] were mixed prior to imaging and 
densitometry was performed using the Fluor-STM Multimager (Bio-rad).  
2.2.6 Single oocyte chemiluminescence 
Oocytes injected with cRNA were maintained in ND96 containing antibiotics, at 
17 ˚C for three days to allow for protein expression. Oocytes were then removed 
from ND96 and blocked with 1 % bovine serum albumin (BSA) in ND96 for 30 
minutes on ice. Oocytes were incubated in anti-HA antibody (3F10) (1:500; 
Roche, Mannheim, Germany) in blocking agent for 1 h. Oocytes were washed 
four times with blocking agent for 15 minutes, which was followed by secondary 
antibody incubation (1:400) in blocking agent for 30 minutes on ice. Finally, 
oocytes were washed six times in blocking agent for 5 minutes, followed by two 
washes with ND96 for 15 minutes on ice. Fifty microlitres of Glo substrate reagent 
(R and D systems, UK) were added to the oocytes immediately before 
measurement. Single oocyte chemiluminescence was measured using a 
luminometer TD-20/20 (Turner Designs, UK). This protocol was adapted from 
Zerangue et al. (411). 
2.2.7 Statistical analysis 
Statistical analysis was performed by one-way ANOVA followed by a Bonferroni’s 
multiple comparison post hoc tests. The data are presented as means ± SEM. 
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2.3 Results 
2.3.1 Topology of NCC 
NCC expression on oocyte surface membrane was quantified by the single-
oocyte chemiluminescence assay. To quantify NCC, extracellular HA-epitopes 
were inserted into the NCC construct and an anti-HA antibody was used to detect 
the exposed epitopes. In order to identify a suitable insertion site for the HA-tag, 
topology of NCC was studied to avoid regions that are required for normal 
function and to limit the chances of disrupting the native structure. Twelve TM 
domains of NCC were identified with five intracellular and six extracellular loops. 
The N- and C-terminus of NCC were predicted as intracellular regions and 
predicted glycosylation sites are shown in Table 2.3-1. The posterior probability 
plot of NCC (Figure 6.1-1) and the statistical score for the potential glycosylated 
residues (Table 6.1-1) are detailed in the appendix.  
Extracellular loops -1, -5 and -6 consist of four to ten amino acids. Due to their 
relatively short amino acid sequences, inserting HA-epitopes into these loops 
may alter NCC structure, and therefore they were unsuitable candidates for the 
introduction of the HA-tag. Extracellular loop-4 is the largest extracellular 
structure and has four predicted glycosylation sites; the number of glycosylation 
sites it harbours implies important functional and structural roles, also making it 
an unsuitable candidate. Extracellular loop-3 does not harbour any predicted 
glycosylation site but it is situated next to the largest extracellular loop; therefore, 
loop-3 was considered unsuitable due to the possibility of larger extracellular 
structures, such as loop-4, shielding the HA-epitopes from antibody detection. 
The results of these topology and glycosylation site predictions suggest that 
extracellular loop-2 is the ideal candidate for inserting HA-epitopes. Even though 
a glycosylation site was predicted in loop-2 at T239, loop-2 was not shown to 
have any functional role in NCC (121). Moreover, loop-2 is further away from 
loop-4 in comparison to loop-3 therefore lowering the probability of larger 
extracellular structures shielding the HA-tags. Two HA-epitopes were inserted at 
Q245, in the middle of extracellular loop-2 (A237-I255), where an anti-HA 
antibody can detect the antigen presented on the surface of oocyte membrane in 
the oocyte chemiluminescence assay (Figure 2.3-1).  
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Table 2.3-1 Glycosylation sites in transmembrane, intracellular and 
extracellular regions of NCC 
Type of domains Amino acid Glycosylation sites 
N-terminus (intracellular) 1-134 T7, T23, S37, S38, T44, 
T48, T120, T122 
TM domain-1 135-154 - 
Extracellular loop-1 155-165 - 
TM domain-2 166-191 S191 
Intracellular loop-1 192-211 T192 
TM domain-3 212-236 - 
Extracellular loop-2 237-255 T239 
TM domain-4 256-275 - 
Intracellular loop-2 276-283 - 
TM domain-5 284-305  - 
Extracellular loop-3 306-336 - 
TM domain-6 337-359 T350 
Intracellular loop-3 360-370 - 
TM domain-7 371-390 T373, T380, T381. T390 
Extracellular loop-4 391-448 S400, T406, T408, T426 
TM domain-8 449-471 T456, S466 
Intracellular loop-4 472-502 - 
TM domain-9 503-522 - 
Extracellular loop-5 523-527 T525 
TM domain-10 528-549 - 
Intracellular loop-5 550-560 T551 
TM domain-11 561-577 - 
Extracellular loop-6 578-582 - 
TM domain-12 583-602 - 
C-terminus (intracellular) 603-1001 S781, T786, T801, T921 
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Figure 2.3-1 Schematic representation pSDS_mNCC2HA 
Schematic diagram of NCC membrane topology, predicted by Phobius (407). 
Twelve TM domains of NCC were identified with intracellular N- and C-terminus, 
and five intracellular and six extracellular loops. Two HA-tags (yellow) were 
inserted into the second extracellular loop, where HA-epitopes are exposed to 
antibody detection in an oocyte chemiluminescence assay.  
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2.3.2 HA-tagged NCC construct synthesis  
The insertion of the HA-epitopes into NCC required a two-part PCR reaction: a) 
the creation of two partial inserts containing the HA-epitope sequence (Figure 
2.3-2a) and b) combining the partial inserts together to create the full length 
NCC2HA (Figure 2.3-2b); the two-part PCR reaction was successful, indicated 
by correct sizes of the PCR products. NCC was excised from the pSDS vector by 
digestion with restriction enzymes (Figure 2.3-2c) and replaced using a ligation 
reaction that inserted the full-length NCC2HA insert. The pSDS_mNCC2HA 
construct was electroporated into competent cells and selected clones were 
successfully digested in a restriction digestion reaction indicated by the presence 
of double bands (Figure 2.3-3); sequencing of the plasmid revealed correct DNA 
sequence. 
Proteins from NCC, NCC2HA and HA-tag-injected oocytes were extracted for 
Western blot analysis to verify expression of the HA-epitopes. Western blot 
analysis revealed NCC expression in both NCC and NCC2HA-injected oocytes 
which was absent in the HA-tag control (Figure 2.3-4). HA-glycoprotein 
expression was detected in both HA-tag control and NCC2HA-injected oocytes 
and was absent in the NCC-injected group, indicating successful insertion and 
expression of HA-tag (Figure 2.3-4).  
107 
 
 
Figure 2.3-2 NCC2HA DNA construct synthesis  
Agarose gel images of the two-part PCR reaction. a) The partial inserts, 
NCC2HA_1 (877 bp) and NCC2HA_2 (228 bp), were created using 
pSDS_mNCC as the template. b) The full length NCC2HA insert (1105 bp) was 
created from the partial inserts. c) NCC (1050 bp) was cut out of pSDS_mNCC 
(6111 bp) using restriction enzymes, and the same enzymes were used to 
produce compatible sticky ends for the ligation of NCC2HA (1105 bp) and pSDS 
vector.  
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Figure 2.3-3 Restriction digestion analysis of pSDS_mNCC2HA 
Plasmid DNA extracted from E. coli cells harbouring pSDS_mNCC2HA were 
digested with restriction enzymes for restriction digestion analysis. Analysis by 
agarose gel showed four successful pSDS_mNCC2HA clones indicated by the 
presence of the double bands at approximately 3876 bp and 2262 bp. 
 
Figure 2.3-4 Western blot analysis of NCC2HA protein expression in 
oocytes 
Western blot analysis of oocytes injected with 30 ng of HA-tag (positive control), 
NCC2HA and NCC cRNA. Expression of NCC was detected in NCC-injected 
oocytes and NCC2HA-injected oocytes. The expression of HA-glycoprotein was 
only detected in oocytes injected with the HA-tag positive control and NCC2HA.  
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2.3.3 Single oocyte chemiluminescence assay 
After successful construction of NCC2HA, oocytes were injected with HA-tag 
positive control, NCC2HA, and uninjected, water-injected and NCC-injected 
negative controls to verify extracellular exposure of HA-epitopes on oocyte 
surface membrane. The HA-tag positive control emitted significant levels of 
chemiluminescence in comparison to all other groups (n= 33, p<0.0001). 
However, NCC2HA showed no significant difference from water, NCC and 
uninjected-oocytes (Figure 2.3-5); this indicates that HA-epitopes in NCC2HA 
were not detected on surface membrane of oocytes. 
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Figure 2.3-5 Single-oocyte chemiluminescence assay 
Oocyte chemiluminescence assay was performed on uninjected oocytes, oocytes 
injected with water (30 nl) and oocytes injected with cRNA (30 ng) of HA-tag 
(positive control), NCC and NCC2HA. Oocytes were maintained in ND96 
containing antibiotics, at 17 ˚C for three days, prior to the experiment. 
Chemiluminescence was measured using a luminometer and values are 
expressed in relative light units per seconds (RLU/s); data are presented as 
means ± SEM, n= 33. Statistical values were calculated using an ANOVA 
followed by a Bonferroni’s multiple comparison test. 
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2.3.4 Co-expression of NCC and HA-tagged CD8 glycoprotein 
After unsuccessful construction of a working NCC construct with extracellular HA-
tags at Q245, another insertion site, I251, was used but also failed to produce a 
working construct. Unsuccessful attempts in HA-tag insertion at extracellular 
loop-2 were followed by an alternative approach where a CD8 glycoprotein with 
three HA-epitopes attached was co-expressed with NCC. Information on the 
topology of CD8 (P01732) was obtained from the UniProt database (412) and 
three HA-epitopes were inserted at P21 between the signal peptide and the 
extracellular domain (Figure 2.3-6).  
A two-part PCR reaction, similar to the approach used previously, was used to 
generate a full length CD8HA insert. The first PCR reaction generated two partial 
inserts required for full length CD8HA (Figure 2.3-7a) and the second part of the 
reaction combined the partial inserts to generate the full length CD8HA (Figure 
2.3-7b); the two-part PCR reaction was successful, indicated by PCR products of 
approximately the correct size as analysed by agarose gel. The stop codon of 
CD8HA was removed and CD8HA fused with the N-terminus of NCC on 
pSDS_mNCC through restriction digestion and ligation. (Figure 2.3-7c). Products 
from the ligation reaction were electroporated into competent cells, however 
restriction digestion analysis of selected clones showed unsuccessful 
construction of pSDS_mNCC_CD8HA, indicated by the absence of double 
bands. This suggests failed restriction digestion and possibly the absence of 
restriction sites on the plasmid (Figure 2.3-7d).  
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Figure 2.3-6 Schematic representation of pSDS_mNCC_CD8HA 
Schematic diagram of pSDS_mNCC_CD8HA membrane topology, predicted by 
Phobius(407). Twelve TM domains of NCC were identified with intracellular N- 
and C-terminus, and five intracellular and six extracellular loops. A signal peptide 
was identified and located at the N-terminus of CD8 and a TM domain was 
identified at the C-terminus. Three extracellular HA-epitopes (yellow) are inserted 
into the extracellular side of CD8, where the epitopes are exposed to antibody 
detection in an oocyte chemiluminescence assay. 
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Figure 2.3-7 NCC_CD8HA DNA construct synthesis  
Agarose gel images of pSDS_mNCC_CD8HA synthesis a) CD8 was used as a 
template to create two partial inserts: CD8HA_A (228 bp) and CD8HA_B (642 
bp). b) The two partial inserts were combined together to generate a full length 
CD8HA (890 bp). c) pSDS_mNCC and CD8HA insert were digested with the 
same restriction enzymes to create sticky ends compatible for ligation. d) Plasmid 
DNA from colonies harbouring pSDS_mNCC_CD8HA were extracted and 
digested with restriction enzymes for analysis. Agarose gel image of the 
restriction digestion analysis shows a single band in all four clones, instead of 
double bands at 5245 bp and 1744 bp, which indicates uncut restriction sites and 
therefore unsuccessful construction of pSDS_mNCC_CD8HA.  
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2.3.5 Plasmid construct synthesis 
KLHL3, CUL3 and SPAK, proteins also involved in the WNK-NCC cascade were 
cloned for co-expression studies with NCC. The amplification of KLHL3 from 
mouse kidney, lungs and testes cDNA were unsuccessful with no PCR product 
detected on agarose gel (data not shown). CUL3 was successfully amplified from 
mouse kidney cDNA (Figure 2.3.8a) and inserted into the pTLB vector; attempted 
restriction digestion of pTLB_CUL3 indicated unsuccessful insertion of CUL3 into 
the vector shown by the absence of double bands (Figure 2.3-8b).  
SPAK was amplified successfully from mouse kidney cDNA (Figure 2.3-8c) and 
inserted into the pTLB vector. All clones of pTLB_SPAK presented two bands on 
an agarose gel when digested, indicating successful insertion of the SPAK gene 
(Figure 2.3-8d). The sequence of pTLB_SPAK was confirmed to be correct and 
in-frame by DNA sequencing. 
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Figure 2.3-8 CUL3 and SPAK DNA construct synthesis 
Agarose gel images of CUL3 and SPAK construct synthesis. a) CUL3 amplified 
from mouse kidney cDNA (2307 bp) and inserted into the pTLB vector. b) 
Restriction digestion analysis of pTLB_CUL3 (5573 bp) clones showed uncut 
restriction sites, indicated by the single bands shown on the gel image instead of 
double bands at 5185 bp and 382 bp. c) SPAK was amplified from mouse kidney 
cDNA (921 bp) and inserted into the pTLB vector. d) All four selected clones of 
pTLB_SPAK were digested with restriction enzymes and showed successful 
restriction digestion, indicated by correct sizes of double bands (3308 bp and 880 
bp) shown on gel image.   
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2.4 Discussion 
NCC expression is regulated by a sequential inhibitory cascade between various 
WNK kinases. To further elucidate the regulatory mechanism underlying the 
WNK-NCC cascade, different ratios of WNK kinases, CUL3, KLHL3 and SPAK 
were co-expressed with NCC to determine changes in NCC activity. For this 
study, a single-oocyte chemiluminescence assay was developed with the aim of 
measuring NCC expression on the surface membrane of oocytes, when 
expressed with WNK kinases, CUL3, KLHL3 and SPAK. Several studies have 
successfully expressed WNK kinases (207), CUL3 (259), KLHL3 (259), SPAK 
(413) and NCC (207) in oocytes, providing the capacity for investigating 
interactions between these proteins. 
2.4.1 Oocyte chemiluminescence assay 
The oocyte chemiluminescence assay was first developed in 1999 by Zerangue 
et al. (411). In the study, HA-epitopes were engineered into ATP-sensitive K+ 
channel subunits. These epitopes were recognised by an anti-HA-epitope tag 
antibody and chemiluminescence were then used to quantify the levels of K+ 
channels expressed on the cell surface of oocytes (411). Epitope tagging has 
been very well characterised and extensively used (414,415). Epitope tags such 
as, the HA-tag, can be genetically grafted into recombinant proteins and 
antibodies against these epitopes are highly specific, providing a dependable tool 
for protein detection in multiple quantitative techniques. Oocyte 
chemiluminescence assay quantifies membrane proteins that are expressed at 
low levels on the cell membrane by using enzyme amplification, and provides 
sensitivity and linearity that are comparable to other chemiluminescence 
technique. Since its development in 1999, this protocol has been used 
extensively in other studies (241,416,417).  
Studies using NCC with HA-tags introduced into the extracellular loops has 
previously been used by Subramanya et al. (121). They inserted HA-epitopes into 
the putative second extracellular loop of NCC and expressed it on the membrane 
of human embryonic kidney 293 (HEK 293) cells. In this present study, two HA-
epitopes were successfully inserted into the second extracellular loop of NCC, 
however, the oocyte chemiluminescence assay failed to detect significant 
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chemiluminescence from NCC2HA-injected oocytes. Since a significant level of 
chemiluminescence was detected from the HA-tag positive control, it is evident 
that the chemiluminescence assay in this experiment has been optimised. The 
expression of HA-glycoproteins in NCC2HA-injected oocytes was confirmed 
through Western blotting, therefore, the lack of chemiluminescence could be due 
to the fact that NCC2HA failed to express on the surface membrane of oocytes 
and were therefore not detected by the antibodies. To verify this, 
immunohistochemistry could be used to visualise the localisation of NCC2HA in 
oocytes (418,419). HA-epitopes were also introduced at I251 in another NCC2HA 
construct, the site used by Subramanya et al. (121), but this construct failed to 
express HA-epitopes.  
The secondary structure of NCC is poorly understood and its crystal structure is 
not available in the current literature. A variety of topology prediction software 
packages are available for proteins with unknown structures; this is especially 
useful for proteins that have not yet been investigated by X-ray crystallography. 
Topology and glycosylation predictions are based on statistics of amino acid 
sequences and known topologies of membrane proteins, which means that 
accurate structural predictions of NCC are limited. Since chemiluminescence was 
not detected in the NCC2HA injected oocytes, it is possible that the HA-epitopes 
were inserted into a region that is not exposed extracellularly. In addition, it is 
also possible for other extracellular structures, such as the extracellular loop-3 
and loop-4, to shield the HA-epitopes from antibody detection in oocytes. The 
unexposed HA-epitopes will not be detected by antibodies and therefore will not 
emit chemiluminescence.  
Therefore, to minimise the risk of modifications interfering with normal NCC 
structure and function, a well characterised reporter protein (CD8) with 
extracellular HA-epitopes inserted, was fused with NCC. The use of reporter 
genes has been well documented since first introduced in 1980 (420); similar to 
the HA-tag, they are easily identified and measured. Several studies have used 
CD8 as a reporter protein and co-expressed it with other membrane proteins 
(421,422). In this study three extracellular HA-epitopes were inserted into CD8 
and attached to the N-terminus of NCC; after multiple attempts in creating the 
NCC_CD8HA construct, it remained unsuccessful. One of the most common 
explanations for unsuccessful cloning is an incorrect DNA sequence of the 
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template. The DNA sequence of the pSDS_mNCC plasmid was verified prior to 
the initial cloning of NCC2HA; however, the CD8 DNA sequence was not verified 
prior to this experiment. It is possible that restriction sites present in the unverified 
CD8 DNA sequence were in fact, absent from the construct; without these 
restriction sites, sticky ends are not generated and NCC and CD8HA will not 
ligate. The DNA sequence of CD8 requires verification, and if the sequence is 
correct, perhaps a NCC construct with extracellular CD8 and the use of a CD8 
antibody would solve the existing problems with HA-tag insertion. 
2.4.2 Other members of the WNK-NCC cascade  
In this study, SPAK was successfully cloned from mouse cDNA but CUL3 and 
KLHL3 were unsuccessful after multiple attempts. A potential reason for 
unsuccessful cloning of KLHL3 (1923 bp) and CUL3 (2307 bp) could be due to 
the fact that these are large genes. Sometimes long amplimers might be present 
in the PCR product but only at low levels, making it harder or impossible to 
visualise on an agarose gel, meaning it is mistaken for a failed amplification. It is 
possible to overcome this issue by performing a two-part PCR reaction to create 
partial inserts and using the partial inserts as templates for the full-length product; 
this is similar to the approach used for the cloning of NCC2HA in this study. 
Alternatively, the gene of interest might be present at low levels in the cDNA 
template, therefore preparing cDNA from tissues that are known to have higher 
expression levels of the gene of interest might aid the cloning process; in this 
instance using the cerebellum for CUL3 and KLHL3 amplification instead of the 
kidneys may have generated better results (177,423). 
2.4.3 Future experiments  
Once these technical issues are overcome, oocytes expressing NCC and the 
WNK kinases could be treated with FK506 and NCC expression can then be 
measured with the oocyte chemiluminescence assay. The single-oocyte 
chemiluminescence assay would have provided a reliable quantification method 
for assessing protein abundance on the plasma membrane and a tool for 
establishment of protein-protein interactions. One of the advantages of using an 
oocyte expression system is the ability to control RNA levels of different proteins 
injected into each oocyte; this can be used to study the effect of different protein 
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levels and its impact on the target protein, stoichiometry of subunits and protein 
complexes.  
 
Whilst the oocyte chemiluminescence assay provides information on the 
membrane abundance of NCC, it does not measure the activity of NCC, 
therefore, oocyte chemiluminescence assay should be used in conjunction with 
other approaches to measure activity. Uptake studies using 22Na and oocytes 
have previously shown successful assessment of NCC activity (121,192,214). In 
addition, Yang et al. (214) used 22Na uptake assays to investigate the interaction 
between the WNK kinases and NCC, and showed that NCC activity was reduced 
by 85 % in oocytes co-expressing NCC and WNK4. 
 
Experiments in this chapter aimed to investigate the interaction between NCC 
and members of the WNK cascade. However, given the technical issues 
encountered, a different approach was required. Phosphorylation seems to be 
the main determinant of protein activity in members in the WNK-NCC cascade, 
and CNIs are known to affect multiple phosphoproteins downstream of 
calcineurin. The interaction between calcineurin and the WNK kinases is poorly 
understood, therefore, quantitative phosphoproteomics (Chapter 3) was used to 
identify and measure protein phosphorylation dysregulated by CNIs and provide 
insights into WNK kinase regulations. 
  
120 
 
 
 
 
 
 
Chapter 3. Exploring the effect of FK506 on the renal 
kinome 
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3.1 Introduction 
Calcineurin is involved in numerous fundamental cellular pathways and plays an 
important role in several immune and developmental processes. Calcineurin is 
the target of CNIs, widely-used immunosuppressants for transplant recipients 
that cause many side effects. These side effects include post-transplant 
metabolic syndrome and electrolyte disorders caused by renal tubule 
dysfunction, such as hyperkalaemia, metabolic acidosis, hypercalciuria and 
hypomagnesaemia. The hypertensive phenotype of FK506 resembles FHHt, 
which is characterised by overactive NCC caused by mutations in the WNK 
kinases, WNK1 and WNK4, and KLHL3 and CUL3.  
 
Phosphorylation is important in determining the activity of proteins in the 
calcineurin-WNK cascade, as shown through the effect of FK506 on NCC 
phosphorylation. WNK3 and WNK4 have opposing roles on NCC regulation and 
are both increased by FK506 (51). The increase in WNK4 contradicts its 
proposed role as an inhibitor of NCC, however WNK4 appears to have different 
roles under different cellular environments and its kinase activity is dependent on 
phosphorylation (244). Most protein phosphorylation is tightly controlled by 
kinase and phosphatase activity, therefore it is plausible that the activity of WNK4 
is regulated and defined by an intermediary signalling pathway downstream of 
calcineurin. Since calcineurin is a protein phosphatase, it is likely that these 
intermediary proteins are inhibited and dephosphorylated by calcineurin under 
normal conditions. We hypothesised that CNI administration would alter the 
phosphorylation state of a number of proteins in the renal cortex of treated 
animals, importantly including the putative upstream regulators of the WNK 
kinase cascade. If we could identify proteins that had their phosphorylation state 
altered in this way, then we might be able to bring a number of analytical 
approaches to bear to identify likely candidates for this putative regulatory 
pathway.  
 
For this study, quantitative phosphoproteomics was used to identify and measure 
changes in the phosphorylation of proteins in the renal cortices of mice treated 
with FK506. Quantitative proteomics (424) and phosphoproteomics (425–427) 
have been widely used in renal research for large-scale high-throughput studies 
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of proteins. Quantitative phosphoproteomics was first used in 2006 by Hoffert et 
al. (428), where a label-free immobilised metal affinity chromatography (IMAC) 
approach was used to quantify phosphopeptides in inner medullary collecting 
duct cells. Several label-free and label-based quantitative techniques are 
available and are commonly used. Label-free approaches offer a wider proteome 
coverage than label-based approaches (429). However, label-based approaches, 
such as Tandem Mass Tags (TMT), offers a greater accuracy of protein ratios 
and the ability to perform multiplexed analysis of multiple samples in a single 
experiment. This approach diminishes variations during sample preparation, 
chromatography and mass spectrometry (MS) acquisition (429). For these 
reasons, TMT was used for quantification in this study. Multiple phosphopeptide 
enrichment techniques are currently available, the most popular of which and 
typically used techniques are IMAC and metal oxide affinity chromatography 
(430), such as TiO2. The two phosphopeptide enrichment strategies have 
comparable enrichment efficiency and number of phosphopeptides identified 
(431,432), however TiO2 enrichment has been shown to be more selective than 
IMAC, and therefore was chosen for this study. 
3.1.1 Aims 
• To investigate and identify an intermediary pathway that regulates the WNK 
cascade and their effects on NCC regulation downstream of calcineurin. 
• To generate a phosphoproteome profile of the renal cortices post-FK506 
treatment, and to determine changes in the phosphorylation of other transport 
proteins altered by FK506.  
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3.2 Materials and methods 
Calcineurin is a protein phosphatase and FK506 has been shown to alter the 
activity of serine/threonine kinases. Using quantitative phosphoproteomics, novel 
phosphoproteins involved in the regulation of WNK-NCC cascade were identified 
and the phosphorylation statuses of these proteins were measured in kidneys of 
FK506/vehicle-treated mice. The experimental procedure performed is illustrated 
in Figure 3.2-1. 
3.2.1 Animals 
Animal studies were carried under the UK ASPA Act, 1986, Amendment 
Regulations 2012. Protocols were approved by UCL (Royal Free Campus) 
Comparative biology Unit AWERB committee (PPL: 70/8064) (PIL: l3635E6BF). 
Male C57BL/6J mice of 6-8 weeks (22.9 g ± 2.25) were administered 2 mg/kg/day 
FK506 (LC laboratories, Boston, US) or vehicle by intraperitoneal (IP) injections 
for 14 days; FK506 was dissolved in vehicle solution containing 10 % ethanol, 10 
% Tween-20 and 0.9 % saline. Mice were kept in metabolic cages over the 
treatment period and urine was collected every 24 h under mineral oil. They were 
fed on a standard rodent maintenance diet (Special Diet Services, UK), 
containing 0.25 % sodium and 0.38 % chloride.  
Mice were terminally anaesthetised with 60 µg/g pentobarbitone sodium 
(Pentoject, Animalcare Ltd, York, UK) via IP injection. Successful anaesthesia 
was determined by the loss of righting and pain reflexes. Two-to five hundred 
microlitres of blood was sampled by cardiac puncture and the mice were 
euthanized by cervical dislocation; death was confirmed by cessation of the 
heartbeat.  
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Figure 3.2-1 Schematic representation of the experimental procedure. 
Mice were injected with vehicle or 2 mg/kg of FK506 daily for 14 days. Kidney 
cortices were isolated, homogenised and fractionated into samples containing the 
membrane or cytosolic fractions. Protein lysates were treated and digested into 
peptides by trypsin. Samples from vehicle or FK506 were chemically labelled with 
TMT2 126 or TMT2 127 reporter ions. TMT2 126 and TMT2 127 labelled samples 
were combined and phosphorylated peptides were enriched using titanium 
dioxide. Samples were injected into the liquid chromatography-mass 
spectrometry (LC-MS/MS) for quantitative phosphoproteomic analysis.  
125 
 
3.2.2 Electrolyte measurements in blood and urine 
Immediately after blood collection, glucose concentration was measured with an 
Accu-Chek Aviva blood glucose meter (Roche, UK); the remaining sample was 
left at room temperature for 15 minutes to allow clotting. Urine and blood were 
centrifuged at 2,000 x g for 10 minutes at 4 ˚C. The resulting supernatant were 
collected and stored at -20 ˚C until use. Haemolysed serum samples were 
discarded. Urine and serum calcium, magnesium, bicarbonate, chloride, 
potassium, sodium and creatinine (using the Jaffe method) were measured using 
the RX Daytona plus clinical chemistry analyser (Randox, UK). Samples were 
processed by Department of Clinical Biochemistry (Royal Free London NHS 
Foundation Trust). 
3.2.3 Kidney protein homogenisation 
Mouse renal cortices or whole kidneys were dissected and homogenised on ice 
with an ultra-turrax (IKA, Staufen, Germany) in homogenisation buffer [1 x TBS, 
300 mM sucrose, 5 mM EDTA, pH 7.5] containing protease (cOmplete tablets, 
Roche, Mannheim, Germany) and phosphatase inhibitors (PhosSTOP tablets, 
Roche, UK). A final concentration of 1 % Triton X-100 was added to the samples, 
which were then incubated at 4 ˚C for 10 minutes. Samples were centrifuged at 
2,000 x g for 5 minutes at 4 ˚C to eliminate debris (pellet); the supernatant, also 
known as the post-nuclear supernatant (PNST), was centrifuged further at 
150,000 x g for 45 minutes at 4 ˚ C. This ultra-centrifugation step allows separation 
of the PNST into cytosolic (supernatant) and membrane (pellet) fraction. The 
membrane fraction was then ultra-sonicated on ice using an ultrasonic processor 
(Hielscher, Teltow, Germany) for 5 cycles at 100 % amplitude, with water 
containing protease and phosphatase inhibitors. Protein concentration was 
determined using a BCA protein assay kit (Pierce, Loughborough, UK), according 
to the manufacturer’s protocol; absorbance was measured at 650 nm using a 
Multimode detector DTX 880 (Beckman Coulter, California, USA). 
The purity of the enrichment was determined through Western blot analysis of a 
cytosolic protein, ERK1/2; details of which are in the Western blot protocol. The 
expression of ERK1/2 was most abundant in the cytosolic fraction and lower in 
the PNST and membrane fraction, indicating successful fractionation (Appendix, 
Figure 6.2-1).  
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3.2.4 Western blot analysis 
Protein samples (30 µg) were separated on a 10 % SDS-PAGE gel. Proteins 
were transferred onto PVDF membrane (Bio-rad, UK) using a Trans-Blot Semi-
Dry Transfer cell (Bio-rad, UK). Membranes were blocked with 5 % milk in 
phosphate-buffered saline (PBS) containing 0.1 % Tween-20 (PBS-T) for 1 h and 
probed with antibody against the following proteins: NCC (1-100) [1:500] and 
phospho-NCC (T60) [1:300] (both from MRC-PPU, Dundee, UK), phospho-
NKCC2 directed at T96/T101 [1:500] (kind gift from C. Wagner), ERK1/2 (K23): 
sc94 [1:1000] (Santa Cruz Biotechnology, UK), phospho-ERK directed at 
T202/Y204 [1:500] and AKT (60203-2-Ig) [1:1000] (both from Proteintech, 
Manchester, UK), and phospho-AKT (S124) [1:500] and anti-β-actin (AC-15) 
[1:2000] (both from Abcam, Cambridge, UK). All antibodies were diluted in PBS-
T and incubated overnight at 4 ˚C. Secondary antibodies were also diluted in 
PBS-T at 1:1000 and incubated for 1 h at room temperature. For details on 
densitometry, see Chapter 2, Section 2.2.5.3.  
3.2.5 Statistics 
Statistical analysis was performed by unpaired t-tests. The data are presented as 
means ± SEM. 
3.2.6 Reduction, alkylation precipitation and tryptic digestion 
Fractionated proteins (1.8-3 mg) from the renal cortices of vehicle or FK506-
treated mice were reduced by adding 10 mM DTT in 0.1 M triethylammonium 
bicarbonate (TEAB) and incubated at 60 ˚C for 10 minutes. This was followed by 
alkylation with 25 mM iodoacetamide in 0.1 M TEAB for 30 minutes in the dark 
and the reaction was quenched with 25 mM DTT in 0.1 M TEAB.  
Samples were precipitated overnight with 6 volumes of iced acetone at -20 ˚C, 
which were then centrifuged at 13,000 x g, at 4˚ C for 15 minutes. The pellet was 
resuspended in 0.1 M TEAB containing 0.5 % sodium dodecyl sulphate (SDS). 
Protein loss after precipitation is very common; to account for this, 15 µg of 
protein before and after acetone precipitation was separated on a 10 % SDS-
PAGE gel. The gel was silver stained with ProteoSilverTM Silver Stain kit (Sigma-
Aldrich, Germany); the staining procedure was performed according to the 
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manufacturer’s protocol. Silver staining showed minimum protein loss post-
precipitation (Appendix, Figure 6.2-2). 
The concentration of SDS in samples was diluted to 0.1 % prior to trypsin 
hydrolysis to avoid enzyme denaturation and inactivation. Proteins were cleaved 
by trypsin (Promega, Southampton, UK), 1 µg of trypsin was used per 100 µg of 
protein, overnight at 37 ˚C in 0.1 M TEAB.  
3.2.7 TMT Labelling and Phosphopeptides enrichment 
Samples were labelled using TMTduplexTM Isobaric Mass Tagging kit (Thermo 
Fisher Scientific, Loughborough, UK), 0.8 mg of TMT reagents were used per 
400 µg of protein and labelling procedures were performed according to the 
manufacturer’s protocol. Labelling efficiency of the samples was evaluated by 
LC-MS/MS to ensure that over 95 % of the peptides were labelled; refer to Figure 
6.2-3 in the Appendix for the labelling efficiency. Moreover, to account for protein 
loss after precipitation and to ensure that the samples are mixed in equal 
proportions, an aliquot (1 µl) from each sample (TMT126 andTMT127) were 
mixed and injected into the LC-MS/MS. The total signal intensity for each of the 
reporter ions was calculated for sample normalisation before phosphopeptide 
enrichment (data not shown). 
For phosphopeptide enrichment, samples were pooled together in a ratio of 1:1 
after normalisation and phosphopeptides were then enriched using a PierceTM 
TiO2 Phosphopeptide Enrichment and Clean-up Kit (Thermo Fisher Scientific, 
Loughborough, UK), following the manufacturer’s protocol. The unbound 
fractions (TiO2 flow-through), containing unphosphorylated peptides, were 
desalted with PierceTM C18 Spin Columns (Thermo Fisher Scientific, UK) and 
injected into the LC-MS/MS to obtain the ratio of TMT126/TMT127, which was 
then used to correct the reporter ion intensities in the datasets (data not shown). 
Fractions containing phosphopeptides specifically eluted from the TiO2 columns 
were purified using the graphite columns provided and eluted thrice with 0.1 % 
formic acid in 50 % acetonitrile. All samples were dehydrated and resuspended 
in 0.1 % formic acid prior to LC-MS/MS analysis.  
128 
 
3.2.8 Mass Spectrometry 
LC–MS/MS analysis was performed with an LTQ-Velos Orbitrap mass 
spectrometer (Thermo Fisher Scientific). Peptide samples were loaded using a 
nanoACQUITY UPLC (Waters, U.K.) with Symmetry C18 180 μm × 20 mm 
(Waters part number 186006527) trapping column for desalting and then 
introduced into the mass spectrometer via a Stonearch fused silica capillary 
column 100 μm i.d.; 360 μm o.d.; 15 cm length; 5 μm C18 particles (Nikkyo 
Technos CO, Tokyo, Japan part number NTCC 360/100-5-153) and a 
nanoelectrospray ion source at a flow rate of 0.42 μL/min. The mobile phase 
comprised H2O with 0.1 % formic acid (buffer A) and 100 % acetonitrile with 0.1 
% formic acid (buffer B). The gradient ranged from 1 % to 50 % buffer B in 136 
minutes and a step gradient to 85 % buffer B for 10 minutes with a flow of 0.42 
μL/min, finally a return to the initial conditions of 1 % buffer B for 20 minutes.  
The full scan precursor survey MS spectra (400–1600 m/z) were acquired in full 
profile with the Velos-Orbitrap analyser with a resolution of r = 60,000. This was 
followed by data dependent MS/MS fragmentation in centroid mode of the most 
intense ion from the survey scan electrospray voltage 1.5 kV; capillary 
temperature 200 °C; and isolation width 2.00. 
Firstly, using collision induced dissociation in the linear ion trap: normalized 
collision energy 35 %; activation Q 0.25 and activation time 10ms and the second 
MS/MS event, the most intense ion from the survey scan was fragmented using 
higher energy collision dissociation (HCD) in the HCD collision cell: normalized 
collision energy 50 %; resolution 7500 and activation time 0.1 ms. The two 
MS/MS scan events was repeated for the top 10 peaks in the MS survey scan, 
the targeted ions were then dynamically excluded for 30 seconds. Singly charged 
ions were excluded from the MS/MS analysis and Xcalibur software version 2.1.0 
SP1 build 1160 (Thermo Fisher Scientific, U.K.) was used for data acquisition. 
Mass spectrometry procedures were performed by M. Crawford. 
3.2.9 Proteins and Peptides Identification, Quantification and Enrichment 
analysis 
Proteome Discoverer 1.3 (Thermo Fisher Scientific, UK) was used to analyse the 
datasets. Raw Data was searched against the UniProt Mus musculus database 
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(version 2015_10) alongside the Mascot search engine. Two trypsin missed 
cleavages were allowed; carbamidomethylation and TMT labels were set as 
static modifications whereas serine, threonine, tyrosine phosphorylation and 
methionine oxidation were set as dynamic modifications. Mass tolerance was set 
to 10 ppm for precursor ions and to 0.8 Da for fragments. False discovery rate at 
the peptide level was set to 0.05 and phosphosites localisation was verified 
through the PhosphoRS package embedded in Proteome Discoverer.  
All phosphopeptide spectra were manually validated to confirm phosphosite 
localisations. For peptide quantification, TMT intensities were extracted from 
HCD scans, and corrected for isotope impurities accordingly to percentages 
provided by the manufacturer. Quantitative information obtained from the MS 
analysis of the TiO2 flow-through samples (Appendix, Figure 6.2-3) were used to 
normalise the reporter ion intensities, in the case of loading imbalances.  
Quantified peptides containing phosphorylation modifications with unique 
identifications were manually validated before being processed. In detail, 
quantified phosphopeptides obtained from the three replicates were grouped into 
unique phosphopeptide groups according to their sequences, pRS site 
probabilities (probability for each putatively phosphorylated site) and MH+ [Da] 
value. The average ratio, standard deviation and coefficient of variation of each 
unique phosphopeptide were calculated. All of the unique phosphopeptides were 
summarised and information on their gene name, protein name, keywords, gene 
ontology (biological process, molecular function, cellular component and IDs), 
KEGG and Reactome were obtained from UniProt Knowledgebase (412) and 
matched to the protein accession number of each phosphopeptide.  
Phosphopeptides with >10 % change (increase or decrease) in phosphorylation 
were considered as FK506-dysregulated phosphopeptides. The proteins 
assigned to these phosphopeptides were submitted into STRING (433), a known 
and predicted protein-protein interactions database, and a protein interaction 
network was generated. These protein interaction networks were analysed 
through Cytoscape (434), a software platform for visualising and integrating 
complex interaction networks and pathways, and protein clusters were identified 
using the ClusterONE plugin (435), a graph clustering algorithm that identifies 
protein complexes in a protein-protein interaction network. Phosphorylation 
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motifs of the phosphopeptides were predicted with Motif-X (436,437), a software 
tool used for classifying phosphorylation sites with regards to overrepresented 
amino acid patterns in the dataset, and phosphorylation motifs with serine, 
threonine or tyrosine as the central residue was searched for. The sub-lists of 
proteins classified as ‘transporters’, ‘channels’, ‘kinases’, ‘phosphatases’ and 
other ‘kinase/phosphatase’ related phosphoproteins obtained from Panther 
(Protein Analysis Through Evolutionary Relationships) Classification system 
(438) were selected for further analysis. Verifications of phosphosites were 
retrieved from PhosphoSitePlus® Database (439). Sequence alignment of 
proteins was performed using the Clustal Omega (1.2.1) multiple sequence 
alignment tool (440).  
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3.3 Results 
3.3.1 Validation of adverse effects caused by CNIs  
FK506 treatment of mice was used to induce some of the known side effects of 
CNIs. To confirm the effectiveness of the treatment, electrolyte levels in urine and 
serum of mice treated with vehicle or FK506 were examined. FK506-treated mice 
demonstrated hypercalciuria and hypomagnesaemia (Table 3.3-1). These are 
well documented effects of FK506 (51,57), indicating that FK506 successfully 
induced dysregulation in electrolyte homeostasis in the mice used in this study.  
Additionally, protein levels of NCC, activated pNCC and pNKCC2 were 
determined through Western blot analysis. Previous studies reported that FK506 
increased pNCC levels and did not affect NCC and pNKCC2 during treatment 
(51). Western blot analysis revealed that FK506 significantly increased pNCC 
levels and confirmed that NCC and pNKCC2 levels remained unaltered (Figure 
3.3-1). Blood pressure was not measured in these animals and therefore 
hypertension could not be confirmed.  
. 
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Table 3.3-1 Serum and urine electrolytes in mice treated with vehicle or 
FK506 
Serum 
 Vehicle FK506 
Ionised calcium (mmol/l) 
(n=5) 
2.05 ± 0.136 2.31 ± 0.051 
Magnesium (mmol/l) 
(n=5) 
1.01 ± 0.068  0.80 ± 0.023 * 
Bicarbonate (mmol/l) 
(n=6) 
12.56 ± 0.756 13.90 ± 0.853 
Glucose (mmol/l) 
(n=5) 
10.42 ± 0.896 13.38 ± 1.630 
Chloride (mmol/l) 
(n=6) 
144 ± 9.462 131.20 ± 2.960 
Potassium (mmol/l) 
(n=6) 
4.80 ± 0.442 4.80 ± 0.251 
Creatinine (μmol/l) 
(n=5) 
43.74 ± 4.136 53.40 ± 11.950 
Urine 
 Vehicle FK506 
Calcium (mmol/mmol) 
(n=5) 
0.06 ± 0.012 0.10 ± 0.010 * 
Volume (ml/day) 
(n=6) 
0.70 - 1.20 0.50 - 1.30 
 
Weight (g) 
(n=5) 
22.74 ± 0.420 21.99 ± 0.264 
Serum and urine electrolytes of FK506-treated mice. Mice administrated 2 
mg/kg/day FK506 for two weeks by daily IP injections. Statistical values were 
calculated using an unpaired t-test. Data are presented as means ± SEM. * 
P<0.05 vs. vehicle. 
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Figure 3.3-1 Protein expression of distal nephron transporters post-FK506 
treatment 
Western blot analysis was performed on kidney membranes of FK506 or vehicle 
treated mice. Representative blots of a) NCC, b) pNCC and c) pNKCC2 are 
shown. Band intensities of the transporters were quantified and normalised to 
those of β-actin and expressed as fold change of the control mean; data are 
presented as means ± SEM, n=5. Statistical values were calculated using an 
unpaired t-test.   
134 
 
3.3.2 Overview of the proteomics dataset 
Using quantitative phosphoproteomics, changes in the phosphorylation status of 
proteins in the renal cortices of FK506-treated mice were identified and 
quantified. Using Proteome Discoverer alongside Mascot, LC-MS/MS identified 
18,971 peptides in the membrane triplicates and 5,395 in the cytosolic triplicates. 
Unphosphorylated, redundant and unquantified peptides without a unique 
identification were filtered out, resulting in a total of 3,962 phosphopeptides in the 
membrane fraction (Appendix, Table 6.3-1) and 1,376 in the cytosolic fraction 
(Appendix, Table 6.3-2).  
The datasets were processed as described previously in the methods section, 
and as a result, 622 unique phosphopeptides were identified in the membrane 
fraction (Appendix, Table 6.3-3) and 415 were identified in the cytosolic fraction 
(Appendix, Table 6.3-4). The total number of unique phosphopeptides in the 
membrane fraction was 1.5-fold higher than the cytosolic fraction. 
The number of unique phosphopeptides shared amongst the replicates for each 
fraction is shown in the Venn diagram (Figure 3.3-2). In the membrane, 64 % of 
unique phosphopeptides are present in two or more replicates and in the cytosol, 
44 % are present in two or more replicates; these percentages represent the 
reproducibility of the experiment, which can vary depending on sample 
complexity. In each MS experiment, phosphopeptides with similar chemical 
properties elute from the LC column at the same time and MS detects the most 
abundant peptides at each time point; this reduces the chance of identifying a 
specific phosphopeptide that is present in every replicate, especially in a complex 
sample. Since the two fractions are products of a subcellular fractionation, the 
contents and the complexity are different. The lower percentage of unique 
phosphopeptides present in the replicates indicates that the cytosolic fraction is 
higher in complexity than the membrane fraction, therefore there is a higher 
chance of identifying different phosphopeptides in each replicate in the cytosolic 
fraction.  
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Figure 3.3-2 The number of unique phosphopeptides identified in the 
membrane and cytosolic fractions.  
Venn diagrams showing the number of unique phosphopeptides identified in 
individual replicates of the membrane (left) and cytosolic fraction (right). A, B and 
C represents individual replicates and the number of unique phosphopeptides 
shared between the replicates are shown. 
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3.3.3 Data interpretation  
Phosphopeptide ratios calculated from the reporter ion intensities 
(TMT127/TMT126) are presented as percentages in the data. The large 
proteomic datasets were analysed using several bioinformatics techniques: 
threshold criterion, network pathways, phosphorylation motifs and candidate 
approach. Using several different bioinformatic techniques to analyse large 
proteomic datasets is highly effective at excluding housekeeping proteins, 
however some proteins of interest, especially when the aim was to identify novel 
phosphoproteins, may be filtered out. Therefore, some proteins of interest 
selected from the main protein table (Appendix, Table 6.3-3 and Table 6.3-4) are 
also presented in Section 3.3.3.6.  
3.3.3.1 FK506-dysregulated proteins 
Phosphopeptides with more than a 10 % change in phosphorylation were 
considered up- or downregulated by FK506. FK506-dysregulated proteins were 
submitted into STRING (441) to search for known and predicted protein-protein 
interactions, and a protein interaction network for each cellular fraction was 
generated. The interactions between pairs of proteins were identified based on 
seven criteria: experimental data, curated database (such as the KEGG pathway 
databases) text mining in all PubMed abstracts, co-expression studies, 
phylogenetic distribution of orthologs of all proteins in Mus musculus, the 
presence of a hybrid gene in the respective protein and their consistency 
observed in the genome neighbourhood. A confidence score was calculated for 
each criterion and these scores were combined (combined score) to form the 
interaction (edge) shown in the network. These combined scores ranged from 0 
to 1, the higher the combined score, the thicker the edges in the protein network, 
and therefore represents a higher confidence level in the established interaction. 
Each interaction, presented in the networks, has a combined score of over 0.4, 
meaning that the established interaction is true, specific and reproducible to a 
medium confidence level. The protein nodes in the network diagrams are colour 
coded, such as that FK506-upregulated proteins are coloured green and FK506-
downregulated proteins are coloured yellow. Proteins without any established 
interactions (disconnected protein nodes) were hidden from the network and are 
not shown in the figures.  
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Using Cytoscape (434), two figures were generated from each protein interaction 
network. Figures 3.3-3 and Figure 3.3-5 contains information regarding protein 
clusters identified in the network dysregulated by FK506 in the membrane and 
cytosolic fractions respectively. The ClusterONE plugin (435) on Cytoscape was 
used to identify protein clusters present in the network. Clusters with a p-value of 
<0.05 were grouped according to their biological processes. In addition, 
Cytoscape also calculates the ‘betweenness centrality’ of the proteins in the 
networks. Betweenness centrality of an individual protein reflects its ability to 
exert its interactions over the interactions of other proteins in the network (442); 
these are directly correlated to the sizes of the protein nodes. Figures 3.3-4 and 
Figures 3.3-6 contain information regarding regulatory proteins associated with 
kinases and phosphatases dysregulated by FK506 in the membrane and 
cytosolic fractions respectively. These proteins were identified using the Panther 
Classification system (438); proteins associated with kinases are square shaped 
and proteins associated with phosphatases are diamond shaped.  
In the membrane fraction, 260 and 151 unique phosphopeptides, represented by 
225 proteins, were up- and downregulated by FK506 respectively. Of these 
proteins, 66 were disconnected from the network and 159 formed 465 interactions 
within the network. Six protein clusters involved in different biological processes 
were identified in the membrane protein network. These include 34 proteins 
involved in gene expression (blue), 13 proteins involved in ion transport (red), 6 
proteins involved in endocytosis (orange), 6 proteins involved in chromatin 
organisation (purple), 6 proteins involved in cell division (pink) and 5 proteins 
involved in protein transport (cyan) (Figure 3.3-3). Six kinase-associated proteins 
(square) and two phosphatase-associated proteins (diamond) were identified in 
the network of FK506-dysregulated phosphoproteins in the membrane fraction 
(Figure 3.3-4). The connections and protein clusters identified in the membrane 
fraction are highly complex, and few phosphoproteins, such as heat shock protein 
HSP 90-β (HSP90AB1) and spectrin α-chain (SPNA2), appeared to act as hubs 
at the centre of the membrane protein network. HSP90AB1 is a chaperone 
protein involved in protein stabilisation and trafficking, and SPNA2 is a 
cytoskeletal protein involved in cell adhesion and cell cycle regulation. 
HSP90AB1 and SPNA2 are both ubiquitously expressed and are connected to 
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most of the protein clusters identified in the network, consistent with the 
pleiotropic effect of HSP90AB1 and SPNA2 in cellular processes. 
In the cytosolic fraction, 90 and 154 unique phosphopeptides, represented by 138 
proteins, were up- and downregulated by FK506 respectively. Of these proteins, 
58 were disconnected from the network and 80 formed 123 interactions within the 
network. Three protein clusters involved in different biological processes were 
identified in the membrane protein network. These include 7 proteins involved in 
translation (blue), 6 proteins involved in ion transport (red) and 3 proteins involved 
in cell division (green) (Figure 3.3-5). Four kinase-associated proteins (square) 
were identified in the network of FK506-dysregulated phosphoproteins in the 
membrane fraction, but no phosphatase-associated proteins were found (Figure 
3.3-6). In contrast to the membrane fraction, the connections and protein clusters 
identified in the cytosolic fraction are less complex. Similar to HSP90AB1, AKT1 
also has pleiotropic effects in multiple cellular processes, including cell 
proliferation, survival and metabolism (443,444), thus AKT1 and HSP90AB1 
appeared to act as the main hubs at the centre of the cytosolic protein network. 
In addition, AKT1 is connected to the clusters of proteins involved in sodium ion 
transport, suggesting that AKT1 may play a role in altered renal sodium transport 
downstream of calcineurin.  
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Figure 3.3-3 Protein clusters identified in the network of FK506-
dysregulated proteins in the membrane fraction 
In the membrane fraction, 465 interactions between 159 proteins were identified. 
Each interaction has a combined score of over 0.4; the edge weights are directly 
correlated to the score. FK506-upregulated protein nodes are coloured green and 
FK506-downregulated protein nodes are coloured yellow. The sizes of the protein 
nodes directly correlate to the betweenness centrality of the protein in the 
network. ClusterONE was used to identify protein clusters (p < 0.05) and proteins 
from these clusters were grouped into different biological processes: gene 
expression (blue), ion transport (red), endocytosis (orange), chromatin 
organisation (purple), cell division (pink) and protein transport (cyan).
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Figure 3.3-4 Regulatory proteins associated with kinase/phosphatase 
identified in the network of FK506-dysregulated proteins in the membrane 
fraction 
In the membrane fraction, 465 interactions between 159 proteins were identified. 
Each interaction has a combined score of over 0.4; the edge weights are directly 
correlated to the score. FK506-upregulated protein nodes are coloured green and 
FK506-downregulated protein nodes are coloured yellow. Regulatory proteins 
associated with kinases are square shaped and those associated with 
phosphatases are diamond shaped. 
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Figure 3.3-5 Protein clusters identified in the network of FK506-
dysregulated proteins in the cytosolic fraction 
In the cytosolic fraction, 123 interactions between 80 proteins were identified. 
Each interaction has a combined score of over 0.4; the edge weights are directly 
correlated to the score. FK506-upregulated protein nodes are coloured green and 
FK506-downregulated protein nodes are coloured yellow. The sizes of the protein 
nodes directly correlate to the betweenness centrality of the protein in the 
network. ClusterONE was used to identify protein clusters (p < 0.05) and proteins 
from these clusters were grouped into different biological processes: translation 
(blue), sodium ion transport (red) and cell division (green). 
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Figure 3.3-6 Regulatory proteins associated with kinase/phosphatase 
identified in the network of FK506-dysregulated proteins in the cytosolic 
fraction 
In the cytosolic fraction, 123 interactions between 80 proteins were identified. 
Each interaction has a combined score of over 0.4; the edge weights are directly 
correlated to the score. FK506-upregulated protein nodes are coloured green and 
FK506-downregulated protein nodes are coloured yellow. Regulatory proteins 
associated with kinases are square shaped and those associated with 
phosphatases are diamond shaped. 
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3.3.3.2 Phosphorylation motifs 
Phosphorylation motifs are specific amino acid sequences that are targeted by 
specific groups of kinases. Identifying these motifs in phosphopeptides can give 
valuable insights into their likely regulatory kinases (445). Using Motif-X 
(436,437), phosphorylation motifs based on repetitive sequences present in the 
dataset were extracted. Motif analysis of phospho-threonine and phospho-
tyrosine peptides identified no phosphorylation motifs in the dataset. Motif 
analysis of phospho-serine peptides showed that 40.5 % of the upregulated and 
36.1 % of the downregulated phosphopeptides were not assigned to any 
phosphorylation motifs in the membrane fraction. In the cytosolic fraction, 72.5 % 
of the upregulated and 36.5 % of the downregulated phosphopeptides were not 
assigned to any phosphorylation motifs. Table 3.3-2 and Table 3.3-3 show the 
amino acid sequence of the phospho-serine motifs extracted, the percentage of 
peptides assigned to these motifs and the group of kinases that are known to 
phosphorylate them.  
In the membrane fraction, proline-directed motifs - ‘xsPx’ (446–448), were found 
in 18.9 % of the phosphopeptides upregulated by FK506 and 33.5 % of the 
phosphopeptides downregulated by FK506. In the cytosolic fraction, ‘xsPx’ 
phosphorylation motifs were found in 27.5 % and 30.1 % of the phosphopeptides 
up and downregulated by FK506 respectively. These are known substrates of 
proline-directed protein kinases which includes ERK1/2, mitogen-activated 
protein kinase (MAPK), cyclin-dependent kinases (CDK) and glycogen synthase 
kinase 3 (GSK3). In the membrane fraction, ‘Rxxs’ phosphorylation motifs, 
targeted by AKT or Ca2+/calmodulin-dependent protein kinase II (CaMK-II) (449–
451), were found in 9.85 % and 12.9 % of FK506-upregulated and downregulated 
phosphopeptides respectively. In the cytosolic fraction, ‘Rxxs’ phosphorylation 
motifs were only found in 14.1 % of phosphopeptides downregulated by FK506, 
but were not identified in phosphopeptides upregulated by FK506. Other motifs 
targeted by casein kinase II (CK-II), ‘sxxE’ (452) and ‘sDxE’ (453), and receptor-
like kinase (RLK) and Ca2+-dependent protein kinase (CDPK), ‘sD’ (454) were 
also identified. An unknown/novel phosphorylation motif - ‘sxxxxE’ was also 
identified in the dataset, however their putative regulatory kinases have not been 
reported in literature.  
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Table 3.3-2 Phosphorylation motifs up and downregulated in the membrane fraction. 
Membrane 
Upregulated 
Percentage of 
peptides 
Putative 
kinases 
Downregulated 
Percentage of 
peptides 
Putative 
kinases 
 
9.47 % CK-II 
 
33.55 % ERK1/2, 
MAPK, CDK, 
GSK3 
 
18.94 % ERK1/2, 
MAPK, CDK, 
GSK3 
 
17.42 % Unknown/Novel 
 
12.12 % CK-II 
 
12.9 % AKT, CaMK-II 
 
9.09 % MAPK, RLK, 
CDPK 
 
9.85 % AKT, CaMK-II 
1
4
4
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Table 3.3-3 Phosphorylation motifs up and downregulated in the cytosolic fraction. 
 
Cytosolic 
Upregulated Percentage of 
peptides 
Putative 
kinases 
Downregulated Percentage of 
peptides 
Putative 
kinases 
 
27.47 % ERK1/2, 
MAPK, CDK, 
GSK3 
 
30.13 % ERK1/2, 
MAPK, CDK, 
GSK3 
   
 
19.23 % CK-II 
   
 
14.1 % AKT, CaMK-II 
1
4
5
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3.3.3.3 Interactions of AKT and ERK1/2 with the calcineurin-NCC cascade 
Analysis of the protein-interaction network suggests that the serine/threonine 
protein kinases AKT1 may play a regulatory role downstream of calcineurin. 
Phosphorylation motif analysis further supported this hypothesis by identifying 
AKT/CaMK-II targeted and proline-directed phosphorylation motifs, the most 
common phosphorylation motifs identified in the data. These motifs are targeted 
by AKT1 and ERK1/2, which may play an important regulatory role in the 
phosphorylation of proteins downstream of calcineurin.  
With the aim of identifying an intermediary pathway that regulates the calcineurin-
WNK-NCC cascade, AKT1, ERK1/2 and components of the calcineurin-WNK-
NCC cascade were submitted into STRING (441) to identify interactions between 
these proteins. The interactions between pairs of proteins were identified based 
on the seven criteria mentioned previously (Section 3.3.3.1). Each interaction, 
presented in the networks, has a combined score of over 0.4, meaning that the 
established interaction is true, specific and reproducible to a medium confidence 
level; the edge weights are directly correlated to the score. The sizes of the 
protein nodes directly correlate to the betweenness centrality of the protein in the 
network. 
In this protein-interaction network, 26 interactions between 12 proteins were 
identified. AKT1 is connected by known or predicted protein interactions to 
calcineurin A α (PPP3CA), ERK1/2, WNK1 and WNK4. This suggests a close 
relationship between AKT1, calcineurin and the WNK kinases; AKT1 may 
therefore be one of the putative ‘intermediate members’ of the calcineurin-NCC 
cascade. In contrast to AKT1, ERK1/2 are only connected to calcineurin and 
AKT1 in the network and no predicted or known interactions between ERK1/2 
and components of the WNK-NCC cascade were identified (Figure 3.3-7). 
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Figure 3.3-7 Interactions between AKT1, ERK1/2 and WNK-NCC cascade 
Calcineurin, AKT1, ERK1/2 and components of the WNK-NCC cascade 
submitted into STRING to generate a protein-interaction network. In this network, 
26 interactions between 12 proteins were identified. Each interaction has a 
combined score of over 0.4; the edge weights are directly correlated to the score. 
The sizes of the protein nodes directly correlate to the betweenness centrality of 
the protein in the network. 
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3.3.3.4 Effects of FK506 on ERK1/2 and AKT 
Analysis of the phosphorylation motifs and protein-network analysis of AKT1, 
ERK1/2 and components of the calcineurin-WNK-NCC cascade, suggest an 
important regulatory role for AKT1 and ERK1/2 in FK506-dysregulated 
phosphoproteins. Therefore, the effects of FK506 on ERK1/2 and AKT1 were 
investigated through protein quantification. Western blot analysis revealed that 
FK506 significantly increased protein levels of ERK1/2 (Figure 3.3-8) and AKT1 
(Figure 3.3-9) but not an activated form of ERK1/2 (pERK1/2). In addition, the 
effect of FK506 on phospho-AKT (pAKT)-S124 was examined, since pAKT-S124 
was upregulated by FK506 in the phosphoproteomic data. Unfortunately, 
Western blot failed to detect signals using the anti-pAKT antibody under several 
conditions. This is possibly due to poor binding of the pAKT antibody to its 
epitopes on the Western blot, an issue commonly associated with phospho-
antibodies.  
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Figure 3.3-8 Protein expression of ERK1/2 and pERK1/2 post-FK506 
treatment 
Western blot analysis was performed on cytosolic fraction of FK506 or vehicle 
treated mice. Representative blots of a) ERK1/2 and b) pERK1/2 are shown. 
Band intensities of the transporters were quantified and normalised to those of β-
actin and expressed as fold change of the control mean; data are presented as 
means ± SEM, n=5. Statistical values were calculated using an unpaired t-test.   
150 
 
 
Figure 3.3-9 Protein expression of AKT1 post-FK506 treatment  
Western blot analysis was performed on cytosolic fraction of FK506 or vehicle 
treated mice. Representative blots of AKT1 is shown on the left. Band intensities 
of the transporters were quantified and normalised to those of β-actin and 
expressed as fold change of the control mean; data are presented as means ± 
SEM, n=5. Statistical values were calculated using an unpaired t-test.   
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3.3.3.5 Candidate approach: FK506-dysregulated transport and regulatory 
proteins  
Calcineurin has pleiotropic effects and CNIs alter renal tubular function by 
dysregulating electrolyte transporters. Using the Panther classification system, 
(438), proteins classified as ‘transporters’, ‘channels’, ‘kinase’, ‘phosphatase’ and 
‘kinase/phosphatase’-related proteins were selected to narrow down the list of 
proteins of interest. Phosphosites identified were validated with the 
PhosphoSitePlus® Database and novel phosphosites are indicated by ‘*’ in the 
tables. Phosphorylation motifs identified previously are also presented in the 
tables. Transport proteins were divided into proximal, distal and ubiquitous, 
depending on where these proteins are expressed in the kidney. 
3.3.3.5.1 Transport proteins  
In the membrane fraction, 55 % of proteins are predominantly expressed in the 
proximal tubule, 15 % are expressed in the distal nephron and 30 % are either 
expressed ubiquitously or present in both proximal and distal part of the nephron 
(Table 3.3-4). Many of the phosphorylation motifs present in the phosphopeptides 
of both membrane and cytosolic fractions are proline-directed or targeted by AKT.  
In the proximal nephron, 55 % of the identified proteins are associated with 
sodium transport. Amongst all sodium transporters, multiple unique 
phosphopeptides were identified in the electrogenic sodium bicarbonate 
cotransporter 1 (NBCe1). Most of the NBCe1 phosphopeptides were upregulated 
with >20 % increase in phosphorylation; only one peptide phosphorylated at 
S1029 and S1044 was shown to be downregulated. A proline-directed 
phosphorylation motif was extracted from the peptide phosphorylated at S245 in 
NBCe1 and was shown to be upregulated. A novel phosphosite-S619 was 
identified in the sodium glucose cotransporter 2 (SGLT2) and was shown to be 
downregulated by FK506. Several other phosphopeptides identified in other 
sodium transporters, such as NaPi-IIa and NHE3, also showed FK506-induced 
changes in phosphorylation.  
FK506-dysregulated phosphorylation of several proteins in the distal nephron that 
are involved in sodium and water reabsorption. S256 and S261 in AQP2 are 
predicted targets of AKT and proline-directed kinases, and FK506 was shown to 
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increase phosphorylation of these two phosphosites. Two phosphopeptides were 
identified in NKCC2; phosphorylation at T114 and S116 was downregulated by 
FK506 and the other phosphopeptide with a novel phosphosite-pY110 was 
upregulated. Nine unique NCC phosphopeptides were identified in the whole 
dataset (Appendix, Table 6.3-1). Six of these phosphopeptides showed >10 % 
change in phosphorylation at T122, S124 and S127; S127 is a novel phosphosite 
and is targeted by proline-directed kinases. FK506 upregulated 5 out of 6 of the 
phosphopeptides with the exception of the peptide phosphorylated at T122 and 
S127 which it downregulated. Since NCC is an important protein in this study, the 
degree of conservation in these phosphosites was investigated. A sequence 
alignment of SLC12A3 in mouse, human and rat revealed that T122 and S124 
are highly conserved in all three species, whereas S127 is conserved in the 
mouse and rat but not in humans.  
The Na+/K+-ATPase subunit γ is expressed in both proximal and distal tubules. A 
novel phosphosite-pS15 was identified in Na+/K+-ATPase subunit γ and was 
downregulated by FK506. Other transport proteins involved in electrolyte 
transport identified in the membrane fraction are shown in Table 3.3-4. 
Eleven transport proteins in the cytosolic fraction were selected from in this 
dataset (Table 3.3-5). In the cytosolic fraction, FK506 downregulated 
phosphopeptides of NBCe1 and NaPi-IIa. The only transport protein expressed 
in the distal nephron identified in the cytosol was NKCC2. Only one 
phosphopeptide was identified in NKCC2 where phosphorylation at S116 and the 
novel phosphosite-Y110 was downregulated. Two transport proteins involved in 
potassium and sodium transport, KCNJ16 and the NHE1, are both expressed in 
the proximal and distal nephron. Two novel phosphosites pS363 and pS366 
identified in KCNJ16 were downregulated by FK506. FK506 also decreased 
phosphorylation of NHE1 at S810. Other transport proteins identified in the 
cytosolic fractions with >10 % change in phosphorylation are shown in Table 3.3-
5. 
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Location 
Gene 
name 
Protein name 
Accession 
No. 
Peptide Sequence Phosphosites Motifs 
Percentage 
Change 
Proximal SLC4A4 
Electrogenic sodium 
bicarbonate cotransporter 
1 
 
O88343 
GSLDsDNDDSDCPYSEKVPsIK 
MFSNPDNGsPAMTHR 
TVsSASR 
GSLDSDNDDsDCPYSEKVPSIK 
NLtSSSLNDISDKPEK 
GSLDsDNDDsDCPYSEK 
NLTSsSLNDISDKPEK 
GSLDsDNDDSDCPYSEK 
MFSNPDNGSPAMtHR 
GsLDsDNDDSDCPYSEK 
KGsLDSDNDDSDCPYSEK 
KGsLDsDNDDsDCPYSEK 
S1029; S1044 
S245 
S232  
S1034 
T254 
S1029; S1034 
S256 
S1029 
T249 
S1026; S1029 
S1026 
S1026; S1029; S1034 
- 
Proline-directed 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 13.92 
+ 20.28 
+ 22.55 
+ 30.74 
+ 40.15 
+ 41.47 
+ 43.57 
+ 50.32 
+ 53.65 
+ 68.21 
+ 73.34 
+ 152.26 
Proximal 
SLC12A6 
Electroneutral 
potassium-chloride 
cotransporter 3 
Q924N4 LTSIGsDEDEETETYQEK S1032 - - 14.07 
Proximal; 
TALH 
SLC43A2 
L-type amino acid 
transporter 4  
Q8CGA3 
LCLsTVDLEVK 
LCLStVDLEVK 
S297 
T298 
- 
- 
- 10.59 
- 24.66 
Proximal SLC51A 
Organic solute 
transporter subunit alpha  
Q8R000 
VGYEACsLPDLDSALKA 
VGYEACsLPDLDsALKA 
S330 
S330; S336 
- 
- 
- 53.04 
- 33.12 
Proximal SLC51B 
Organic solute 
transporter subunit beta 
Q80WK2 
 
ENNsQVFLR 
EKDSsLVFLPDPQETES 
EKDsSLVFLPDPQETES 
S88* 
S116 
S115* 
- 
- 
- 
- 51.06 
- 58.06 
- 41.99 
Proximal SLC6A20B 
Sodium- and chloride-
dependent transporter 
XTRP3B 
O88575 sTECAHPGVVEK S35* AKT substrate + 40.18 
Proximal SLC5A2 
Sodium/glucose 
cotransporter 2  
Q923I7 sGSGSPPPTTEEVAATTR S619* - - 11.04 
Proximal; 
TALH 
SLC9A3 
Sodium/hydrogen 
exchanger 3  
G3X939 ENVsAVCLDMQSLEQR S588 - + 28.70 
Proximal SLC34A1 
Sodium/phosphate 
cotransporter 2A  
Q60825 VFLEELPPAtPsPR T621; S623 Proline-directed S623 - 58.73 
Proximal SLC23A1 
Sodium-dependent 
vitamin C transporter 1 
Q9Z2J0 KTQNQPPVLEDTPDNIETGsVCtKV S600; T603 - - 39.39 
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Proximal SLC26A1 
Sulfate anion transporter 
1 
P58735 DQGPEVGVsNR S587  - + 20.49 
Distal AQP2 Aquaporin-2 P56402 RQsVELHsPQSLPR S256; S261 
AKT substrate S256; 
Proline-directed S261 
+ 27.21 
Distal SLC12A1 
Kidney-specific Na-K-Cl 
symporter 2 
P55014 
 
IEYYRNtGsVSGPK 
IEyyRNTGSVSGPK 
T114; S116 
Y110*; Y111 
- 
- 
- 23.09 
+ 31.43 
Distal SLC12A3 
Thiazide-sensitive 
sodium-chloride 
cotransporter 
P59158 
 
ELTDGLVEDETGtNSEKsPGEPVR 
ELTDGLVEDETGtNsEKSPGEPVR 
ELTDGLVEDETGTNsEKSPGEPVR 
ELTDGLVEDETGtNSEK 
ELTDGLVEDETGTNSEKsPGEPVR 
ELTDGLVEDETGTNsEKsPGEPVR 
T122; S127* 
T122; S124 
S124 
T122 
S127* 
S124; S127* 
Proline-directed S127 
- 
- 
- 
Proline directed 
Proline directed S127 
- 23.56 
+ 13.12 
+ 20.16 
+ 20.65 
+ 26.22 
+ 29.40 
Proximal; 
Distal 
FXYD2 
Sodium/potassium-
transporting ATPase 
subunit gamma 
Q04646 AGEISDLSANSGGsAK S15* - - 19.85 
Proximal; 
Distal 
CACNA1E 
Voltage-dependent R-
type calcium channel 
subunit alpha-1E 
Q61290 SFStIR T1983* - + 30.99 
Ubiquitous AP3D1 
AP-3 complex subunit 
delta-1 
O54774 
 
HSSLPtEsDEDIAPAQR 
HSSLPTEsDEDIAPAQR 
T758; S760 
S760 
- 
- 
+ 14.99 
+24.66 
Ubiquitous SLC33A1 Acetyl-CoA transporter 1 Q99J27 RDsVGGEGDREVLLGDAGPGDLPK S42  AKT substrate + 27.39 
Ubiquitous TOMM20 
Mitochondrial import 
receptor subunit TOM20 
homolog 
Q9DCC8 
IVsAQsLAEDDVE 
IVsAQSLAEDDVE 
S135; S138 
S135 
AKT substrate S135 
AKT substrate 
- 13.93 
+14.61 
N/A SLC35A5 
Probable UDP-sugar 
transporter protein 
Q921R7 
LKSDDsDDDTL 
LKsDDsDDDTL 
S432 
S429; S432 
- 
- 
+ 10.49 
+ 16.58 
* Novel phosphopeptides 
 
Table 3.3-4 FK506-dysregulated transport proteins identified in the membrane fraction  
Identification and quantification of phosphosites in transport proteins, in the membrane, after FK506 treatment. Novel phosphorylation 
sites were previously unidentified in PhosphoSitePlus® Database.
1
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Location Gene name Protein name 
Accession 
No. 
Peptide Sequence Phosphosites Motifs 
 % 
Change 
Proximal SLC4A4 
Electrogenic 
sodium bicarbonate 
cotransporter 1 
O88343 
TVssASR 
NLtSsSLNDISDKPEK  
sSTFLER 
GSLDsDNDDSDCPYSEK 
TVsSAsR 
KGsLDsDNDDSDCPYSEK 
NLTSSsLNDIsDKPEKDQLK 
TVsSASR 
MFSNPDNGsPAMTHR 
S232; S233 
T254; S256; S257 
S1069 
S1029 
S232; S235 
S1026; S1029 
S257; S262 
S232 
T249 
- 
 AKT substrate S256 
- 
- 
- 
- 
- 
- 
Proline-directed 
- 47.99 
- 48.12 
- 44.51 
- 39.44 
- 38.40 
- 21.43 
- 21.35 
- 21.35 
- 11.90 
Proximal; TALH SLC43A2 
L-type amino acid 
transporter 4  
Q8CGA3 LCLsTVDLEVK S297 - - 23.87 
Proximal SLC34A1 
Sodium/phosphate 
cotransporter 2A  
Q60825 
 
VFLEELPPAtPsPR 
VFLEELPPATPsPR 
sPQLPPR 
T621; S623 
S623 
S605 
Proline-directed S623 
Proline-directed 
Proline-directed 
- 72.21 
- 47.55 
- 46.94 
TALH; Macula 
densa SLC12A1 
Kidney-specific 
Na-K-Cl symporter 
2 
P55014 IEyYRNTGSVsGPK Y110*; S116 - - 33.74 
Proximal; Distal KCNJ16 
Inward rectifier 
potassium channel 
16 
Q9Z307 TSPARGsCNsDTNTR S363*; S366* AKT substrate S366 - 35.12 
Ubiquitous AP3D1 
AP-3 complex 
subunit delta-1 
O54774 
 
HSSLPtEsDEDIAPAQR 
HSSLPTEsDEDIAPAQR 
T758; S760 
S760 
- 
- 
- 24.00 
- 19.19 
Ubiquitous SORT1 
Neurotensin 
receptor 3 
Q6PHU5 SGYHDDsDEDLLE S819  - 27.10 
Ubiquitous SLC9A1 
Sodium/hydrogen 
exchanger 1  
Q61165 SKEPSSPGTDDVFTPGSSDSPsSQR S790 - - 19.37 
Ubiquitous, highly 
expressed in the 
distal nephron 
TRPP2 
Transient receptor 
potential cation 
channel subfamily 
P member 2 
O35245 SLDDsEEEDDEDSGHSSR S810 - + 15.51 
 
1
5
5
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Table 3.3-5 FK506-dysregulated transport proteins identified in the cytosolic fraction 
Identification and quantification of phosphosites in transport proteins, in the cytosol, after FK506 treatment. Novel phosphorylation sites 
were previously unidentified in PhosphoSitePlus® Database. 
N/A SLC35A5 
Probable UDP-
sugar transporter 
protein 
Q921R7 LKSDDsDDDTL S432 - - 10.12 
* Novel phosphosites  
  
 
 
1
5
6
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3.3.3.5.2 Classified transport proteins identified in the membrane and 
cytosolic fractions 
A small number of unique phosphopeptides from NBCe1, L-type amino acid 
transporter 4 (LAT4) and NaPi-IIa were identified in both the membrane and 
cytosolic fractions. LAT4 and NaPi-IIa demonstrated downregulated 
phosphorylation of the same unique phosphopeptides in both fractions. In 
contrast, NBCe1 phosphopeptides were differentially regulated in the two 
fractions; peptides phosphorylated at S232, T249 and S1029 and at S1026 and 
S1029 were upregulated in the membrane fraction and downregulated in the 
cytosolic fraction. In addition, phosphopeptides from two other proteins, AP-3 
complex subunit delta-1 (AP3D1) and probable UDP-sugar transporter protein, 
were also differentially regulated in the two fractions (Table 3.3-6).
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Table 3.3-6 FK506-dysregulated transport proteins identified in membrane and cytosolic fractions  
Identification and quantification of phosphosites in transport proteins, in the membrane and cytosolic fraction, after FK506 treatment. 
Novel phosphorylation sites were previously unidentified in PhosphoSitePlus® Database. 
 
Gene name Protein name 
Accession 
No. 
Peptide Sequence Phosphosites 
Percentage change 
Memb    Cyto 
SLC4A4 Electrogenic sodium bicarbonate cotransporter 1  O88343 
tVsSASR 
mFSNPDNGsPAMTHR 
gSLDsDNDDSDcPYSEk 
kGsLDsDNDDSDcPYSEk 
S232 
T249 
S1029 
S1026; S1029 
+ 22.55 
+ 53.62 
+ 53.62 
+ 67.00 
- 21.35 
-11.90 
-39.44 
-21.43 
SLC43A2 L-type amino acid transporter 4  Q8CGA3 lcLsTVDLEVk S297 - 10.59 - 23.87 
SLC34A1 Sodium/phosphate cotransporter 2A  Q60825 vFLEELPPAtPsPR T621; S623 - 58.73 - 72.21 
AP3D1 AP-3 complex subunit delta-1  O54774 
hSSLPtEsDEDIAPAQR 
hSSLPTEsDEDIAPAQR 
T758; S760 
S760 
+ 14.99 
+24.66 
- 24.00 
-19.19 
SLC35A5 Probable UDP-sugar transporter protein Q921R7 lkSDDsDDDTL S432 + 10.49 - 10.12 
1
5
8
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3.3.3.5.3 Regulatory proteins  
Fifteen proteins in the membrane fraction (Table 3.3-7) and nine in the cytosolic 
fraction (Table 3.3-8) were classified as ‘kinase’, ‘phosphatase’ and 
‘kinase/phosphatase’-related proteins. A novel phosphosite, pS1001 in 
Phosphatidylinositol 4,5 biphosphate 5-phosphatase, was identified in the 
cytosol. Five AKT-phosphorylation motifs, 4 proline-directed phosphorylation 
motifs and a CK-II-phosphorylated motif were identified in the membrane fraction. 
Four proline-directed phosphorylation motifs and an AKT-phosphorylation motif 
were identified in the cytosolic fraction.  
CDK11b is a member of the CDK family and targets proline-directed 
phosphosites. CDK11b was identified in the membrane fraction and 
phosphorylated at S115; this phosphopeptide was upregulated and is a predicted 
target of AKT phosphorylation.  
MAPK 8-interacting protein 4 (MAPK8IP4) is a member of the MAPK and targets 
proline-directed phosphosites. MAPK8IP4 was identified in the cytosol, and the 
phosphopeptide identified was downregulated at S732 and S733. S732 is a 
predicted target of AKT, indicated by the phosphorylation motif extracted from the 
peptide sequence, and no phosphorylation motifs were found for S733.  
AKT was identified in the cytosol and targets a group of phosphopeptides 
identified in these datasets; it was shown to be upregulated at pS124 and pS126 
where phosphorylation of S124 is proline-directed.  
Phosphopeptides from cyclin-K, diacylglycerol kinase theta (DGKQ) and 
sphingosine-1-phosphatase 1 (SGPP1) were identified in both membrane and 
cytosolic fractions (Table 3.3-9). The behaviour of the phosphopeptides identified 
in cyclin-K and DGKQ was the same in both fractions, whereas the 
phosphopeptide identified in SGPP1 showed an increase in phosphorylation in 
the membrane fraction and a decrease in cytosolic fraction. 
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Gene 
name 
Protein name Accession 
No. 
Peptide Sequence Phosphosites Motifs Percentage 
Change 
PRKAA1 AMPK subunit alpha-1 Q5EG47 SIDDEITEAKsGTAtPQR S486; T490 - + 11.35 
AAK1 AP2-associated protein kinase 1  Q3UHJ0 SATTTPSGsPR  
VGSLtPPSsPK 
S676 
T618; S622 
 
- 
- 11.15 
+10.69 
BCKDK BCKD-kinase O55028 sTSATDTHHVELAR 
STSAtDTHHVELAR 
S31 
T35 
Akt substrate 
- 
+ 28.85 
+ 32.27 
BMP2K BMP-2-inducible protein kinase Q91Z96 RDsQSsNEFLTISDSK S1010; S1013 Akt substrate S1010 + 22.94 
CDK11B Cyclin-dependent kinase 11B  P24788 SHsAEGGK S115 Akt substrate + 38.52 
CCNK Cyclin-K O88874 KPsPQPsPPR S325; S329 Proline-directed - 16.78 
DGKQ Diacylglycerol kinase theta  Q6P5E8 LGsPAGsPVLGISGR S22; S26 Proline-directed - 17.19 
PRKRA Interferon-inducible double-stranded RNA-
dependent protein kinase activator A  
Q9WTX2 EDsGTFSLGK S18 Akt substrate + 20.46 
NUCKS1 Nuclear ubiquitous casein and cyclin-
dependent kinase substrate 1  
Q80XU3 SGDEGSEDEAsSGED S230 - - 35.36 
PALLD Palladin Q9ET54 SRDsGDENEPIQER S1146 - - 13.15 
PI4KB Phosphatidylinositol 4-kinase beta  Q8BKC8 sVENLPECGITHEQR S428 - + 13.09 
PPP1R2 Protein phosphatase inhibitor 2  Q9DCL8 TREQEssGEEDNDsLSPEER S122; S123 CK-II substrate + 23.55 
KIAA0445 Rootletin  Q8CJ40 sQPPsPGLIASPAPPDLDPEAVR S1479; S1483 Proline-directed S1483 + 68.99 
1
6
0
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Table 3.3-7 FK506-dysregulated kinase/phosphatase-associated proteins identified in the membrane fraction 
Identification and quantification of phosphosites in kinases, phosphatases and other related proteins in the membrane post-FK506 
treatment. Novel phosphorylation sites were previously unidentified in PhosphoSitePlus® Database. 
  
SGPP1 Sphingosine-1-phosphatase 1 Q9JI99 NsLTGEEGELVK S101  Akt substrate + 30.13 
TNS2 Tensin-like C1 domain-containing phosphatase Q8CGB6 GYPSPGAHsPR S825 Proline-directed - 14.74 
* Novel phosphosites  
  
 
 
1
6
1
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Table 3.3-8 FK506-dysregulated kinase/phosphatase-associated proteins identified in the cytosolic fraction  
Identification and quantification of phosphosites in kinases, phosphatases and other related proteins in the cytososl post-FK506 treatment. 
Novel phosphorylation sites were previously unidentified in PhosphoSitePlus® Database.  
Gene name Protein name Accession 
No. 
Peptide Sequence Phosphosites Motif Percentage 
Change 
PRKAB1 5'-AMP-activated protein kinase subunit beta-1 Q9R078 RDsSGGAK S24 - - 27.41 
ANP32B Acidic leucine-rich nuclear phosphoprotein 32 
family member B  
Q9EST5 KREtDDEGEDD T265 - - 23.41 
CCNK Cyclin-K  O88874 KPsPQPsPPR S325; S329 Proline- directed - 14.77 
DGKQ Diacylglycerol kinase theta  Q6P5E8 LGsPAGsPVLGISGR S22; S26 Proline-directed - 21.27 
MAPK8IP4 Mitogen-activated protein kinase 8-interacting 
protein 4 
Q58A65 SASQssLDKLDQELKEQQK S732; S733 Akt substrate S732 - 23.38 
MTMR2 Phosphatidylinositol-3,5-bisphosphate 3-
phosphatase  
Q9Z2D1 SSsCEsLGAQLPAAR S6; S9 - -11.52 
INPP5J Phosphatidylinositol 4,5-bisphosphate 5-
phosphatase A  
P59644 GGsRsPsPQSR S907; S909; 
S1001* 
Proline directed S909; 
S1001 
- 23.53 
AKT Protein kinase B  P31750 SGsPsDNSGAEEMEVSLAKPK S124; S126 Proline-directed S124 + 39.15 
SGPP1 Sphingosine-1-phosphate phosphatase 1  Q9JI99 RNsLTGEEGELVK S101 - - 18.71 
* Novel phosphosites 
 
1
6
2
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Table 3.3-9 FK506-dysregulated kinase/phosphatase-associated proteins identified in the membrane and cytosolic fractions 
Identification and quantification of phosphosites in regulatory proteins, in the membrane and cytosolic fraction, after FK506 treatment. 
Novel phosphorylation sites were previously unidentified in PhosphoSitePlus® Database. 
Gene name Protein name Accession No. Peptide Sequence Phosphosites Percentage change 
   Memb      Cyto 
CCNK Cyclin-K  O88874 kPsPQPsPPR S325; S329 - 16.78 - 14.77 
DGKQ Diacylglycerol kinase theta  Q6P5E8 lGsPAGsPVLGISGR S22; S26 - 17.19 - 21.27 
SGPP1 Sphingosine-1-phosphatase 1  Q9JI99 nsLTGEEGELVk S101  + 32.97 - 18.71 
 
1
6
3
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3.3.3.6 Candidate approach: ACE and NHERF1 
The bioinformatic techniques used in this study generated a selection of proteins 
and phosphosites that may play a significant role in CNI-induced renal tubular 
dysregulation. These filters are highly effective at excluding housekeeping 
proteins and proteins that unlikely to play a significant role in the cascade; 
however, proteins that were excluded because they did not meet the criteria set 
in each analytical technique might still be important. Interesting candidates in the 
datasets that were excluded include, ACE and NHERF1.  
ACE is involved in blood pressure regulation and is therefore a protein of interest. 
In this study, only one phosphopeptide (S1305) was identified in ACE in the 
cytosolic fraction, which showed >20 % upregulation by FK506 and no 
phosphorylation motif was found in this phosphopeptide. Regulators of S1305 in 
mice is currently unknown; however, in humans, the homologous site is S1299 
and phosphorylation is regulated by CK-II. CK-II is a serine/threonine-selective 
protein kinase and has been proposed to determine plasma levels of ACE by 
phosphorylating ACE and preventing proteolytic cleavage of ACE from the 
membrane (455).  
NHERF1 has pleiotropic roles and, is involved in phosphate, acid-base and 
sodium homeostasis (456–458). Twenty-seven unique phosphopeptides of 
NHERF1 in the membrane fraction and 15 phosphopeptides in the cytosolic 
fraction were identified; ambiguous phosphopeptides are not presented in Table 
3.3-10. A total of twenty unique phosphopeptides were identified in the two 
fractions. A novel phosphosite S277 was identified in NHERF1 in the membrane 
fraction and was shown to be downregulated by FK506. Several phosphosites 
are regulated by leptin (459), these include S275, S285, S286 and S289 and 
some phosphosites are regulated by tuberous sclerosis complex 2 (460), these 
include S275, S283, S285 and S286. Other phosphosites were shown to be 
affected by rapamycin (461) and are associated with type II diabetes (462).  
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Gene name Protein name Accession 
No. Phosphosites 
Percentage 
Change 
Memb   Cyto 
SLC9A3R1 
Sodium-hydrogen 
antiporter 3 regulator 1 
(NHERF1) 
P70441 
S275 - + 12.18 
S277 * - 16.59 - 
S283 0.0 - 
S285 - 1.92 - 17.26 
S286 - 18.22 + 2.51 
T288 - 3.20 - 
S289 + 7.76 - 
S297 - 25.86 - 
S283; S285 - 19.85 - 
S285; S286 - 0.24 - 
S285; T288 - 26.99 - 18.23 
S285; S297 - 28.80 - 
S286; T288 - 11.40 - 
S286; S289 - 13.81 - 5.51 
T288; S289 - 1.40 + 21.63 
S294; S297 - 3.83 - 
S283; S285; S286 + 2.31 + 8.16 
S285, S286, T288 - + 22.57 
S285; S286; S289 - 13.45 - 12.58 
S286; T288; S289 - 12.14 - 2.58 
* Novel phosphosite     
 
Table 3.3-10 FK506-dysregulated phosphosites in NHERF1 
Identification and quantification of phosphosites in NHERF1, in the membrane 
and cytosolic fraction, after FK506 treatment. Novel phosphorylation sites were 
previously unidentified in PhosphoSitePlus® Database. 
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3.4 Discussion 
3.4.1 Overview of quantitative phosphoproteomics  
Proteomics was used to generate a phosphoproteome profile of the renal cortices 
from FK506-treated mice. To generate a complete proteome profile, it is important 
to fractionate the samples to reduce their complexity; not only does fractionating 
samples improve proteome coverage, it also allows LC-MS/MS to identify 
peptides of lower abundance, enhances quantitative detection of TMT reporter 
ions on peptides and increases efficiency of phosphopeptide enrichment 
(430,463). In this study, the renal cortices of FK506-treated mice were extracted 
and separated into membrane and cytosolic fractions through ultracentrifugation. 
A cytosolic protein, ERK1, was used to confirm successful fractionation 
(Appendix, Figure 6.2-1). Since the purpose of the fractionation was to lower 
sample complexity, absolute enrichment of the subcellular compartments was not 
deemed necessary.  
Numerous bioinformatics techniques are available for proteomics data analysis. 
Each of these techniques have different properties and act as filters to select 
protein of interests from the complex mixture of proteins. Currently, there are no 
set guidelines on how one should interpret proteomics data; therefore, it is 
important to choose bioinformatic techniques that fit the purpose of the specific 
research. Since the aim of this study was to identify a novel regulatory pathway 
for the WNK cascade and to determine changes in the phosphorylation of other 
FK506-dysregulated transport proteins, the data was analysed utilising several 
bioinformatics techniques. An arbitrary cut-off point/threshold is commonly used 
in quantitative proteomics to filter out proteins of interest (464,465). These 
thresholds are often tailored to individual studies, depending on factors such as 
the type of samples used and the purpose of the research. Some studies that use 
quantitative proteomics and biomarkers for diagnostic purposes, have used 
higher thresholds to increase the sensitivity of the diagnostic screening (466). 
This approach is not necessarily beneficial for the type of research presented in 
this chapter as it can result in a large loss of information. Therefore, a 10 % 
threshold was used to prevent important proteins from being excluded at the early 
stages of data interpretation. Phosphopeptides with >10 % change in 
phosphorylation were considered to be dysregulated by FK506. These 
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phosphopeptides were also processed by other bioinformatics techniques, such 
as protein-protein interaction database and phosphorylation motif extractor 
software, resulting in a refined list of proteins of interests. 
3.4.2 AKT and the WNK-NCC cascade 
The protein network analysis revealed that a small number of phosphoproteins 
appeared to act as hubs at the centre of the networks of both the cytoplasmic and 
membrane fractions. In the cytosolic fraction, the serine/threonine kinase AKT is 
particularly prominent, connecting clusters of phosphoproteins involved in 
membrane solute transport, intracellular trafficking, transcription, translation and 
glucose metabolism. AKT plays an important role as part of the phosphoinositide-
3-kinase (PI3K)-mediated insulin and insulin-like growth factor 1 (IGF1) signalling 
pathway governing glucose homeostasis (467,468).  
The pathophysiology of the metabolic syndrome involves insulin resistance and 
the mechanisms underlying the development of insulin resistance differs in the 
kidney from other glucogenic tissues, such as muscle and adipose tissues 
(469,470). Using a mouse model of the metabolic syndrome, the activity of the 
PI3K and AKT in the kidneys were increased (471), whereas a decrease in AKT 
activity was detected in the muscles and adipose tissues of these mice (472,473).  
The activity of AKT is increased by insulin through PI3K phosphorylation at T308 
and S473 (474). This process is reversible by calcineurin, which directly 
dephosphorylates AKT in the AKT-calcineurin complex, as shown in ischemic rat 
retina (475) and in cardiomyocytes (476). In the current study, FK506 has been 
shown to increase protein levels of AKT1 and pNCC in the kidneys. This indicates 
that calcineurin inhibition and the use of CNIs increases AKT protein levels, 
prevents the dephosphorylation of AKT and increases its kinase activity. 
Unfortunately, AKT-pT308 and pS473 regulated by PI3K and calcineurin were 
not identified in phosphoproteomics. However, FK506 increased the 
phosphorylation of S124 and S126, and these may also play a role in AKT activity. 
The PI3K/AKT signalling pathway has previously shown to phosphorylate and 
activate the SPAK/OSR1-NCC cascade in the kidneys in a SGK1 independent 
manner. This led to the development of salt-sensitive hypertension in 
hyperinsulinaemic mice (471) and was suggested to be one of the mechanisms 
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involved in the pathogenesis of essential hypertension. AKT phosphorylation 
motifs were previously identified in the WNK kinases (110,123,477) and together 
with the information obtained from this study, these suggest that AKT is the 
intermediary protein that phosphorylates and defines the activities of the WNK 
kinases downstream of calcineurin, thereby regulating NCC activity. 
3.4.3 HSP90, AKT and the metabolic syndrome 
The second protein hub prominently present in the protein network of both the 
membrane and cytosolic fraction was HSP90AB1. HSP90AB1 is a ubiquitous 
chaperone protein involved in protein stabilisation and trafficking, preventing 
misfolding during protein synthesis or denaturing stress. Although the number of 
known HSP90 client proteins exceeds 100, one of better characterised is AKT. 
HSP90 is vital to AKT function as decreased AKT-HSP90 binding results in 
decreased AKT function (478). Both AKT and HSP90 act synergistically to 
increase the activity of endothelial nitric oxide synthase (eNOS), which produces 
the vasodilatory NO (479).  
Furthermore, in eukaryotes, cytoplasmic HSP90 complexes with other chaperone 
proteins, notably those containing tetratricopeptide repeat (TPR) domains such 
as the immunophilins, cyclophilin 40, FKBP51/FKBP52 (480). HSP90 and these 
immunophilins (e.g. FKBP52) are required to translocate the glucocorticoid 
receptor (GR) from the cytosol to the nucleus (481). This is achieved in a complex 
with the motor protein dynein which powers movement along the cytosolic 
microtubule network (481). The same mechanism applies for the MR (482). 
Moreover, GR polymorphism which leads to GR dysfunction is associated with 
hyperinsulinaemia and insulin resistance, which are components of the metabolic 
syndrome (483).  
3.4.4 ERK1/2 and the WNK-NCC cascade 
Similar to AKT, ERK is also a ubiquitous serine/threonine kinase that is essential 
in many biological functions, including cell growth, survival and phosphorylation 
of proteins in numerous signalling pathways (447). FK506 was shown to increase 
protein levels of ERK1/2 but not phospho-ERK1/2. The relationship between 
ERK1/2 and members of the WNK-NCC cascade was supported by little evidence 
in the protein-interaction network. However ERK1/2 have been shown to regulate 
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NCC expression by Zhou et al. (484). WNK4 was reported to increase the 
phosphorylation of ERK1/2 in mDCT cells in a dose-dependent manner. This 
effect was also increased in hypertonic conditions, and reversed in a WNK4 
knock-down model and WNK4 with FHHt-type mutations in mDCT cells (484). 
Knock-down models of WNK4 and ERK1/2 both significantly increase total 
expression of NCC along with cell surface expression, which suggests that WNK4 
inhibits NCC through the activation of ERK1/2 signalling pathway. It has been 
proposed that two signalling pathways, SPAK/OSR1 and ERK1/2 , downstream 
of WNK4 independently regulate NCC, and are activated under different 
stimulants (484). This could mean that the WNK4-ERK1/2 pathway may inhibit 
NCC under normal conditions and the WNK4-SPAK pathway may regulate NCC 
in response to dietary sodium chloride intake. Together with the data obtained in 
this study, these results suggest that ERK1/2 are involved in regulating NCC 
downstream of the WNK kinases. 
3.4.5 Candidate approach 
3.4.5.1 Hypertension 
CNI-induced hypertension is caused by an increase in NaCl reabsorption, 
through NCC overactivity (51), and an increase in water reabsorption. SPAK and 
OSR1 phosphorylate NCC at T53, T58 and S71 to activate NCC, resulting in the 
increase in NaCl reabsorption. NCC-pT53 and -pT58 defines NCC transport 
activity and do not play a role in NCC membrane trafficking (82,106,111,116). 
These phosphosites were not identified in this study, however, T122, S124 and 
a novel phosphosite-S127 were heavily phosphorylated in mice treated with 
FK506, therefore, might play a role in CNI-induced hypertension. Alignments of 
T122, S124 and S127 showed that T122 and S124 are highly conserved residues 
and S127 is a proline-directed phosphorylation that is only conserved in mice and 
rats but not in humans. Functional characterisation of pT122 and pS127 is 
currently unknown, but a recent study by Rosenbaek et al (485) showed that 
S124 plays a role in the transport activity of NCC and its phosphorylation is 
stimulated by the RAAS (485). A serine to alanine mutation at S124 reduced the 
transport activity of NCC but to a much lesser extent than T48A, T53A and T58A 
mutants (485), which indicates that the effect of pS124 alone may not define NCC 
activity (485). The regulation of NCC-pS124 differs from the other phosphosites. 
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S124 is not phosphorylated by SPAK/OSR1, instead, a protein kinase array 
experiment suggests that IRAK2 (IL-1 receptor-associated kinase 2), 
CDK6/Cyclin-D1, NLK (Nemo-Like Kinase) and mTOR may phosphorylate NCC-
S124 (485). mTOR is a member of the PI3K/AKT signalling pathway and is one 
of the many targets of AKT. This indicates that when PI3K/AKT is stimulated, 
mTOR may also phosphorylate NCC alongside the WNK-SPAK pathway. In 
addition to T53, T58 and S71, CNIs also increased the phosphorylation of S124. 
The functional characterisation and regulation of NCC-S124 differs from the other 
phosphosites (485). NCC-S124 is phosphorylated inside the Golgi apparatus, 
therefore it was speculated that NCC-S124 may play a role in the maturation and 
trafficking of NCC, leading to increased pNCC abundance and sodium chloride 
reabsorption (485). The underlying mechanism of this process is unclear, 
however a similar maturation process has been reported in the vasopressin-
regulated water channel AQP2, involving the phosphorylation of AQP2-S256 
(486).  
AQP2 is predominantly expressed in the apical membrane of the CD, where it is 
responsible for urinary concentration (487). Vasopressin induces phosphorylation 
of AQP2 at S256, S261, S264 and S269 (488); these serine residues are highly 
conserved and are located at the C-terminus of AQP2. S256 plays an important 
role in membrane trafficking of AQP2. Once AQP2-S256 is phosphorylated in the 
Golgi apparatus, AQP2 is trafficked to the plasma membrane in the vesicles, 
resulting in the increase of AQP2 abundance (486,489). The function of AQP2-
S261 remains unclear but unlike S256, it is not involved in membrane trafficking 
(490). Previous studies demonstrated that FK506 has no effect on the protein 
and mRNA expression of AQP2 (491). However, FK506 increased 
phosphorylation of S256 and S261 in this study, which could increase AQP2 
abundance in the plasma membrane and increase water reabsorption. 
NKCC2 is responsible for reabsorbing 25 % of NaCl in the TALH and several 
studies have suggested that it plays a role in the pathogenesis of CNI-induced 
hypertension. Esteva-Font et al. (492) previously reported that hypertension 
induced by CyA was associated with increased levels of NKCC2 in the loop of 
Henle of rats, however the functional significance of NKCC2 was not studied. In 
contrast, Aker et al. (493) showed that CyA downregulated NKCC2 and FK506 
upregulated NKCC2 activity in MDCK cells. This result was also different from the 
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Hoorn et al (51) study where NKCC2 and pNKCC2 (pT96, pT101 and pT114) 
protein levels remained unchanged in FK506-treated mice. Consistent with the 
Hoorn et al. study, FK506 had no effects on the membrane abundance of 
pNKCC2 in mice used in this thesis. Several NKCC2 phosphosites with unknown 
functional characterisation were identified in this study. FK506 increased 
phosphorylation of NKCC2 at Y110 and Y111 and decreased phosphorylation at 
Y110 and S116, and T114 and S116. These changes induced by FK506 may 
play a significant role in NKCC2 activity and membrane trafficking, which may 
provide an explanation for the differences shown in the studies mentioned above. 
ACE is an essential component of the RAAS and plays a significant role in blood 
pressure regulation. ACE inhibitors are widely used as anti-hypertensives and for 
cardiovascular disease. ACE was phosphorylated by FK506 at S1305 in this 
study, which is homologous to human S1299 and S1270. CK2 mediates ACE 
S1299 phosphorylation in humans, which prevents the release of ACE into the 
plasma (455). Increased phosphorylation of S1305 by FK506 might thus suggest 
lowered plasma levels of ACE, which might be a compensatory mechanism to 
reduce further NaCl and water reabsorption. 
NHERF1 was initially identified as an exclusive regulatory factor of NHE, but 
recent studies have shown pleiotropic role of NHERF1 in other solute transport 
process, such as sodium and phosphate reabsorption in the proximal tubule 
(456). Being a negative regulator of NHE3 (494), dysregulation in NHERF1 may 
induce changes in acid-base homeostasis (457), sodium/fluid reabsorption and 
blood pressure regulation (458,495). Over 20 unique phosphopeptides with 
different combinations of phosphosites were identified in NHERF1; these 
phospho-residues have various functional properties and require investigations 
into their role in renal electrolyte and fluid handling.  
3.4.5.2 Metabolic acidosis  
Metabolic acidosis is more prevalent in FK506-treated patients than those treated 
with CyA (54,496). FK506-induced acidosis could be caused by defective 
bicarbonate (HCO3-) reabsorption in the proximal tubule (497) and/or impaired 
acid (H+) excretion in the distal tubule (498). However, acid-base homeostasis 
extends beyond bicarbonate reabsorption and H+ excretion, and requires several 
other urinary buffers, such as NH3, HPO42-, HCO3- and C6H5O73−, all of which 
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carry free H+ to maintain pH balance in the urine (499). FK506 has been shown 
to affect transport proteins involved in acid-base transport, such as, NBCe1, 
NHE3 and NaPi-IIa (457).  
Downregulation of NBCe1 has previously been shown to induce metabolic 
acidosis in knockout mice where HCO3- reabsorption was lowered (500). This 
thesis showed that NBCe1 is heavily phosphorylated in the membrane fractions 
and phosphorylation was reduced in the cytosolic fractions of FK506-treated 
mice. Using Protter (406), topology studies of NBCe1 shows that these 
phosphosites are located in the intracellular domains of NBCe1; this provides an 
explanation for the difference shown in the two fractions where phosphorylation 
of these residues may occur after NBCe1 has been inserted into the membrane. 
The function of these phosphosites require further investigation and they may 
play an important role in the downregulation of NBCe1 activity and contribute to 
acidosis following FK506 treatment. In conjunction with lowered NBCe1 levels, 
FK506 also reduces levels of NHE3 to induce acidosis (457). Apical NHE3 
reabsorbs Na+ into the cell and excretes H+ in the proximal tubule, and 
phosphorylation of NHE3-S588 was increased by FK506, suggesting that 
phosphorylation of S588 might reduce the activity of NHE3 and lower H+ 
secretion, thereby causing acidosis.  
HPO42- is one of the H+ buffering systems in the urine; linking phosphate transport 
to acid-base homeostasis. The divalent HPO42- is reabsorbed by NaPi-IIa in the 
proximal tubule, but the titrated monovalent (H2PO4-) is not. CNIs cause 
hyperphosphaturia through reduction in the protein and mRNA expression of 
NaPi-IIa (59,457) and phosphorylation of NaPi-IIa-T621, S623 and S605 were 
downregulated by FK506, which might contribute to the decrease in phosphate 
reabsorption by NaPi-IIa. Under normal conditions, hyperphosphaturia is often 
associated with metabolic alkalosis as a result of a compensatory mechanism 
that restores acid-base balance in the tubular fluid by promoting of H+ secretion. 
However, since FK506 downregulates NHE3, H+ secretion is reduced and 
remains in the blood. 
3.4.5.3 Glucose transport  
SGLT2 is involved in reabsorbing 97 % of the filtered glucose in the proximal 
tubule (501). It is the target of SGLT2 inhibitors which block the tubular 
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reabsorption of glucose, which may be an effective treatment for type 2 diabetes 
(502). FK506 has been reported to induce post-transplantation diabetes in up to 
12 % of patients (503), however, the mechanism for FK506-induced diabetes 
remains unclear, and the effects of FK506 on SGLT2 have yet to be investigated. 
A novel phosphosite in SGLT2-S619 was identified in this study and 
downregulated by FK506. The function of SGLT2-S619 is unknown, however 
since SGLT2 is already reabsorbing glucose at almost maximal capacity under 
normal condition, phosphorylation at S619 may increase the membrane 
abundance of SGLT2, enhancing glucose reabsorption.  
AMPK is another regulator with pleiotropic effects on electrolyte homeostasis that 
are involved in the pathogenesis of the metabolic syndrome (504). AMPK has 
nutrient sensing abilities and is activated in response to low cellular energy levels 
to regulate glucose homeostasis (504). In this study, phosphorylation of the 
AMPK α1 subunit was increased by FK506 at S486 and T490, and 
phosphorylation of the AMPK β1 subunit was shown to be decreased by FK506 
at S24; these phosphorylation events may contribute to the dysregulation in 
glucose homeostasis seen with CNI treatments.  
3.4.5.4 Potassium homeostasis  
FK506 alters potassium transport in the kidneys and induces hyperkalaemia. 
KCNJ16 is expressed in both proximal and distal tubules. KCNJ16 null mice have 
a hypokalaemic phenotype, demonstrating the importance of KCNJ16 in 
potassium homeostasis (505). This current study identified two novel 
phosphosites S363 and S366 in KCNJ16, which were downregulated by FK506. 
A phosphosite, S1032 in KCC3 was also detected; decrease in the 
phosphorylation of which was found to be mediated by FK506. These 
phosphosites may have suppressive effects on the activity of these potassium 
transporters under normal conditions, therefore when FK506 decreases 
phosphorylation of these residues, potassium reabsorption increases. 
3.4.5.5 Ubiquitous transport proteins 
Na+/K+-ATPase maintains Na+ and K+ across the cell membrane and provides an 
electrochemical gradient that drives the active transport of electrolytes. CNIs 
reduce basolateral Na+/K+-ATPase abundance in the kidneys of rats (506) and 
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this reduction is likely to affect the ion transport systems that rely on Na+/K+-
ATPase as a driving force. Phosphorylation of the γ subunit of Na+/K+-ATPase 
was reduced by FK506 at S15. Mutations in the γ-subunit reduce the binding of 
the γ-subunit to the pump. This results in reduced Na+ and K+ affinity, decreasing 
in the activity of Na+/K+-ATPase (161,507), causing hypomagnesaemia in IDH. 
Hypomagnesaemia is a well-known effect of FK505, and of course occurred in 
the animals used in this study.  
3.4.6 Future experiments 
The phosphoproteome profile of the FK506-dysregulated renal cortices 
generated in this study covered all segments of the nephron found in the cortex; 
for a coverage with higher specificity of the PCT or DCT, cells from these 
segments can be isolated through the use of cell markers and flow cytometry. For 
example, the co-labelling of CD10 and CD13 have been used for cell sorting of 
proximal tubular epithelial cells (508). A similar method has also been used to 
extract distal tubule and collecting duct cells from human kidneys (509). The 
epithelial membrane antigen (EMA) is expressed in the distal tubule and the 
collecting duct, and it is most abundant at the TALH. EMA expression gradually 
decrease along the distal tubule with the lowest expression at the collecting duct. 
Therefore, purification of EMA-positive cells with the strongest expression can 
separate distal tubule cells from collecting duct cells (509).  
Alternatively, manual microdissection is a valuable tool in isolating desired tissue 
segments (510). However, this approach is time consuming and requires great 
precision, which makes this technique less reliable than newer approaches, such 
as, laser capture microdissection (LCM) (511,512). LCM applies a thermoplastic 
film, made of ethylene vinyl acetate polymers, onto tissue sections pre-stained 
with haematoxylin and eosin. An inverted microscope is used to produce localised 
heat-activation of the film, allowing targeted cells to fuse with the film, resulting in 
selective procurement of targeted cells in a heterogeneous tissue. LCM is 
becoming the method of choice in isolating specific cells in heterogeneous tissues 
due to its reliability, versatility and high throughput. However, LCM processed 
samples are subjected to processing-induced changes, for example, the dyes 
used to stain tissue samples can interfere with two-dimensional polyacrylamide 
gel electrophoresis used in proteomic analysis (513). 
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FK506-dysregulated proteins identified in this study require verification and 
investigation into the functional properties and changes in the phosphorylation of 
specific residues, which can be determined through Western blot analysis or 
immunohistochemistry using phosphosite specific antibodies. However, many 
phosphosite specific antibodies are not often commercially available, which 
means that customised antibodies are required; this can be time consuming and 
costly, therefore, functional characterisation of these phospho-residues can be 
beneficial prior to antibody production. In order to investigate the functional 
properties of specific phospho-residues, such as S122 found in NCC, uptake 
studies using 22Na can be used to determine and evaluate their role. As an 
example, S122 is highly conserved in NCC, but the functional properties of NCC-
S122 are currently unknown. An NCC-S122A mutant could be cloned and co-
expressed with the WNK kinases and calcineurin in uptake studies to investigate 
its role in NCC activity (121,192).  
The insulin/PI3K/AKT pathway has been shown to activate NCC through WNK-
SPAK/OSR1 (471). To confirm that both PI3K and AKT are involved in the 
cascade, a PI3K inhibitor (e.g. GDC-0941) (514) and an AKT inhibitor (e.g. MK-
2206) (515) could be used in conjunction with CNIs to investigate their effects on 
pNCC levels in mice. Since the activity of the WNK kinases is defined by 
phosphorylation and AKT is their upstream regulator, further studies are required 
to investigate the effects of AKT on the WNK kinases. Using a similar approach 
to previous oocyte studies, AKT, the WNK kinases, NCC and other members of 
the cascade can be co-expressed in oocytes and the activity of NCC can be 
measure using 22Na, to investigate the interactions of these proteins (121,192). 
AKT phospho-S124 and phospho-S126 identified in this study require further 
investigation to determine their role in AKT activity, mutation at these residues in 
an AKT construct can be used to identify their function, which could then be 
compared to residues with established function such as, T308 and S473. 
To investigate whether the FK506-dysregulated proteins identified in this study 
are also dysregulated in humans, biopsies from CNI-treated patients could be 
used for phosphoproteome profiling. Alternatively, the use of urinary exosomes 
and mass spectrometry have been well documented and have shown great 
potential for identifying diseases and evaluating disease progression (426,516). 
Therefore, urinary exosomes derived from CNI-treated subjects could also be 
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used for profiling and possibly be used for identifying biomarkers for the metabolic 
syndrome. 
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Chapter 4. The effects of FK506 on distal renal 
calcium handling 
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4.1 Introduction 
Hypercalciuria can cause serious health concerns, such as kidney stones and 
bone demineralisation. Kidney stones affect around 1 in 10 people in the U.K. 
(35) and the incidence and prevalence is increasing globally (32–34). Bone 
demineralisation can lead to osteoporosis, which has been reported to cause over 
9 million bone fractures per year (31). Kidney stone disease and osteoporosis are 
strongly associated with the highly prevalent metabolic syndrome (26,27), 
therefore it is important to understand the underlying mechanisms that govern 
calcium handling in the kidneys.  
The side effects of CNIs resemble FHHt and they both cause hypercalciuria and 
hypertension. CNI-induced hypercalciuria was thought to be caused by the 
decrease in mRNA and protein expression of TRPV5 and calbindin-D28K, 
resulting in a reduction in calcium reabsorption (57). CNI-induced hypertension 
is caused by the increase in NCC activity, resulting in an increase in sodium 
chloride reabsorption (51). The inhibition of calcineurin dysregulates multiple 
renal transport pathways, suggesting that these pathways are interlinked. Other 
evidence that supports the hypothesis of a close relationship between sodium 
and calcium handling in the DCT are demonstrated in FHHt patients with 
mutations in WNK4 and KLHL3 (60,390,392). Both of these mutations increase 
WNK4 abundance and activity in the DCT, and activates SPAK and NCC. This 
raises the possibility that WNK4 may induce hypercalciuria through SPAK-NCC 
activation. 
Thiazide diuretics are widely used in FHHt patients and specifically target NCC 
to decrease water and sodium reabsorption but they can cause hypocalciuria and 
hypercalcemia as side effects (385). Several studies have investigated the effects 
of thiazides on the regulatory and transport proteins involved in calcium handling 
in the DCT. However, its effects remain controversial due to a number of studies 
showing conflicting results (64,386,388), such as that thiazides may or may not 
increase TRPV5 and calbindin-D28K expression, and that the distal tubules may 
or may not be solely responsible for thiazide-induced hypocalciuria. Similar to 
patients treated with thiazides, hypocalciuria is also present in Gitelman patients. 
In a NCC knock-in mouse model of Gitelman syndrome, mRNA expression of 
TRPV5, and TRPV6 were increased. Increased abundance of the calcium 
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channels suggests that calcium influx may increase, causing hypocalciuria in 
Gitelman patients. These studies provide evidence to support an underlying 
mechanism that governs both sodium and calcium handling in the DCT. 
4.1.1 Aims 
• To investigate the effects of FK506 on calcium transport and regulatory 
proteins in the DCT  
• To identify a possible unifying mechanism for calcium and sodium 
reabsorption in the DCT. 
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4.2 Materials and methods 
CNI-induced hypercalciuria is thought to be caused by altered calcium handling 
in the distal nephron (57). The effects of FK506 and HSD on the expression of 
calcium transport and regulatory proteins were investigated. In addition, sodium 
transport proteins were also examined to investigate the relationship between 
sodium and calcium handling in the DCT.  
4.2.1 Animals 
Male C57BL/6J mice of 6-8 weeks were divided into four treatment groups: 
vehicle or FK506 fed on a normal diet, and vehicle or FK506 fed on a HSD 
containing additional 1.5 % NaCl. For further details regarding the treatments, 
diets, housing conditions and the Schedule 1 protocol for euthanasia, see 
Chapter 3, Section 3.2.1. For details regarding electrolyte measurements in 
serum and urine, see Chapter 3, Section 3.2.2. 
4.2.2 Real-time PCR 
Mouse kidneys were homogenised with liquid nitrogen using a pestle and mortar, 
under RNase free conditions. Powdered kidney tissue (100 mg) was added to 1 
ml of Trizol reagent (Sigma-Aldrich Co., Ltd., Poole, UK) and incubated for 5 
minutes at room temperature. RNA was obtained by phenol-chloroform extraction 
and precipitated with isopropanol. The concentration and purity of RNA was 
determined using a NanoDrop-1000 spectrophotometer (Labtech International, 
UK), samples contaminated with impurities were discarded. RNA samples were 
stored at -80 ˚C. 
RNA samples (1 µg) were treated with 2 units of DNase I (PCR Biosystems, 
Prague, Czech Republic) and 1 X DNaseI buffer [10 mM Tris at pH 7.5, 2.5 mM 
MgCl2, 0.5 mM CaCl2] (PCR Biosystems, Prague, Czech Republic). This mixture 
was incubated at room temperature for 15 minutes. DNase I was inactivated by 
adding 5 mM EDTA (Ethylenediaminetetraacetic acid) and incubation at 65 ˚C for 
10 minutes. RNA samples (1 µg) were reverse transcribed into cDNA using a 
qPCRBIO cDNA synthesis kit (PCR Biosystems, Prague, Czech Republic) 
according to the manufacturer’s protocol. Each transcription reaction was run in 
parallel with a negative control reaction lacking reverse transcriptase; samples 
were stored at -20 ˚C. 
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One microlitre of the resulting cDNA transcripts was amplified in a real-time 
quantitative PCR (RT-qPCR) reaction using primers from the RT² qPCR Primer 
Assays (Qiagen, Crawley, UK), a RT-qPCR master mix from the Applied 
Biosystems SYBR Green RT-qPCR reagents kit (Fisher Scientific, 
Loughborough, UK) and the Roche LightCycler 96 System (Roche, Lewes, UK); 
reactions were performed according to the manufacturer’s protocol. RT-qPCR 
reaction underwent 35 cycles following the programme shown in Table 4.2-1. 
mRNA expression was quantified and a ratio of the relative abundance of each 
gene against the housekeeping gene β-actin was calculated using the 
LightCycler Relative Quantification software (Roche Diagnostics, Lewes, UK). 
The PCR products of these samples were ran on a 2 % agarose-TAE gel 
containing 0.5 µg/ml ethidium bromide (Sigma-Aldrich Co., Ltd., Poole, UK) and 
imaged with a UV transilluminator (Peqlab, Netherlands) to check for correct size 
of amplicons. 
4.2.3 Western blot analysis 
The extraction of mouse kidney proteins and Western blotting were performed 
according to Chapter 3, Section 3.2.3 and Section 3.2.4. Membranes were 
incubated with primary antibody in PBS-T against the following proteins: TRPV5 
[1:500] (kind gift from C. Wagner), NCX1 [1:1000] (Swant, Switzerland), calnexin 
[1:1000] (Proteintech, USA), ADCY6 (ab192652) [1:500] and β-actin (AC-15) 
[1:2000] (both from Abcam, Cambridge, UK), NCC (1-100) [1:500] and phospho-
NCC (T60) [1:300] (both from MRC-PPU, Dundee, UK), and calbindin-D28K (c-
20) [1:1000], PMCA (F-3) [1:1000], R-type Ca2+ CPα1E (C-20) [1:1000], Na+/K+-
ATPase (H-300) [1:1000], PKC α (sc-8393) [1:400], PKC β1 (sc-209) [1:200], 
PKC δ (sc-937) [1:500], PKC ε (sc-214) [1:500] and phospho-PKC β1 (T641) 
[1:200] (all from Santa Cruz Biotechnology, UK). For details on densitometry, see 
Chapter 2, Section 2.2.5.3. 
4.2.1 Statistics 
Statistical analysis was performed by unpaired t-tests in datasets with two 
treatment groups or ANOVA followed by a Bonferroni’s multiple comparison test 
in datasets with three or more treatment groups. The data are presented as 
means ± SEM. 
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Table 4.2-1 RT-qPCR programme 
RT-qPCR Programme 
Pre-incubation 95 °C 10 minutes 
35 cycles of Amplification 
95 °C 
60 °C 
72 °C 
10 seconds 
10 seconds 
10 seconds 
High Resolution Melting 
95 °C 
65 °C 
97 °C 
10 seconds 
60 seconds 
continuous 
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4.3 Results 
4.3.1 Effects of FK506 on transcripts of respective calcium regulatory and 
transport proteins 
The DCT is a principal site of sodium and calcium reabsorption. FK506 and 
thiazide diuretics alter sodium chloride handling through NCC and dysregulate 
calcium homeostasis, causing hypercalciuria (57) and hypocalciuria (385) 
respectively. To determine the effects of FK506 on these proteins, the mRNA 
expression and protein expression of calcium regulatory and transport proteins 
expressed in the distal tubules were examined.  
Renal mRNA expression of calbindin-D28K, calcineurin Aα, TRPV5, NCX1 and 
PMCA1 and 4 were determined through RT-qPCR. Similar to previous studies, 
FK506 significantly decreased mRNA expression of calbindin-D28K (57). In 
contrast, FK506 significantly increased mRNA expression of TRPV5. The 
decrease in calbindin-D28K mRNA expression in FK506-treated mice indicates 
low intracellular calcium level, however, the increase in TRPV5 mRNA expression 
suggests an increase in calcium reabsorption in the distal nephron. FK506 did 
not significantly alter the mRNA expression of calcineurin, NCX1, PMCA1 and 
PMCA4 (Figure 4.3-1).  
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Figure 4.3-1 mRNA expression of calcium regulatory and transport proteins in the kidneys post-FK506 treatment 
RT-qPCR quantification of a) calbindin-D28K, b) Calcineurin-Aα, c) TRPV5, d) NCX1, e) PMCA and f) PMCA4 in kidneys of FK506 or 
vehicle treated mice. Data are presented as means ± SEM, n=6. Statistical values were calculated using an unpaired t-test. 
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4.3.2 Effects of FK506 and a high salt diet on calcium transport and buffering 
proteins in the DCT 
To determine whether the changes in mRNA expression would result in changes 
in the expression of the respective proteins, Western blot analysis was used to 
quantify the protein expression of TRPV5, calbindin-D28K, NCX1 and PMCA in 
the kidneys of FK506-treated mice. Since FK506 and thiazides both target NCC, 
a high NaCl diet (HSD) was fed to mice treated with vehicle or FK506 to 
investigate the relationship between sodium and calcium handling. In addition, 
the protein expression of NCC, pNCC and the Na+/K+-ATPase (493,506) of mice 
treated with FK506 were re-examined along with FK506-treated mice that were 
fed a HSD. To confirm the effectiveness of the treatment, the net urinary excretion 
of Ca2+ and serum Mg2+ levels of vehicle, HSD, FK506 and FK506 + HSD treated 
mice were determined and are depicted in Table 4.3-1. FK506-treated mice and 
FK506 + HSD treated mice had hypercalciuria and hypomagnesaemia. HSD 
alone did not significantly alter net calcium excretion or serum magnesium levels, 
however the effect of HSD significantly enhanced the net calcium excretion of 
FK506-treated mice. 
The protein expression of TRPV5, calbindin-D28K, NCX1 and PMCA in mice fed 
a HSD or/and treated with FK506 were determined through Western blot analysis. 
Previously FK506 was shown to decrease mRNA expression (57) and protein 
expression of TRPV5 (51,57); in contrast, this study showed that the mRNA 
expression of TRPV5 was increased in FK506-treated mice (Figure 4.3-1) and 
the protein expression of TRPV5 remained unchanged (Figure 4.3-2). Similar to 
the FK506 treatment, TRPV5 protein expression in FK506 + HSD treated mice 
remained unchanged. The effect of HSD alone appears to increase TRPV5, 
however this effect was not statistically significant (p=0.07).  
Similar to previously studies (57), FK506 decreased mRNA (Figure 4.3-1) and 
protein expression of calbindin-D28K (Figure 4.3-3) and this effect was also 
shown in mice treated with FK506 and fed a HSD in this chapter. The difference 
in calbindin-D28K protein expression between FK506 and FK506 + HSD treated 
mice was not statistically significant (p=0.051); however, there was a tendency 
for HSD to enhance the effect of FK506. HSD alone increased levels of calbindin-
D28K. These results indicate that FK506 may only affect calbindin-D28K on a 
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transcriptional level, which results in a lower protein expression of calbindin-D28K 
in the kidney.  
Next, the effect of FK506 on the basolateral calcium transport proteins were 
examined. Western blot analysis of NCX1 (Figure 4.3-4) and PMCA (Figure 4.3-
5) revealed that FK506 significantly increased the membrane abundance of 
NCX1 and PMCA. Western blot analysis also revealed that the effect of FK506 
on NCX1 and PMCA was not enhanced by HSD. Instead, expression of NCX1 in 
mice treated with FK506 and fed a HSD revealed that a HSD partially decreased 
the effect of FK506. In contrast, PMCA levels in FK506 + HSD treated mice were 
restored to baseline levels. Mice on a HSD were shown to have increased levels 
of NCX1 while the levels of PMCA remained unchanged. 
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Table 4.3-1 Calcium creatinine ratio and serum magnesium levels of FK506 
or vehicle treated mice 
Treatment group 
(n=5) 
Calcium creatinine ratio 
(mmol/mmol) 
Serum Magnesium levels 
(mmol/l) 
Vehicle 0.057 ± 0.012 1.010 ± 0.068 
HSD 0.035 ± 0.010 0.930 ± 0.023 
FK506 0.101 ± 0.010 * # 0.800 ± 0.023 * 
FK506 + HSD 0.172 ± 0.014 ** ᵼ 0.772 ± 0.044 * 
 
The effect of FK506 treatment on the calcium creatinine ratio and serum 
magnesium level in mice. FK506-treated mice administrated 2mg/kg/day FK506 
for two weeks by daily IP injections and HSD (1.5 % NaCl) were fed to 50 % of 
vehicle or FK506-treated mice. Statistical values were calculated using an 
ANOVA followed by a Bonferroni’s multiple comparison test. Data are presented 
as means ± SEM. * P<0.05 vs. vehicle; # P<0.05 vs. HSD; ** P<0.01 vs. FK506; 
ᵼ P<0.001 vs. vehicle and vs. HSD. 
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Figure 4.3-2 The effects of FK506 and HSD on TRPV5 protein expression in 
the kidney membrane 
Western blot analysis was performed on kidney membranes of vehicle, a) FK506 
or FK506 + HSD and b) HSD treated mice. Representative blots (left) and protein 
expression (right) of TRPV5 are shown. Band intensities of TRPV5 were 
quantified and normalised to those of β-actin and expressed as a fold change of 
the control mean; data are presented as means ± SEM, n=5-6. Statistical values 
were calculated using an unpaired t-test for vehicle vs. HSD treatment and 
ANOVA followed by a Bonferroni’s multiple comparison test for vehicle vs. FK506 
vs. FK506 + HSD treatment.  
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Figure 4.3-3 The effects of FK506 and HSD on calbindin-D28K protein 
expression in the kidney  
Western blot analysis was performed on kidneys of vehicle, a) FK506 or FK506 
+ HSD and b) HSD treated mice. Representative blots (left) and protein 
expression (right) of calbindin-D28K are shown. Band intensities of calbindin-
D28K were quantified and normalised to those of β-actin and expressed as a fold 
change of the control mean; data are presented as means ± SEM, n=5-6. 
Statistical values were calculated using an unpaired t-test for vehicle vs. HSD 
treatment and ANOVA followed by a Bonferroni’s multiple comparison test for 
vehicle vs. FK506 vs. FK506 + HSD treatment.   
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Figure 4.3-4 The effects of FK506 and HSD on NCX1 protein expression in 
the kidney membrane 
Western blot analysis was performed on kidney membranes of vehicle, a) FK506 
or FK506 + HSD and b) HSD treated mice. Representative blots (left) and protein 
expression (right) of NCX1 are shown. Band intensities of NCX1 were quantified 
and normalised to those of β-actin and expressed as a fold change of the control 
mean; data are presented as means ± SEM, n=5-6. Statistical values were 
calculated using an unpaired t-test for vehicle vs. HSD treatment and ANOVA 
followed by a Bonferroni’s multiple comparison test for vehicle vs. FK506 vs. 
FK506 + HSD treatment.  
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Figure 4.3-5 The effects of FK506 and HSD on PMCA1/4 protein expression 
in the kidney membrane 
Western blot analysis was performed on kidney membranes of vehicle, a) FK506 
or FK506 + HSD and b) HSD treated mice. Representative blots (left) and protein 
expression (right) of PMCA are shown. Band intensities of PMCA were quantified 
and normalised to those of β-actin and expressed as a fold change of the control 
mean; data are presented as means ± SEM, n=5-6. Statistical values were 
calculated using an unpaired t-test for vehicle vs. HSD treatment and ANOVA 
followed by a Bonferroni’s multiple comparison test for vehicle vs. FK506 vs. 
FK506 + HSD treatment.   
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4.3.3 Effects of FK506 and a high salt diet on DCT sodium transport proteins 
Dietary NaCl affects calcium transport protein expression in the DCT, therefore, 
the effect of FK506 on sodium transport proteins and regulatory proteins involved 
in both calcium and sodium handling were investigated. The effect of FK506 on 
the protein expression of NCC and pNCC have previously been examined in 
Chapter 3, Section 3.3.1. This chapter examines the effect of a HSD on NCC, 
pNCC and Na+/K+-ATPase in kidneys of mice treated with vehicle and FK506. 
Western blot analysis revealed that FK506, FK506 with HSD and HSD treatments 
have no significant effects on NCC levels (Figure 4.3-6). Next, Western blot 
analysis of pNCC in mice fed on a HSD and treated with FK506 showed a 
significant increase in pNCC expression when compared to the control. However, 
the difference between FK506 with HSD and FK506 alone was not significant 
(p=0.13), which indicates that HSD did not significantly enhance the effect of 
FK506. The abundance of pNCC in mice fed on a HSD was not significantly 
different than those fed on a normal diet (Figure 4.3-7).  
In keeping with previous studies (493,506), protein expression of Na+/K+-ATPase 
decreased in FK506-treated mice. The effect of HSD on mice treated with FK506 
was not significantly different from those treated with FK506 alone (p=0.127); 
however, a slight increase in Na+/K+-ATPase was observed in mice treated with 
FK506 + HSD. Mice fed a HSD showed a significant increase in the protein 
abundance of Na+/K+-ATPase (Figure 4.3-8).   
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Figure 4.3-6 The effects of FK506 and HSD on NCC protein expression in 
the kidney membrane 
Western blot analysis was performed on kidney membranes of vehicle, a) FK506 
or FK506 + HSD and b) HSD treated mice. Representative blots (left) and protein 
expression (right) of NCC are shown. Band intensities of NCC were quantified 
and normalised to those of β-actin and expressed as a fold change of the control 
mean; data are presented as means ± SEM, n=5-6. Statistical values were 
calculated using an unpaired t-test for vehicle vs. HSD treatment and ANOVA 
followed by a Bonferroni’s multiple comparison test for vehicle vs. FK506 vs. 
FK506 + HSD treatment.  
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Figure 4.3-7 The effects of FK506 and HSD on pNCC protein expression in 
the kidney membrane  
Western blot analysis was performed on kidney membranes of vehicle, a) FK506 
or FK506 + HSD and b) HSD treated mice. Representative blots (left) and protein 
expression (right) of pNCC are shown. Band intensities of pNCC were quantified 
and normalised to those of β-actin and expressed as a fold change of the control 
mean; data are presented as means ± SEM, n=5-6. Statistical values were 
calculated using an unpaired t-test for vehicle vs. HSD treatment and ANOVA 
followed by a Bonferroni’s multiple comparison test for vehicle vs. FK506 vs. 
FK506 + HSD treatment.   
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Figure 4.3-8 The effects of FK506 and HSD on Na+/K+-ATPase protein 
expression in the kidney membrane  
Western blot analysis was performed on kidney membranes of vehicle, a) FK506 
or FK506 + HSD and b) HSD treated mice. Representative blots (left) and protein 
expression (right) of Na+/K+-ATPase are shown. Band intensities of Na+/K+-
ATPase were quantified and normalised to those of β-actin and expressed as a 
fold change of the control mean; data are presented as means ± SEM, n=5-6. 
Statistical values were calculated using an unpaired t-test for vehicle vs. HSD 
treatment and ANOVA followed by a Bonferroni’s multiple comparison test for 
vehicle vs. FK506 vs. FK506 + HSD treatment.   
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4.3.4 Effects of FK506 and a high salt diet on PKC 
PTH is a regulator of sodium and calcium handling in the DCT known to 
downregulate NCC and upregulate TRPV5 activity (308,517). PTH signals PKC 
to increase TRPV5 expression on surface membranes and WNK4 was reported 
to enhance this process (315,337). PKC phosphorylates KLHL3 to prevent WNK4 
degradation and increases phosphorylation of WNK4, which may increase NCC 
activity through SPAK/OSR1 signalling pathway (244,261). The effects of FK506 
on the protein expression of PKC (α, β1, δ and ε) and phospho-PKC β1 were 
examined and quantified using Western blot analysis.  
The protein expression of PKC β1 (Figure 4.3-9) and PKC δ (Figure 4.3-10) 
remained unchanged in mice treated with FK506, FK506 with HSD and HSD 
alone. The effect of FK506 alone did not alter the protein expression of PKC ε, 
however, the levels of PKC ε increased significantly in FK506-treated mice fed a 
HSD. The protein expression of PKC ε in mice fed a HSD remained unchanged 
(Figure 4.3-11). The levels of PKC α and phospho-PKC β1 were also examined, 
however Western blot failed to detect signals using these antibodies under 
several conditions. The potential causes of this include low protein expression in 
the renal cortices and antibodies being incompatible with the Western blot 
technique, therefore the effects of FK506 on PKC α and phospho-PKC β1 remain 
inconclusive. 
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Figure 4.3-9 The effects of FK506 and HSD on PKC β1 protein expression in 
the kidney 
Western blot analysis was performed on kidneys of vehicle, a) FK506 or FK506 
+ HSD and b) HSD treated mice. Representative blots (left) and protein 
expression (right) of PKC β1 are shown. Band intensities of PKC β1 were 
quantified and normalised to those of β-actin and expressed as a fold change of 
the control mean; data are presented as means ± SEM, n=5-6. Statistical values 
were calculated using an unpaired t-test for vehicle vs. HSD treatment and 
ANOVA followed by a Bonferroni’s multiple comparison test for vehicle vs. FK506 
vs. FK506 + HSD treatment.  
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Figure 4.3-10 The effects of FK506 and HSD on PKC δ protein expression in 
the kidney 
Western blot analysis was performed on kidneys of vehicle, a) FK506 or FK506 
+ HSD and b) HSD treated mice. Representative blots (left) and protein 
expression (right) of PKC δ are shown. Band intensities of PKC δ were quantified 
and normalised to those of β-actin and expressed as a fold change of the control 
mean; data are presented as means ± SEM, n=5-6. Statistical values were 
calculated using an unpaired t-test for vehicle vs. HSD treatment and ANOVA 
followed by a Bonferroni’s multiple comparison test for vehicle vs. FK506 vs. 
FK506 + HSD treatment.  
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Figure 4.3-11 The effects of FK506 and HSD on PKC ε protein expression in 
the kidney  
Western blot analysis was performed on kidneys of vehicle, a) FK506 or FK506 
+ HSD and b) HSD treated mice. Representative blots (left) and protein 
expression (right) of PKC ε are shown. Band intensities of PKC ε were quantified 
and normalised to those of β-actin and expressed as a fold change of the control 
mean; data are presented as means ± SEM, n=5-6. Statistical values were 
calculated using an unpaired t-test for vehicle vs. HSD treatment and ANOVA 
followed by a Bonferroni’s multiple comparison test for vehicle vs. FK506 vs. 
FK506 + HSD treatment.   
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4.3.5 Phosphoproteins in FK506-treated mice that may play a role in distal renal 
calcium handling 
Since FK506 did not induce significant changes in PKC (β1, δ and ε) protein 
expression in the kidney, an alternative approach was used to identify other 
upstream regulators involved in both renal calcium and sodium handling. The 
phosphoproteome profile generated from Chapter 3, was used to identify proteins 
that may play a role in calcium handling in the distal nephron. Phosphoproteins 
identified in the membrane and cytosolic fraction were filtered by GO terms from 
the main proteomic tables (Appendix Table 6.3-3 and Table 6.3-4), searching for 
the keyword “calcium”. Thirty-five phosphopeptides, which correspond to 19 
proteins, were selected from the membrane fraction (Appendix, Table 6.3-5) and 
19 phosphopeptides, which correspond to 12 proteins, were identified in the 
cytosolic fraction (Appendix, Table 3.6-6).  
Phosphoproteins that are likely to be involved in FK506-dysregulated calcium 
homeostasis, hypertension and the metabolic syndrome were selected and 
presented in Table 4.3-2. ADCY6 is involved in water and electrolyte 
homeostasis, such as in calcium and phosphate handling (518), and FK506 was 
shown to increase phosphorylation of ADCY6 at S53 by 32 % in the renal cortices 
of FK506-treated mice. FK506 increased phosphorylation of PMCA at S1155 and 
T1165 by 3.43 %. Since the 10 % cut-off point was set in the previous chapter for 
FK506-dysregulated phosphopeptides, the effect of FK506 was unlikely to have 
a significant effect on PMCA.  
FK506 increased the phosphorylation of the calcium voltage-gated channel 
subunit α1E (CACNA1E), involved in calcium binding and transport, and glucose 
homeostasis (519), by 31 % at a novel phosphosite, T1983. A total of 7 
phosphopeptides were dysregulated by FK506 in another calcium binding 
protein, calnexin (CANX). FK506 increased phosphorylation of CANX in the 
membrane fraction but it was shown to decrease its phosphorylation in the 
cytosolic fraction. This might indicate that CANX is phosphorylated after it has 
been inserted into the membrane. The calcium/calmodulin-dependent serine 
protein kinase (CASK) is co-expressed with PMCA and calbindin-D28K in the 
DCT (520), and it is likely to be involved in renal calcium handling. FK506 
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decreased the phosphorylation of CASK at S582, however, this effect is not likely 
to have a significant impact as CASK-pS582 was only downregulated by 4.71 %.  
Megalin interacts with the H+/Cl- exchange transporter 5 (CLCN5) and NHERF2 
(521), and mutations in CLCN5 are known to cause Dent’s disease, which causes 
hypercalciuria (522,523). Therefore, megalin may play a role in renal calcium 
handling. FK506 was shown to decrease the phosphorylation of megalin at S4624 
(8.19 %) and at a novel phosphosite, T4583. The effect of FK506 on T4583 is not 
likely to be significant, since megalin-T4583 was only downregulated by 3.17 %. 
TRPM7 is a divalent cation channel that is permeable to both Ca2+ and Mg2+. 
FK506 was shown to dysregulate the phosphorylation of TRPM7 at S1502, 
however, the changes may not be significant since the change in phosphorylation 
was only 3.44 %. Another TRP family member, the transient receptor potential 
cation channel subfamily P member 2 (TRPP2), was also dysregulated by FK506. 
TRPP2 is cation channel that is permeable to calcium ions. TRPP2 is expressed 
in the cilia of tubular epithelial cells and is associated with polycystic kidney 
disease (524). FK506 was shown to increase phosphorylation of TRPP2 at S810 
in both the membrane (12.35 %) and cytosolic fraction (15.51 %), however since 
TRPP2 is a non-selective cation channel with diverse physiological functions 
including cell proliferation and apoptosis, and that its role in calcium handling in 
the nephron is unknown, the effects of FK506 on TRPP2 was not examined in 
this chapter.  
The effect of FK506 on the protein expression of ADCY6, CANX and CACNA1E 
were investigated because they were dysregulated by FK506 (over 10 % change 
in phosphorylation) and could be feasibly involved in components of the metabolic 
syndrome. The protein expression of ADCY6 (Figure 4.3-12) remained 
unchanged in mice treated with FK506, FK506 with HSD and HSD alone. 
Western blot analysis was performed on kidneys of FK506-treated mice and 
revealed that FK506 did not have any effects on the protein expression of CANX. 
The levels of CANX increased in the kidneys of mice treated with FK506 and fed 
a HSD but the effect of HSD alone was not statistically significant (Figure 4.3-13). 
Unfortunately, there was no signal detected in the Western blot analysis of 
CACNA1E, possibly due to poor binding of the CACNA1E antibody to its epitopes 
on the Western blot. The effect of FK506 on CACNA1E remains inconclusive.  
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Gene name Protein name Accession No. Peptide Sequence Phosphosites 
Percentage Change 
 Memb              Cyto 
ADCY6 Adenylyl cyclase 6  Q01341 NAEPPsPTPAAHTR S53 + 32.32 - 
ATP2B1 
Plasma membrane calcium-transporting ATPase 
1  
(PMCA1) 
G5E829 IEDsEPHIPLIDDtDAEDDAPTKR S1155; T1165 + 3.43 - 
CACNA1E 
Voltage-dependent R-type calcium channel 
subunit alpha-1E 
Q61290 SFStIR T1983 * + 30.99 - 
CANX Calnexin P35564 
QKsDAEEDGVTGSQDEEDSKPK 
SDAEEDGVTGsQDEEDSKPK 
AEEDEILNRsPR 
QKsDAEEDGVtGSQDEEDSKPK 
QKsDAEEDGVTGsQDEEDSKPK 
QKSDAEEDGVtGsQDEEDSKPK 
QKSDAEEDGVTGsQDEEDsKPK 
S553 
S563 
S582 
S553; T561 
S553; S563 
T561; S563 
S563; S569 
+ 15.79 
+ 21.24 
+ 10.96 
- 
+ 25.45 
+ 6.08 
+ 11.34 
- 14.77 
- 
- 11.28 
- 35.99 
- 
- 
- 
CASK 
Calcium/calmodulin-dependent serine protein 
kinase 
O70589 TQSSSCERDsPSTSR S582 - 0.32 - 4.71 
LRP2 Megalin A2ARV4 
SIDPSEIVPEPKPASPGADEtQGTK 
EAVAVAPPPsPSLPAK 
T4583 * 
S4624 
- 
- 1.11 
- 3.17 
- 8.19 
2
0
2
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TRPM7 
Transient receptor potential cation channel 
subfamily M member 7 
Q923J1 RAsTEDSPEVDSK S1502 + 3.44 - 
TRPP2 
Transient receptor potential cation channel 
subfamily P member 2 
O35245 SLDDsEEEDDEDSGHSSR S810 + 12.35 + 15.51 
* Novel phosphosite 
 
Table 4.3-2 FK506-dysregulated phosphoproteins involved in calcium handling identified in the nephron 
Identification and quantification of phosphosites in calcium-associated proteins after FK506 treatment. Novel phosphorylation sites were 
previously unidentified in PhosphoSitePlus® Database. 
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Figure 4.3-12 The effects of FK506 and HSD on ADCY6 protein expression 
in the kidney 
Western blot analysis was performed on kidneys of vehicle, a) FK506 or FK506 
+ HSD and b) HSD treated mice. Representative blots (left) and protein 
expression (right) of ADCY6 are shown. Band intensities of ADCY6 were 
quantified and normalised to those of β-actin and expressed as a fold change of 
the control mean; data are presented as means ± SEM, n=5-6. Statistical values 
were calculated using an unpaired t-test for vehicle vs. HSD treatment and 
ANOVA followed by a Bonferroni’s multiple comparison test for vehicle vs. FK506 
vs. FK506 + HSD treatment.  
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Figure 4.3-13 The effects of FK506 and HSD on Calnexin protein expression 
in the kidney 
Western blot analysis was performed on kidneys of vehicle, a) FK506 or FK506 
+ HSD and b) HSD treated mice. Representative blots (left) and protein 
expression (right) of calnexin are shown. Band intensities of calnexin were 
quantified and normalised to those of β-actin and expressed as a fold change of 
the control mean; data are presented as means ± SEM, n=5-6. Statistical values 
were calculated using an unpaired t-test for vehicle vs. HSD treatment and 
ANOVA followed by a Bonferroni’s multiple comparison test for vehicle vs. FK506 
vs. FK506 + HSD treatment.  
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4.4 Discussion 
FK506 alters sodium and calcium transcellular transport systems in the DCT by 
dysregulating transporters expressed at the apical and basolateral surface of the 
cell membrane. The effects of FK506 on TRPV5 and calbindin-D28K have been 
investigated in several studies (57,51), in which it was suggested that 
downregulation of TRPV5 and calbindin-D28K disrupts transcellular reabsorption 
of calcium in the distal nephron and contributes to the pathogenesis of CNI-
induced hypercalciuria. These studies focused on the changes in the transport 
process at the apical membrane; the effects of FK506 on the basolateral 
membrane transporters remain unclear. Results obtained in this chapter suggest 
that basolateral transport proteins in the DCT may play a role in the 
pathophysiology of CNI-induced hypercalciuria.  
In this chapter, FK506 was found to increase urinary calcium excretion and 
decrease calbindin-D28K expression. In contrast to previous studies (51,57), 
FK506 was shown to increase mRNA expression of TRPV5 and its protein 
expression remained unchanged in mice in this study. Nijenhuis et al. (57) 
showed that daily administration of FK506 by oral gavage for 7 days decreased 
TRPV5 mRNA expression in rats. In the Hoorn et al study (51), TRPV5 protein 
expression decreased in FK506-treated mice, however, Western blot analysis of 
TRPV5 was performed on whole kidney lysates, which differs from the 
fractionated kidney samples used in this study. FK506 has no transcriptional 
effect on NCX1 and PMCA, however treatment with FK506 increased the 
abundance of these proteins in the kidney membrane fraction. Overall, these 
results showed low calbindin-D28K expression, which suggests low transcellular 
calcium movement, and an increase in the protein abundance of the basolateral 
calcium transport proteins, which may correlate with an increase in their activity. 
4.4.1 The novel mechanism of CNI-induced hypercalciuria 
The link between sodium and calcium transport at the DCT is evident; this is 
demonstrated by the resemblance between calcium disturbances in thiazide-
treated patients and Gitelman patients, and also between CNI-treated patients 
and FHHt patients. In order to decipher the relationship between calcium and 
sodium handling, the effects of FK506 on sodium transport were also studied. 
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Corroborating previous studies (51,493,506), FK506 increased pNCC and 
decreased Na+/K+-ATPase expression. The effects of FK506 on sodium and 
calcium transport proteins reported in this study have led to the development of 
a hypothetical model of FK506-induced hypercalciuria.  
Under normal conditions, the activity of Na+/K+-ATPase is the rate limiting step 
that exports sodium across the basolateral membrane (80) as it creates an 
electrochemical gradient for apical transporters such as NCC. Na+/K+-ATPase 
expression decreases during FK506 treatment, but the continuous influx of 
sodium chloride through activated NCC causes an accumulation of sodium inside 
the cell. This causes depolarisation of the basolateral membrane and reverses 
the transport direction of NCX1 (354,355,525), causing calcium influx and sodium 
efflux, compensating for the reduction in Na+/K+-ATPase-mediated sodium efflux.  
The membrane abundance of NCX1 was increased in FK506-treated mice. This 
should exacerbate the increase in the intracellular calcium concentration and thus 
reduce the electrochemical gradient favouring calcium uptake by TRPV5. 
Reduction in calcium uptake increases urinary calcium excretion, and thereby 
causing hypercalciuria. The increase in PMCA abundance is likely a 
compensatory effect to prevent toxic levels of cytosolic calcium caused by NCX1-
mediated calcium influx (Figure 4.4-1).  
With this model of CNI-induced hypercalciuria, the magnitude of chloride and 
potassium efflux must be equal to their influx. In the DCT, chloride is primarily 
exported by CLCNKB (83) and also by KCC4 (84). The magnitude of chloride 
efflux by CLCNKB and KCC4 must equal to the chloride influx by NCC in this 
model, therefore it is predicted that FK506 would not decrease the expression or 
activity of these transporters. Potassium is exported by KCNJ10 and several other 
basolateral K+ channels, such as KCNJ15 and KCNJ16, in the DCT (103). 
KCNJ10 is known to recycle potassium from Na+/K+-ATPase (101) and reduction 
in KCNJ10 is associated with reduced Na+/K+-ATPase activity (162). It is 
therefore theorised that low levels of Na+/K+-ATPase might be accompanied by 
a reduction in KCNJ10. However, the exact effects of FK506 on these basolateral 
transport proteins are unknown and require further investigation.  
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Figure 4.4-1 Schematic model of CNI-induced hypercalciuria in the DCT 
A novel model of CNI-induced hypercalciuria. a) An increase in intracellular Ca2+ activates calcineurin, which inhibits NCC and activates 
Na+/K+-ATPase. b) When calcineurin is inhibited by CNIs, pNCC expression increases and Na+/K+-ATPase decreases, causing Na+ 
accumulation in the cytosol. c) Na+ accumulation depolarises the basolateral membrane and reverses the transport direction of NCX1, 
causing Na+ efflux and Ca2+ influx, reducing the electrochemical gradient required for Ca2+ uptake through TRPV5, resulting in an increase 
in urinary Ca2+; this is augmented by low D28K level, which indicates low Ca2+ shuttling across the cell.  
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4.4.2 FK506 with a HSD reversed the effect of FK506 on the calcium transport 
proteins 
High dietary salt intake and FK506 can both cause salt-sensitive hypertension 
(51). Previous studies used 1.5 % NaCl to enhance the disease phenotype of 
rodents susceptible to hypertension (526,527). Therefore, a HSD was fed to 
FK506-treated mice in this study to enhance the side effects of CNIs. As shown 
in the previous chapter, FK506 mainly dysregulated proteins at a post-
translational level, therefore the effects of FK506 + HSD or HSD on mRNA 
expression of proteins of interests were not determined.  
HSD enhanced the effect of FK506 on urinary calcium excretion and had no 
effects on TRPV5 protein expression in FK506-treated mice. Although not 
statistically significant, the protein expression of pNCC and calbindin-D28K in 
FK506 + HSD-treated mice showed a tendency for HSD to enhance the effect of 
FK506.  
Vehicle-treated mice fed on a HSD showed a significant increase in the protein 
expression of Na+/K+-ATPase, and FK506 treatment resulted in a significant 
decrease in Na+/K+-ATPase. HSD and FK506 counteract each other in the 
expression of Na+/K+-ATPase, and HSD appeared to restore Na+/K+-ATPase 
expression in FK506 + HSD-treated mice. HSD reduced the effect of FK506 by 
decreasing the abundance of NCX1 and PMCA. Even though a HSD significantly 
reduced NCX1 in FK506-treated mice, NCX1 expression remained significantly 
higher than the control group, whereas PMCA was restored to the baseline level 
by a HSD during FK506 treatment.  
Reduced expression of NCX1 in FK506 + HSD treated mice could be a 
downstream effect of Na+/K+-ATPase, since its expression level was restored; 
sodium can exit the cell through Na+/K+-ATPase or NCX1, reducing sodium 
accumulation and lessening the depolarisation of the basolateral membrane. 
NCX1 will continue to export sodium and import calcium into the cell as long as 
the cell is depolarised. However, since PMCA expression remained at baseline 
level in FK506 + HSD treated mice, the transport direction of NCX1 may alternate 
depending on intracellular sodium and calcium concentration.  
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4.4.3 The effect of increased NaCl intake on calcium transport proteins 
Since HSD altered the effect of FK506 on some of the transport proteins in FK506 
+ HSD treated mice, the effect of a HSD alone was examined. The purpose of 
the HSD was to enhance the effect of FK506, therefore administration of this diet 
to vehicle-treated mice for 2 weeks might not be sufficient to cause salt-induced 
hypertension. Several groups have reported that a diet containing 2.8 % NaCl 
was considered to be a moderately-high salt diet for rats; this is comparable with 
a daily intake of 14 g NaCl in humans (528,529), which is above the average 
Western diet. Ball and Meneely (529) showed that progressive salt-induced 
hypertension is time and dose dependent, requiring up to 12 months on a 2.8 % 
NaCl diet before hypertension becomes apparent. This means that the two-week 
treatment period used in this study for mice fed on a 1.5 % NaCl diet may not be 
sufficient and may require a treatment period of over 12 months for hypertension 
to develop. Other studies using higher percentages of NaCl, such as 4 or 8 %, 
can cause hypertension in less than 7 weeks (530,531), however these studies 
were performed on rodents susceptible to hypertension, such as spontaneously 
hypertensive rats. Given the length of treatment used in this study, a diet 
containing >8 % of NaCl might be required to induce hypertension and changes 
in transporters since a 1.5 % NaCl diet had no effects on NCC and pNCC.  
Although the 1.5 % NaCl diet did not induce hypertension, it was shown to alter 
the expression of calcium transporters in the DCT. This is possibly due to a 
compensatory signalling mechanism that was aimed to reduce NaCl 
reabsorption, which resulted in increased calcium reabsorption. The diet 
containing 1.5 % NaCl increased Na+/K+-ATPase and NCX1 expression. Calcium 
efflux through NCX1 is coupled with sodium influx, which is then recycled through 
Na+/K+-ATPase, providing an electrochemical gradient for cation entry through 
the apical membrane. Although not statistically significant, the HSD had the 
tendency to increase TRPV5. This together with the electrochemical gradient 
would drive calcium into the cell. The increased expression of calbindin-D28K 
indicates an increase in intracellular calcium and calcium shuttling across the cell. 
The increase in intracellular calcium will activate calcineurin and may act as a 
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homeostatic mechanism that inhibits the WNK-NCC cascade and sodium 
chloride influx.  
4.4.4 The effects of FK506 on PKC  
The DCT is a principle site for sodium and calcium handling with reabsorption 
occurring primarily through NCC and TRPV5, respectively. PTH is known to 
downregulate NCC and upregulate TRPV5 activity (308,517) and the presented 
hypothetical model posits that intracellular calcium may act as a homeostatic 
mechanism to regulate NCC. PTH regulation of TRPV5 involves PKA and PKC 
signalling pathways (313,314).  
PTH stimulates TRPV5 through activation of the ADCY-cAMP-PKA pathway and 
PKA has been reported to phosphorylate TRPV5 at T709, prevent calmodulin 
and TRPV5 interaction, and increase the open probability of the channel for 
calcium uptake (314). Several PKA and calmodulin-targeted motifs have been 
identified on TRPV5, however amino acid sequence alignments of TRPV5 
revealed that these motifs are only conserved in rabbits, mice and rats but not in 
humans. A recent study comparing the effects of PKA on rabbit and human 
TRPV5 showed that PKA stimulated rabbit TRPV5, but not human TRPV5 (532). 
Together, these indicate that PKA-mediated TRPV5 stimulation in rabbits might 
be a signalling mechanism unique to rodents, therefore these results may not be 
representative of the same behaviour in humans, hence the effects of FK506 on 
PKA were not investigated in this chapter. 
PTH signals PKC to inhibit caveola-mediated endocytosis of TRPV5, which 
results in the accumulation of TRPV5 at the cell membrane (313,315,337). In 
addition, PKA and PKC also regulate the kinase activity of WNK4. PKA and PKC 
are known to phosphorylate KLHL3 to prevent WNK4 degradation and increases 
phosphorylation of WNK4 at S64 and S1196, and the autophosphorylation of 
WNK4 at S332; this results in the increase in WNK4 kinase activity, which 
promotes NCC activity (244). Since PKC is an upstream regulator of WNK4, and 
both PKC and WNK4 regulate TRPV5 cell surface expression, the effect of FK506 
was examined on PKC. There are fifteen isoenzymes in the PKC family and these 
are divided into three subfamilies, the conventional, novel and atypical PKCs 
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(533). Conventional PKCs, such as PKC α and PKC β1, require diacylglycerol 
(DAG) and calcium for activation, whereas novel PKCs, such as PKC δ and PKC 
ε, do not require calcium for activation. PKC α, β1, δ and ε have been shown to 
be expressed at the PCT, DCT and CD of mice (534). This study shows that 
FK506 or a diet containing an additional 1.5 % NaCl did not alter PKC β1, δ and 
ε protein expression. In addition, FK506 + HSD did not affect the expression of 
PKC β1 and δ, but the expression of PKC ε was increased, which suggests that 
it might play a role in the pathophysiology of renal electrolyte handling. CNIs are 
known to dysregulate the phosphorylation state of proteins and the effect of 
FK506 on the phosphorylation of PKC isoenzymes are unknown, therefore further 
investigations into the expression of PKC α, pPKC β1 and the expression of other 
phospho-PKC isoenzymes are required.  
4.4.5 Other calcium regulatory proteins  
The phosphoproteome profile generated from Chapter 3 identified several 
phosphoproteins involved in calcium homeostasis that could also be involved in 
the development of CNI-induced hypercalciuria or other adverse effects of CNIs. 
4.4.5.1 Adenylyl cyclase 6 
ADCY6 is expressed all along the nephron but it is most abundant in the distal 
tubules (535). ADCY6 is inhibited by extracellular calcium and plays an important 
role as part of the PKA-mediated PTH signalling pathway regulating TRPV5 
(314,518). FK506 increased the phosphorylation of ADCY6 at S53 in the renal 
cortices of FK506-treated mice. ADCY6 also plays an important role in sodium 
handling at the DCT. ADCY6 phosphorylates and activates AKT (536), resulting 
in the activation of the WNK-NCC cascade (471). Quantitative analysis of ADCY6 
in the kidneys of FK506-treated mice revealed that the total protein expression of 
ADCY6 remained unchanged, this suggests that FK506 does not interfere with 
the total level of ADCY6 but dysregulates phosphorylation of ADCY6, which may 
induce changes in the activity of PKA. 
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4.4.5.2 R-type calcium channel subunit α-1E 
CACNA1E is a R-type calcium channel that is expressed in the brain (537), 
pancreas (538) and kidneys (539). It is best known for its role in synaptic plasticity 
in the nervous system where it mediates calcium influx into excitable cells (537). 
It has also been shown to play a role in sperm motility (540), pain transmission 
(541) and the regulation of the heart rate (542). CACNA1E also plays a role in 
glucose homeostasis and polymorphism in CACNA1E are associated with Type 
II diabetes and reduced insulin secretion (538,543,544), which are characteristics 
of the metabolic syndrome along with hypertension and hypercalciuria. Previous 
studies reported CACNA1E expression at the distal tubule, where it is 
predominantly expressed on the apical membrane but is also expressed at lower 
levels on the basolateral membrane and the cytoplasm (539). In this study, FK506 
increased phosphorylation of CACNA1E at a novel phosphosite, T1983. 
However, the role of CACNA1E in the distal tubules is poorly understood and 
further investigation into pT1983 is required to determine whether it is involved in 
calcium and sodium homeostasis. 
4.4.5.3 Calnexin 
Calnexin is one of the molecular chaperones that assists protein folding in the 
ER. The ER plays a dynamic role in many cellular processes, which includes 
protein folding, lipid biosynthesis and calcium homeostasis (545). Protein folding 
occurs inside the ER and folded proteins are transported through the Golgi 
apparatus. Misfolded proteins are not exported and are retained in the ER until 
they are degraded in the cytoplasm. Many processes can alter ER homeostasis 
and cause ER stress. ER stress is caused by the accumulation of misfolded 
proteins in the ER, altered ER calcium homeostasis, viral infections and 
increased protein synthesis (545). ER stress can be alleviated under normal 
condition by the increase in the expression of protein folding chaperones, to 
accommodate the increase in protein synthesis, or the inhibition of general 
protein translation and increased degradation of misfolded proteins. However, if 
ER stress is not alleviated or it is severe, cell apoptosis will be induced (545) and 
this has been associated with the pathogenesis of many diseases, such as 
hypertension, type 2 diabetes and obesity (546,547).  
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Calcineurin has been shown to alleviate ER stress by inhibiting protein translation 
and restoring Ca2+ stores in the ER for optimal protein folding conditions. To 
restore Ca2+ stores, calcineurin causes intracellular Ca2+ oscillation by 
dephosphorylating calnexin at S563; this reduces the interaction between 
calnexin and the sarco/endoplasmic reticulum calcium ATPase 2b (SERCA) and 
prevents calnexin from inhibiting the SERCA (548). FK506 increased 
phosphorylation of calnexin at S563 in this study, which inhibits SERCA, prevents 
restoration of ER Ca2+ homeostasis and prolongs ER stress (549). Quantitative 
analysis of calnexin in the kidneys of FK506-treated mice revealed that the total 
protein expression of calnexin remained unchanged, indicating that FK506 does 
not interfere with total level of calnexin but dysregulates its phosphorylation. 
Moreover, FK506 + HSD significantly increased the total protein expression of 
calnexin. The causes of increased calnexin during FK506 + HSD treatment is 
unclear, but increased calnexin levels could accentuate SERCA inhibition, 
thereby increasing ER stress.   
4.4.6 Future studies 
The model proposed in this study is one of NCC-mediated sodium transport 
increasing the intracellular calcium concentration which decreases reabsorption 
of calcium from the urine. The model predicts that the magnitude of chloride and 
potassium influx must be equal to their efflux. The abundance of chloride and 
potassium transport proteins, such as CLCNKB and KCNJ10, can be verified 
through Western blot analysis and immunohistochemistry.  
Intracellular calcium can be imaged in an intact kidney of a live FK506-treated 
mouse, using calcium sensitive dyes and multiphoton microscopy (550). Real-
time imaging of Ca2+ signals can be used to visualise calcium influx and efflux 
through reversed NCX1 and PMCA, respectively, and Ca2+ ions localised at the 
basolateral membrane, in the event of sodium accumulation and membrane 
depolarisation. This approach may reveal alternative pathways of calcium 
transport in the DCT, such as that calcium may not be imported into the cell 
through TRPV5. 
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This model suggests that sodium accumulation and subsequent membrane 
depolarisation may reduce the electrochemical gradient required for calcium 
uptake through TRPV5. The net movement of ions across the cell generates a 
transepithelial voltage that is equal to the difference in voltage between the apical 
and basolateral membrane. With an Ussing chamber, the transepithelial voltage 
of a confluent monolayer of murine distal convoluted tubule cells from 
microdissected kidneys, could be measured using a current clamp method (551).   
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Chapter 5. Discussion 
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5.1 Summary of the thesis 
CNIs are the main immunosuppressants used in organ transplantation. It causes 
complications such as hypertension, hypercalciuria, hyperkalaemia, metabolic 
acidosis and diabetes mellitus, which mimics the metabolic syndrome. 
Calcineurin is a protein phosphatase with pleiotropic effects, and the discovery of 
the calcineurin-WNK cascade has provided insights into the regulation of blood 
pressure in the kidney. The WNK cascade is extremely complex and regulates 
NCC through a sequential inhibitory signalling pathway, however, the underlying 
mechanism remains unclear due to conflicting evidence presented in literature. 
With the aim of elucidating the signalling pathways that govern the WNK-NCC 
cascade, a single-oocyte chemiluminescence assay was used. This assay uses 
chemiluminescence emitted from the epitope-tagged oocytes to quantify NCC 
expression on the surface membrane, offering a promising approach for 
investigating protein interactions between regulatory and transmembrane 
proteins. Unfortunately, technical issues were encountered in the production of 
DNA constructs, therefore, a different approach focusing on phosphorylation in 
CNI-treated animals was used to investigate the calcineurin-NCC cascade.  
Phosphorylation is an important post-translational modification that defines the 
activity of members of the WNK-NCC cascade. Using quantitative 
phosphoproteomics, a phosphoproteome profile of the renal cortices from FK506-
treated mice was generated, and 411 unique phosphopeptides in the membrane 
fraction and 244 in the cytosolic fraction were found to be dysregulated by FK506. 
In this data, AKT was found to be phosphorylated by FK506 and may act as the 
intermediary protein in the calcineurin-WNK cascade. In addition, ERK1/2 was 
also dysregulated by FK506 and may regulate NCC through the WNK4-ERK1/2 
pathway in a WNK-SPAK pathway independent manner. Due to the pleiotropic 
effects of calcineurin, the phosphoproteome profile also revealed several FK506-
dysregulated phosphoproteins that are involved in sodium, acid-base, glucose 
and potassium handling, all of which require further investigation as to their role 
in the adverse effects of CNIs.  
Previously, CNI-induced hypercalciuria was thought to be caused by a reduction 
in the apically expressed TRPV5 and the cytosolic protein calcium binding 
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protein, calbindin-D28K. In this thesis, a novel mechanism underlying CNI-
induced hypercalciuria is proposed where the decrease in calcium reabsorption 
in the DCT of FK506-treated mice may in fact be a result of basolateral membrane 
depolarisation and an increase in NCX1 expression. This eliminates the driving 
force for calcium influx through TRPV5. In addition, a regulatory mechanism that 
prevents sodium chloride overload is also proposed, in which the increase in 
calcium influx in the DCT will increase intracellular calcium concentration, 
activating calcineurin to inhibit NCC in a homoeostatic negative feedback loop.  
5.2 The effect of insulin resistance on sodium retention in the 
metabolic syndrome 
CNI-induced metabolic syndrome is highly prevalent amongst transplant 
recipients. Since the development of the metabolic syndrome can involve both 
genetic and behavioural risk factors, polymorphisms in the subunits of calcineurin 
or genes downstream of calcineurin, such as AKT and ERK1, may increase the 
susceptibility of developing the metabolic syndrome in transplant recipients.  
Insulin has a variety of effects on the nephron, including the regulation of sodium 
reabsorption, glucose uptake and the prevention of cell apoptosis. Insulin binds 
to a tyrosine kinase receptor (RTK) that phosphorylates and activates the 
PI3K/AKT and the MAP kinase signalling pathways. Activated PI3K activates the 
3-phosphoinositide-dependent protein kinase 1, causing AKT phosphorylation 
and activation. AKT phosphorylates its substrates and activates a series of 
signalling pathways that results in the activation of eNOS, an increase in glucose 
uptake and storage, an increase in protein and lipid synthesis, and a decrease in 
gluconeogenesis and lipolysis. The MAP kinase pathway, which involves MAP 
kinase kinase and ERK1/2, acts in parallel to the PI3K/AKT pathway, is involved 
in cell proliferation and differentiation, is also activated. 
Hyperinsulinaemia requires hyperglycaemia to induce sodium reabsorption in the 
PCT, TALH and DCT (552). In the distal tubule, insulin increases the expression 
of NCC and ENaC via two different mechanisms. When insulin binds to its 
receptor, PI3K/AKT and the PI3K/mTOR complex 2/SGK1 pathways are 
activated (553). The WNK4-NCC cascade is stimulated by AKT (471), whereas 
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the membrane expression of ENaC is increased by inhibiting Nedd4 through the 
PI3K/mTOR complex 2/SGK1 pathway, resulting in increased sodium uptake 
(553). Similar to the effect of aldosterone, hyperglycaemia also increases SGK1 
expression and phosphorylation (554). The increase in SGK1 activity may also 
contribute to increased NCC activity through the WNK kinases, causing sodium 
retention.  
Insulin resistance forms part of the metabolic syndrome and the PI3K/AKT 
signalling pathway is impaired in glucogenic tissues, such as muscle and adipose 
tissues (469,470), whilst the MAP kinase pathway remains intact. In contrast, the 
kidney is not affected by insulin resistance in the same manner; only the glomeruli 
can develop insulin resistance in which the activity of the PI3K/AKT pathway is 
reduced (555). In other parts of the nephron, such as the distal tubules, the 
insulin/PI3K/AKT pathway remains active (469). Since the distal tubules remain 
sensitive to insulin, hyperinsulinaemia will stimulate sodium retention through 
NCC and ENaC.  
The thesis demonstrated that AKT was increased, phosphorylated and possibly 
activated in CNI-treated mice. This is consistent with previous reports in which 
AKT was increased in the kidneys of diabetic mice (469,471) and CNI was shown 
to prevent the dephosphorylation of AKT by calcineurin (475,476). The PI3K-AKT 
pathway has been shown to activate the WNK-NCC pathway in diabetic models, 
which suggests that AKT may be involved in stimulating NCC in CNI-treated 
animals. The activity of AKT was not determined in this study, however this may 
be an interesting avenue for future investigation. Since both NCC and ENaC are 
stimulated by the PI3K/AKT pathway, hyperinsulinaemia and the downregulation 
of calcineurin in the kidneys may contribute to sodium retention and the 
development of hypertension in the metabolic syndrome (Figure 5.2-1).  
5.2.1 The effect of insulin resistance and ER stress in the metabolic syndrome 
An activated PI3K/AKT cascade can cause ER stress by overproducing NO 
(556). If ER stress is not alleviated, accumulated ER stress can contribute to the 
development of hypertension, type 2 diabetes and obesity (546,547). As 
previously mentioned, one of the mechanisms for alleviating ER stress by 
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calnexin is to restore Ca2+ homeostasis in the ER. In the current study, FK506 
prevented the dephosphorylation of calnexin, which inhibited SERCA activation, 
resulting in prolonged ER stress; a possible trigger for the development of the 
metabolic syndrome (549).  
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Figure 5.2-1 Sodium retention in the distal tubule of insulin resistant mice 
In insulin resistant mice, the insulin signalling pathway is activated in the distal 
tubule, which promotes sodium retention via two interlinked pathways. PI3K 
stimulates the mTORC2-SGK1 signalling cascade, causing an increase in ENaC 
membrane expression and stimulates the AKT-WNK cascade, causing an 
increase in NCC activity. In addition, mTORC2 also stimulates AKT and PDK1 
also stimulates SGK1, which may further increase sodium retention. CNIs prevent 
AKT dephosphorylation and deactivation, activating the WNK cascade and 
resulting in NCC activation, which leads to hypertension.   
222 
 
 
5.3 Fast calcium binding to calmodulin supports calcineurin 
activation with calcium influx into the DCT  
Calcineurin has a basal inhibitory effect on NCC. The activation of calcineurin 
requires an increase in intracellular calcium and the binding of calcium ions to 
calmodulin and calcineurin B. Similar to calbindin-D28K, calmodulin plays a 
crucial role in buffering calcium ions in the cell to prevent cell toxicity, especially 
at high intracellular calcium concentration (557). 
Recently, a study on the kinetics of calcium binding showed that calmodulin may 
act as a calcium ion detector, responsible for the fast buffering of incoming 
calcium ions in the cell (558). Calmodulin binds to free calcium ions much faster 
than other major calcium binding proteins, such as calbindin-D28K, and directly 
intercepts calcium ions before other calcium binding proteins can bind them 
(558). Calmodulin can bind up to four calcium ions, two at the N-terminus and two 
at the C-terminus globular domains. These domains have different kinetic 
properties (279). The initial binding of calcium is dependent on the domains in 
the N-terminus of calmodulin, which acts as a fast but low affinity buffer. Calcium 
ions are then transferred to the C-terminus globular domain of calmodulin, which 
has a higher affinity than the N-terminus, before finally binding to a slow but high 
affinity calcium binding protein, calbindin-D28K, which determines the final 
intracellular calcium concentration (558).  
In Chapter 4, a 1.5 % NaCl diet was not sufficient to alter pNCC expression. 
Instead, it was proposed that the 1.5 % NaCl diet might have activated a 
compensatory mechanism, such as the PTH or vitamin D3 signalling pathway 
(517,559) to reduce salt reabsorption during salt overload. This proposed 
mechanism would prevent sodium retention through increased calcium 
reabsorption. During salt overload, the membrane abundance of TRPV5 and 
NCX1 are elevated, increasing the electrochemical gradient for calcium ions and 
causing calcium influx. The sequential binding of incoming calcium ions allows 
calmodulin activation, which causes calcineurin activation and NCC inhibition. 
Calcium ions bound to calbindin-D28K are shuttled to the basolateral membrane 
and extruded through NCX1 in exchange for sodium ions, which are recycled by 
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Na+/K+-ATPase (Figure 5.3-1). This putative mechanism posits that calcium 
homeostasis indirectly modulates sodium homeostasis via calmodulin and 
calcineurin.  
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Figure 5.3-1 A proposed model of a compensatory mechanism to prevent 
sodium reabsorption during salt overload 
The activation of calcineurin requires an increase in intracellular calcium and the 
binding of calmodulin. During salt overload, the expression of TRPV5, calbindin-
D28K, NCX1 and Na+/K+-ATPase are increased. Calcium ions enter the DCT 
through TRPV5 and are immediately bound to calmodulin. Calmodulin activates 
calcineurin, which inhibits the WNK cascade to prevent NCC activation. 
Calmodulin transfers calcium ions to calbindin-D28K and calcium ions are 
extruded through NCX1, in exchange for sodium ions which are recycled by 
Na+/K+-ATPase.  
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5.4 Underlying causes of the metabolic syndrome 
The pathogenesis of the metabolic syndrome is currently unknown, however, 
there is ample evidence to indicate that environmental factors play a critical role. 
Vitamin D3 and PTH are regulators of calcium and phosphate homeostasis and 
form a feedback loop that regulate the secretion of each other. The role of Vitamin 
D3 and PTH in the development of the metabolic syndrome has been examined 
by several epidemiological studies.  
5.4.1 Vitamin D3 deficiency 
Vitamin D3 deficiency has become a widespread epidemic with an estimate of 
over a billion children and adults affected worldwide (560). Vitamin D3 deficiency 
is associated with many modern day diseases, including osteoporosis (561), 
neuro-degenerative diseases, such as Alzheimer’s (562), and the metabolic 
syndrome (563–565). Vitamin D3 deficiency is also prevalent in transplant 
recipients treated with CNIs (566,567), with 51 % to 97 % with vitamin D3 
insufficiency and 26 % to 33 % with severe vitamin D3 deficiency (568). In addition 
to low serum levels of vitamin D3, the expression of vitamin D3 receptors in the 
kidney are also reduced by CNI treatment (569). These findings indicate that 
vitamin D3 deficiency is associated with many diseases and the dysregulation of 
the 1,25(OH)2D3 signalling pathway may contribute to the development of the 
components in the metabolic syndrome. 
Vitamin D3 has many physiological roles in the body and it is best known for its 
role in calcium and phosphate homeostasis. Vitamin D3 regulates calcium 
handling in the DCT by increasing TRPV5, calbindin-D28K, and PMCA 
expression, and promoting calcium reabsorption. Calcium and sodium handling 
are inversely regulated, therefore an increase in calcium reabsorption will activate 
calcineurin, causing NCC inhibition and reduced sodium chloride reabsorption. In 
addition, vitamin D3 also regulates blood pressure in a process that is 
independent from calcium, phosphate and PTH. Vitamin D3 interacts with the 
RAAS and suppresses renin expression (559,570). Low serum levels of vitamin 
D3 are associated with increased renin activity and serum ANGII levels (571,572), 
which may contribute to increased sodium reabsorption in the distal nephron. 
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Lower levels of 1,25(OH)2D3 are also detected in individuals with essential 
hypertension (564), suggesting a role for vitamin D3 in the development of 
hypertension.  
New evidence has recently emerged indicating that vitamin D3 may also play a 
role in insulin secretion and glucose homeostasis (51,64). Low serum vitamin D3 
levels are associated with dysfunctional β-pancreatic islets cells, increased 
resistance to insulin and decreased glucose tolerance, resulting in insulin 
resistance and eventually diabetes (573,574). Some studies suggest that the 
stimulatory effects of vitamin D3 on calbindin-D28K may play a role in the 
development of diabetes by preventing apoptosis of β-pancreatic islets cells since 
calbindin-D28K is the only endogenous inhibitor of caspase 3 (575). Upon 
stimulation, calbindin-D28K inhibits caspase 3-induced cytokine secretion and 
the sequential activation of cell apoptosis (575) that can lead to β-pancreatic islets 
cell deaths.  
There is also strong evidence to support the association between low serum 
vitamin D3 levels and increased adipose tissue mass in obese individuals (563). 
However the role of vitamin D in the development of obesity remains controversial 
due to the fact that vitamin D3 has been reported to act as a stimulant and an 
inhibitor in the differentiation of preadipocytes to mature adipocytes (576,577). 
Lastly, the metabolic syndrome has been described as a chronic state of low-
grade inflammation (578). Interestingly, vitamin D3 deficiency is also associated 
with inflammatory diseases, such as inflammatory polyarthritis (579). Vitamin D3 
has anti-inflammatory properties and inhibits the expression of pro-inflammatory 
cytokines and the activation of immune cells (580,581).  
5.4.2 PTH 
Low serum vitamin D3 levels are often associated with increased serum PTH due 
to the feedback loop that governs calcium and phosphate homeostasis. In 
contrast to vitamin D3 deficiency, the association between serum PTH levels and 
the metabolic syndrome are inconsistent (582–584). However elevated levels of 
PTH are detected in renal-transplant recipients (567), and are associated with the 
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metabolic syndrome (584) and elevated blood pressure (585), suggesting a role 
for PTH in the development of hypertension in the metabolic syndrome. 
5.4.2.1 Hyperparathyroidism  
Primary hyperparathyroidism is an endocrine disorder characterised by the 
overexpression of PTH. It is the predominant cause of hypercalcemia and is 
primarily known for its association with the development of bone diseases. It has 
become increasingly evident that hyperparathyroidism is also associated with an 
increased risk of developing hypertension, diabetes, hyperlipidaemia and 
cardiovascular morbidity and mortality (586–588). The underlying mechanism 
has been suggested to involve PTH and the RAAS, where PTH may stimulate 
the activity of the RAAS components, increasing blood pressure (589–591). PTH 
also enhances renin and aldosterone secretion through multiple pathways (591–
593), and patients with primary hyperparathyroidism have also been shown to 
develop primary aldosteronism (594), which can be reversed by surgical 
parathyroidectomy (594). In contrast, other observational studies have shown no 
connection between RAAS and hyperparathyroidism (595), therefore further 
investigations are required to decipher this relationship. 
5.4.2.2 Hypoparathyroidism  
Hypoparathyroidism is a group of metabolic disorders characterised by 
hypocalcaemia and hyperphosphatemia, which is caused by low serum PTH 
levels or PTH resistance in the target organ, including the kidney and the skeleton 
(596). In patients with primary hypoparathyroidism, low levels of PTH are 
detected in the serum whereas PTH resistance and high levels of PTH are 
detected in the serum from those with pseudohypoparathyroidism (PsHP).  
5.4.2.3 Pseudohypoparathyroidism 
Hypertension is common in patients with PsHP and it is strongly associated with 
obesity (597). Although the pathophysiology of hypertension in PsHP is unclear, 
impairment of the PTH signalling pathway may lead to the increase in sodium 
chloride reabsorption and decrease in calcium reabsorption in the distal tubule, 
causing hypertension and calcium wasting, and possibly hypocalcaemia.  
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In addition to PTH resistance, PsHP may induce hypertension through 
hypocalcaemia. The association between serum calcium levels and renin 
secretion has been examined by several research groups. Serum calcium levels 
affect the calcium sensing receptors (CaSR) located on juxtaglomerular cells and 
inhibits renin secretion upon stimulation (598,599). In vivo studies showed that 
acute elevation of serum calcium or increased renal calcium delivery are 
associated with suppressed renin secretion and this effect is more prominent 
under renin-stimulated conditions, such as a low salt diet (598,600–602). The 
hypercalcaemic effect is also mimicked by pharmacologically stimulating the 
CaSR (603). Interestingly, chronic stimulation of the CaSR is associated with high 
serum renin activity. Chronic hypercalcaemia is often detected in patients with 
primary hyperparathyroidism, however serum renin activity is not always elevated 
(604,605). The underlying signal transduction pathway is not clear, however, 
changes in serum calcium levels may affect renin secretion through indirect 
interaction with the renin-signalling pathway.  
5.5 Further avenues of investigation 
The quantitative phosphoproteomics data generated in this thesis holds a large 
amount of information that can be used to decipher the tubular disturbances 
commonly associated with CNIs. These data may provide valuable insights into 
the relationship between hypertension, type II diabetes, hypomagnesaemia and 
many other components of the metabolic syndrome, and may provide new drug 
targets for these metabolic disorders.  
Calcineurin is a protein phosphatase with pleiotropic effects and plays an 
important role in electrolyte homeostasis in the kidneys. In addition, calcineurin 
is also involved in regulating insulin expression in pancreatic β cells (606) and 
inhibiting differentiation of preadipocytes to adipocytes (607), which are all 
dysregulated by CNI and in the metabolic syndrome. Although the 
phosphoproteomic data is renal specific, these data may still provide transferable 
information into the signalling pathways dysregulated by CNIs.  
The DCT is highly metabolically active and a critical segment of the nephron 
involved in electrolyte homeostasis. The existence of several inherited electrolyte 
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disorders has provided significant insight into the molecular machinery that 
governs these processes. As this segment is so important in blood pressure 
homeostasis, full elucidation of this machinery is of interest and clinical 
importance. Further work in this area is sure to follow. 
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6.1 Topology and glycosylation of mouse NCC 
 
Figure 6.1-1 Posterior probabilities plot of mouse NCC  
The amino acid sequence of mNCC (NM_019415.2; Q543E4) was submitted into 
Protter and Phobius (406,407) and the posterior probabilities plot of NCC was 
generated. This plot demonstrates the probabilities of individual residues 
belonging to the TM region (grey), intracellular/cytoplasmic (green) and 
extracellular/non-cytoplasmic (blue) regions, and residues that may belong to a 
signal peptide (red). This plot is only a complementary source of information to 
the membrane topology prediction (Figure 2.3-1) because it only considered 
probabilities of individual amino acids but did not consider the properties of the 
amino acid sequence. 
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Table 6.1-1 Predicted glycosylation sites in mouse NCC  
 
Amino acid 
position 
Residue Score Prediction 
7 T 0.447 Potential Glycosylated 
23 T 0.062 Potential Glycosylated 
37 S 0.087 Potential Glycosylated 
38 S 0.038 Potential Glycosylated 
44 T 0.074 Potential Glycosylated 
48 T 0.079 Potential Glycosylated 
120 T 0.081 Potential Glycosylated 
122 T 0.106 Potential Glycosylated 
191 S 0.132 Potential Glycosylated 
192 T 0.078 Potential Glycosylated 
239 T 0.037 Potential Glycosylated 
350 T 0.152 Potential Glycosylated 
373 T 0.191 Potential Glycosylated 
380 T 0.141 Potential Glycosylated 
381 T 0.142 Potential Glycosylated 
390 T 0.218 Potential Glycosylated 
400 S 0.114 Potential Glycosylated 
406 T 0.189 Potential Glycosylated 
408 T 0.227 Potential Glycosylated 
426 T 0.011 Potential Glycosylated 
456 T 0.190 Potential Glycosylated 
466 S 0.049 Potential Glycosylated 
525 T 0.012 Potential Glycosylated 
551 T 0.187 Potential Glycosylated 
781 S 0.069 Potential Glycosylated 
786 T 0.152 Potential Glycosylated 
801 T 0.053 Potential Glycosylated 
912 T 0.127 Potential Glycosylated 
 
Potentially glycosylated residues in mNCC (NM_019415.2; Q543E4) were 
predicted with GlycoEP (408). The table shows the amino acid position, the 
residue and a score that shows the confidence level of each prediction. The 
higher the score, the higher the confidence and therefore the probability of a false 
positive is lower.   
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6.2 Proteomics quality checks 
 
Figure 6.2-1 Purity of fractionated samples  
The renal cortices of the treated animals were isolated and divided into 
membrane and cytosolic fractions. The purity of the enrichment was determined 
through Western blot analysis of a cytosolic protein, ERK1. Expression level of 
ERK1/2 in the three fractions obtained from the renal cortices. Lane 1, 3 and 5 
are protein samples from vehicle treated animal. Lane 2, 4 and 6 are protein 
samples obtained from FK506 treated animal. Expression of ERK1/2 was the 
most abundant in the cytosolic fraction. ERK1/2 expression in PNST and 
membrane fraction was lower, indicating successful fractionation.  
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Figure 6.2-2 Protein recovery after acetone precipitation 
After acetone precipitation, samples were separated on a SDS-PAGE gel and 
silver stained. Silver stained gel showed minimum protein loss post-precipitation. 
Samples were then re-suspended in the appropriate buffer and digested with 
trypsin. Silver stained SDS-PAGE gel of the cytosolic and membrane fraction 
before and after acetone precipitation. Fifteen µg of protein were loaded onto 
each lane. Lane 1 and 3 were samples before acetone precipitation and lane 2 
and 4 were samples precipitated with acetone. The silver stained gel showed 
minimum loss of proteins. A positive control was included in lane 6.   
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Table 6.2-1 Labelling efficiency of the membrane and cytosolic fractions 
 
Following trypsin digestion, peptides were labelled with TMT and the labelling 
efficiency was determined through LC-MS/MS. All three replicates from the 
membrane and cytosolic fraction showed over 98 % labelling efficiency. The 
correction factor was also calculated from this set of data (data not shown) and 
TMT126 and TMT127, were combined in equal proportion before 
phosphopeptide enrichment.  
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6.3 Quantitative phosphoproteomic tables 
For quantitative phosphoproteomic tables, see the attached CD. Table captions 
are as follows. 
Table 6.3-1 Quantified phosphopeptides identified in the membrane fraction 
Quantified peptides containing phosphorylation modification with a unique 
identification, in the membrane fraction of the renal cortices from FK506-treated 
mice, were manually validated before being processed. These quantified 
phosphopeptides obtained from the three replicates were grouped into unique 
phosphopeptide groups according to their sequences, pRS site probabilities 
(probability for each putatively phosphorylated site) and MH+ [Da] value. The 
average ratio, standard deviation and coefficient of variation of each unique 
phosphopeptide were calculated. 
Table 6.3-2 Quantified phosphopeptides identified in the cytosolic fraction 
Quantified peptides containing phosphorylation modification with a unique 
identification, in the cytosolic fraction of the renal cortices from FK506-treated 
mice, were manually validated before being processed. These quantified 
phosphopeptides obtained from the three replicates were grouped into unique 
phosphopeptide groups according to their sequences, pRS site probabilities 
(probability for each putatively phosphorylated site) and MH+ [Da] value. The 
average ratio, standard deviation and coefficient of variation of each unique 
phosphopeptide were calculated. 
Table 6.3-3 Unique phosphopeptides identified in the membrane fraction 
The unique phosphopeptides identified in the membrane fraction of the renal 
cortices from FK506-treated mice were summarised. Information on their gene 
name, protein name, keywords, gene ontology, KEGG and Reactome were 
obtained from UniProt Knowledgebase and matched to the protein accession 
number of each phosphopeptide.  
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Table 6.3-4 Unique phosphopeptides identified in the cytosolic fraction 
The unique phosphopeptides identified in the cytosolic fraction of the renal 
cortices from FK506-treated mice were summarised. Information on their gene 
name, protein name, keywords, gene ontology, KEGG and Reactome were 
obtained from UniProt Knowledgebase and matched to the protein accession 
number of each phosphopeptide.  
Table 6.3-5 Unique phosphopeptides identified in calcium-associated 
proteins in the membrane fraction 
The unique phosphopeptides identified in the membrane fraction of the renal 
cortices from FK506-treated mice filtered by the GO term “calcium” and are 
presented in this table.  
Table 6.3-6 Unique phosphopeptides identified in calcium-associated 
proteins in the cytosolic fraction 
The unique phosphopeptides identified in the cytosolic fraction of the renal 
cortices from FK506-treated mice filtered by the GO term “calcium” and are 
presented in this table.    
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